

# CITATION REPORT

List of articles citing

## Human induced pluripotent stem cells free of vector and transgene sequences

DOI: 10.1126/science.1172482  
Science, 2009, 324, 797-801.

**Source:** <https://exaly.com/paper-pdf/47108321/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2047	References. 205-220		
2046	Induced pluripotent stem cells: advances to applications. <b>2010</b> , 3, 29-37		13
2045	[P53, ARF and P16: the last defence against reprogramming]. <b>2009</b> , 25, 793-4		0
2044	Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. <b>2009</b> , 4, e7118		62
2043	State of the stem cell. <b>2009</b> ,		
2042	Look now! Human iPS cells with no genetic integration. <b>2009</b> ,		
2041	What does reprogramming do?. <b>2009</b> ,		
2040	Reprogramming to pluripotency without genetic engineering. <b>2009</b> ,		
2039	Retinal pigment epithelium differentiation of stem cells: current status and challenges. <b>2009</b> , 37, 355-75		11
2038	A simple and efficient cryopreservation method for feeder-free dissociated human induced pluripotent stem cells and human embryonic stem cells. <b>2009</b> , 24, 2468-76		83
2037	Induced pluripotent stem cells: it's like déjà vu all over again. <b>2009</b> , 120, 1462-4		8
2036	Derivation of induced pluripotent stem cells from pig somatic cells. <b>2009</b> , 106, 10993-8		381
2035	The tumorigenicity of diploid and aneuploid human pluripotent stem cells. <b>2009</b> , 8, 3822-30		106
2034	Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons. <b>2009</b> , 89, 147-60		8
2033	Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. <b>2009</b> , 106, 15720-5		421
2032	Nuclear receptor regulation of stemness and stem cell differentiation. <b>2009</b> , 41, 525-37		54
2031	Genome 10K: a proposal to obtain whole-genome sequence for 10,000 vertebrate species. <b>2009</b> , 100, 659-74		418

2030	FDA regulation of stem cell-based products. <i>Science</i> , <b>2009</b> , 324, 1662-3	33.3	116
2029	Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. <b>2009</b> , 119, 2818-29		153
2028	Induced pluripotent stem cells and the promise of proliferation. <b>2009</b> , 105, 1159-61		
2027	DERIVATION AND THERAPEUTIC POTENTIALS OF INDUCED PLURIPOTENT STEM CELLS. <b>2009</b> , 04, 81-104		
2026	Rapid development of pluripotent stem cells as a potential therapeutic modality. <b>2009</b> , 17, 929-30		2
2025	On the road to iPS cell cardiovascular applications. <b>2009</b> , 105, 617-9		31
2024	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. <b>2009</b> , 106, 12759-64		222
2023	Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. <b>2009</b> , 18, 4340-9		146
2022	iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. <b>2009</b> , 105, 648-56		92
2021	Current advances and travails in islet transplantation. <b>2009</b> , 58, 2175-84		159
2020	Derivation of insulin-producing cells from human embryonic stem cells. <i>Stem Cell Research</i> , <b>2009</b> , 3, 73-87.6		91
2019	Progenitor cell therapy for heart disease. <b>2009</b> , 315, 3077-85		54
2018	T lineage differentiation from induced pluripotent stem cells. <b>2009</b> , 260, 1-5		41
2017	Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. <b>2009</b> , 8, 819-29		85
2016	Determinants of pluripotency: from avian, rodents, to primates. <b>2010</b> , 109, 16-25		16
2015	Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. <b>2010</b> , 109, 292-301		28
2014	Are induced pluripotent stem cells the future of cell-based regenerative therapies for spinal cord injury?. <b>2010</b> , 222, 515-21		42
2013	Molecular genetic analysis of Down syndrome. <b>2009</b> , 126, 195-214		156

2012	New strategies to generate induced pluripotent stem cells. <b>2009</b> , 20, 516-21	48
2011	Induced pluripotent stem cells for retinal degenerative diseases: a new perspective on the challenges. <b>2009</b> , 88, 417-24	51
2010	Current progress and prospects of induced pluripotent stem cells. <b>2009</b> , 52, 622-36	21
2009	Genetic basis of inherited macular dystrophies and implications for stem cell therapy. <b>2009</b> , 27, 2833-45	9
2008	Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. <b>2009</b> , 27, 2509-15	85
2007	Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. <b>2009</b> , 27, 2427-34	351
2006	Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. <b>2009</b> , 27, 2655-66	135
2005	Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. <b>2009</b> , 27, 2667-74	405
2004	Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. <b>2009</b> , 27, 2686-90	159
2003	Klf4 interacts directly with Oct4 and Sox2 to promote reprogramming. <b>2009</b> , 27, 2969-78	93
2002	Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. <b>2009</b> , 27, 2992-3000	260
2001	Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. <b>2010</b> , 28, 221-8	105
2000	Regenerative medicine: a 2009 overview. <b>2009</b> , 266, 303-10	14
1999	Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. <b>2009</b> , 19, 1233-42	398
1998	Elite and stochastic models for induced pluripotent stem cell generation. <b>2009</b> , 460, 49-52	410
1997	Variation in the safety of induced pluripotent stem cell lines. <b>2009</b> , 27, 743-5	702
1996	Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. <b>2009</b> , 27, 1033-7	404
1995	Stem cells: Fast and furious. <b>2009</b> , 458, 962-5	34

1994	Developing safe therapies from human pluripotent stem cells. <b>2009</b> , 27, 606-13	110
1993	The gold rush for induced pluripotent stem cells. <b>2009</b> , 27, 977-9	12
1992	A safer stem cell: inducing pluripotency. <b>2009</b> , 15, 1001-2	7
1991	A safer stem cell: on guard against cancer. <b>2009</b> , 15, 999-1001	35
1990	EOS lentiviral vector selection system for human induced pluripotent stem cells. <b>2009</b> , 4, 1828-44	67
1989	Induced pluripotent stem cells and reprogramming: seeing the science through the hype. <b>2009</b> , 10, 878-83	85
1988	Could co-transplantation of iPS cells derived hepatocytes and MSCs cure end-stage liver disease?. <b>2009</b> , 33, 1180-3	10
1987	Generation of pluripotent stem cells from patients with type 1 diabetes. <b>2009</b> , 106, 15768-73	461
1986	Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. <b>2009</b> , 106, 8912-7	331
1985	In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. <b>2009</b> , 385, 497-502	190
1984	Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. <b>2009</b> , 4, 472-6	1506
1983	Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. <b>2009</b> , 5, 111-23	816
1982	Pluripotent stem cells and disease modeling. <b>2009</b> , 5, 244-7	88
1981	Regeneration next: toward heart stem cell therapeutics. <b>2009</b> , 5, 364-77	153
1980	Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. <b>2009</b> , 5, 353-7	334
1979	Technical challenges in using human induced pluripotent stem cells to model disease. <b>2009</b> , 5, 584-95	328
1978	Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. <b>2009</b> , 30, 536-45	66
1977	Pluripotent stem cells. <b>2009</b> , 16, 65-9	11

1976	Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?. <b>2009</b> , 85, 549-56	11
1975	Induced pluripotent stem cells in regenerative medicine: an argument for continued research on human embryonic stem cells. <b>2009</b> , 4, 759-69	44
1974	Senescence impairs successful reprogramming to pluripotent stem cells. <b>2009</b> , 23, 2134-9	472
1973	Induced pluripotent stem cells free of exogenous reprogramming factors. <b>2009</b> , 10, 220	13
1972	Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. <b>2009</b> , 84, 893-902	142
1971	Application of induced pluripotent stem cells to hematologic disease. <b>2009</b> , 11, 980-9	21
1970	Future alternative therapies for $\beta$ -thalassemia. <b>2009</b> , 2, 685	21
1969	Cellular cardiac regenerative therapy in which patients?. <b>2009</b> , 7, 911-9	41
1968	Epigenetic signatures in stem cells and cancer stem cells. <b>2009</b> , 1, 261-80	15
1967	Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. <b>2009</b> , 114, 3513-23	123
1966	Functional neutrophils from human ES cells. <b>2009</b> , 113, 6503-5	1
1965	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. <b>2009</b> , 114, 5473-80	314
1964	Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. <b>2009</b> , 85, 348-62	1000
1963	TRANSLATIONAL PERSPECTIVES $\square$ TRANSIENT EPIGENETIC GENE THERAPY: HAZARD-FREE CELL REPROGRAMMING APPROACH AND RISING ARM OF A UNIVERSAL STEM CELL GENE THERAPY PLATFORM. <b>2009</b> , 04, 11-39	5
1962	Life, and ... Neurosurgery after the first "synthetic cell". <b>2010</b> , 67, N14-5	
1961	Improving intraoperative visualization of anaplastic foci within gliomas. <b>2010</b> , 67, N21-2	3
1960	Exciting neurons: controversies in cortical stimulation. <b>2010</b> , 67, N20-1	
1959	Evaluation of 28 human embryonic stem cell lines for use as unrelated donors in stem cell therapy: implications of HLA and ABO genotypes. <b>2010</b> , 19, 1383-95	38

1958	Production of pancreatic beta-cells from stem cells. <b>2010</b> , 6, 184-90	29
1957	The future of regenerating the myocardium. <b>2010</b> , 25, 575-82	16
1956	Turning everything into brain?. <b>2010</b> , 67, N16-7	1
1955	Blood pressure treatment in acute ischemic stroke: a review of studies and recommendations. <b>2010</b> , 23, 46-52	10
1954	Induced pluripotent stem cell therapies for retinal disease. <b>2010</b> , 23, 4-9	29
1953	Surgery for spinal stenosis in older patients: what's the problem?. <b>2010</b> , 67, N17-8	
1952	Multiplicative impact of smoking and genetic predisposition on intracranial aneurysm formation. <b>2010</b> , 67, N15-6	2
1951	Evolution of induced pluripotent stem cell technology. <b>2010</b> , 17, 276-80	41
1950	Emerging use of stem cells in regenerative medicine. <b>2010</b> , 428, 11-23	77
1949	Optimal radiotherapy in patients with multiple intracranial metastases. <b>2010</b> , 67, N19-20	1
1948	Roles of integrins in human induced pluripotent stem cell growth on Matrigel and vitronectin. <b>2010</b> , 19, 1231-40	117
1947	Stem cell therapy: pieces of the puzzle. <b>2010</b> , 3, 49-60	18
1946	Cellular models for disease exploring and drug screening. <b>2010</b> , 1, 355-362	6
1945	iPS cells--alternative pluripotent cells to embryo stem cells. <b>2010</b> , 53, 154-156	2
1944	Epigenetic reprogramming: roads to pluripotency. <b>2010</b> , 5, 8-11	1
1943	Differential effects of recombinant fusion proteins TAT-OCT4 and TAT-NANOG on adult human fibroblasts. <b>2010</b> , 5, 424-430	1
1942	The promise of stem cell research in pigs and other ungulate species. <b>2010</b> , 6, 31-41	69
1941	Promising new sources for pluripotent stem cells. <b>2010</b> , 6, 15-26	53

1940	Progress and promise towards safe induced pluripotent stem cells for therapy. <b>2010</b> , 6, 297-306	55
1939	A transcriptional roadmap to the induction of pluripotency in somatic cells. <b>2010</b> , 6, 282-96	65
1938	The iPS technique provides hope for Parkinson's disease treatment. <b>2010</b> , 6, 398-404	11
1937	Pluripotent stem cells: origin, maintenance and induction. <b>2010</b> , 6, 633-49	39
1936	Progenitor cells for regenerative medicine and consequences of ART and cloning-associated epimutations. <b>2010</b> , 45, 187-97	
1935	Multifunctional nanocomplexes for gene transfer and gene therapy. <b>2010</b> , 26, 69-81	61
1934	Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery. <b>2010</b> , 126, 109-18	16
1933	Collaboration between WNT and BMP signaling promotes hemoangiogenic cell development from human fibroblast-derived iPS cells. <i>Stem Cell Research</i> , <b>2010</b> , 4, 223-31	1.6 12
1932	p53 and stem cells: new developments and new concerns. <b>2010</b> , 20, 170-5	115
1931	AutoSOME: a clustering method for identifying gene expression modules without prior knowledge of cluster number. <b>2010</b> , 11, 117	77
1930	Homologous recombination in human iPS and ES cells for use in gene correction therapy. <b>2010</b> , 15, 198-202	13
1929	Gene therapy, gene targeting and induced pluripotent stem cells: applications in monogenic disease treatment. <b>2010</b> , 28, 715-24	6
1928	Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. <b>2010</b> , 38, 154-62	79
1927	In vivo generation of beta-cell-like cells from CD34(+) cells differentiated from human embryonic stem cells. <b>2010</b> , 38, 516-525.e4	16
1926	Induction of pluripotency in human cord blood unrestricted somatic stem cells. <b>2010</b> , 38, 809-18, 818.e1-2	51
1925	Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. <b>2010</b> , 51, 1088-9	11
1924	Degree of portal vein thrombosis. <b>2010</b> , 51, 1089-90	92
1923	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. <b>2010</b> , 52, 1170-1	6



1922	Possible role of adipocytokines in the development of nonalcoholic steatohepatitis-related hepatocellular carcinoma. <b>2010</b> , 52, 1172	
1921	Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. <b>2010</b> , 52, 1171-2	4
1920	"Normal" alanine aminotransferase and Christopher Boorse. <b>2010</b> , 52, 1173	3
1919	Treating fatty liver for the prevention of cardiovascular diseases. <b>2010</b> , 52, 1174-5	4
1918	Optimal dosage of ribavirin. <b>2010</b> , 52, 1174	
1917	Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules. <b>2010</b> , 52, 1169; author reply 1169-70	6
1916	Reply:. <b>2010</b> , 52, 1169-1170	3
1915	Is iPS cell the panacea?. <b>2010</b> , 62, 170-5	9
1914	Porcine induced pluripotent stem cells may bridge the gap between mouse and human iPS. <b>2010</b> , 62, 277-82	8
1913	Genome modification in human embryonic stem cells. <b>2010</b> , 222, 278-81	32
1912	A step closer to complete chemical reprogramming for generating iPS cells. <b>2010</b> , 11, 755-7	12
1911	Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. <b>2010</b> , 12, 848-58	8
1910	Stem cell-derived hepatocytes and their use in toxicology. <b>2010</b> , 270, 3-9	76
1909	Adult cell therapy for brain neuronal damages and the role of tissue engineering. <b>2010</b> , 31, 2105-20	143
1908	Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. <b>2010</b> , 31, 2779-87	25
1907	Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. <b>2010</b> , 10, 81	169
1906	Achievements and challenges in bioartificial kidney development. <b>2010</b> , 3, 14	32
1905	Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men. <b>2010</b> , 28, 419-30	65

1904	Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. <b>2010</b> , 28, 704-12	320
1903	No evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells. <b>2010</b> , 28, 687-94	32
1902	Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. <b>2010</b> , 28, 713-20	355
1901	Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. <b>2010</b> , 28, 1893-904	246
1900	Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. <b>2010</b> , 28, 1760-71	35
1899	Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation. <b>2010</b> , 28, 1981-91	156
1898	Establishment of induced pluripotent stem cells from human neonatal tissues. <b>2010</b> , 23, 113-8	17
1897	Hematopoietic differentiation from human ESCs as a model for developmental studies and future clinical translations. Invited review following the FEBS Anniversary Prize received on 5 July 2009 at the 34th FEBS Congress in Prague. <b>2010</b> , 277, 5014-25	12
1896	An introduction to induced pluripotent stem cells. <b>2010</b> , 151, 16-24	22
1895	Induced pluripotent stem cells: paths to new medicines. A catalyst for disease modelling, drug discovery and regenerative therapy. <b>2010</b> , 11, 161-5	28
1894	Induced pluripotent stem cells and senescence: learning the biology to improve the technology. <b>2010</b> , 11, 353-9	85
1893	Fresh powder on Waddington's slopes. <b>2010</b> , 11, 490-2	3
1892	Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. <b>2010</b> , 465, 175-81	649
1891	Human adult germline stem cells in question. <b>2010</b> , 465, E1; discussion E3	67
1890	Conrad et al. reply. <b>2010</b> , 465, E3-E3	2
1889	Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. <b>2010</b> , 17, 1230-7	35
1888	Up for grabs. <b>2010</b> , 28, 544-6	3
1887	Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. <b>2010</b> , 42, 1113-7	773

1886	A nonviral minicircle vector for deriving human iPS cells. <b>2010</b> , 7, 197-9	590
1885	IPSCs: One cell to rule them all?. <b>2010</b> , 7, 81-85	5
1884	Generation of mouse-induced pluripotent stem cells with plasmid vectors. <b>2010</b> , 5, 418-28	174
1883	Human stem cells and drug screening: opportunities and challenges. <b>2010</b> , 9, 367-72	125
1882	iPS cell technology in regenerative medicine. <b>2010</b> , 1192, 38-44	76
1881	Direct reprogramming 101. <i>Development Growth and Differentiation</i> , <b>2010</b> , 52, 319-33	3 15
1880	Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. <b>2010</b> , 54, 965-90	21
1879	The generation of human induced pluripotent stem (iPS) cells from liver progenitor cells by only small molecules and the risk for malignant transformations of the cells. <b>2010</b> , 2, 5-9	1
1878	Porcine induced pluripotent stem cells analogous to naïve and primed embryonic stem cells of the mouse. <b>2010</b> , 54, 1703-11	90
1877	Faithful reprogramming to pluripotency in mammals - what does nuclear transfer teach us?. <b>2010</b> , 54, 1609-21	7
1876	Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. <b>2010</b> , 5, e11756	75
1875	Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate?. <b>2010</b> , 5, e12664	42
1874	High-efficient generation of induced pluripotent stem cells from human astrocytes. <b>2010</b> , 5, e15526	53
1873	Emerging options for the management of age-related macular degeneration with stem cells. <b>2010</b> , 4, 1-10	1
1872	Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. <b>2010</b> , 6, 796-805	71
1871	Stem cell patents: an innovative approach to anti-cancer drug discovery. <b>2010</b> , 5, 14-21	1
1870	Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction. <b>2010</b> , 285, 26384-9	16
1869	Progress toward the clinical application of patient-specific pluripotent stem cells. <b>2010</b> , 120, 51-9	272

1868	Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. <b>2010</b> , 54, 1743-54	52
1867	Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. <b>2010</b> , 121, 1113-23	416
1866	Induced pluripotent stem cell technology in regenerative medicine and biology. <b>2010</b> , 123, 127-41	22
1865	Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. <b>2010</b> , 285, 11227-34	140
1864	Generation of induced pluripotent stem cells using site-specific integration with phage integrase. <b>2010</b> , 107, 19467-72	38
1863	Exploring refined conditions for reprogramming cells by recombinant Oct4 protein. <b>2010</b> , 54, 1713-21	55
1862	Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC. <b>2010</b> , 16, 2197-206	71
1861	Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. <b>2010</b> , 16, 856-68	59
1860	Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery. <b>2010</b> , 5, 557-68	22
1859	Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. <b>2010</b> , 107, 15921-6	375
1858	Gene-delivery systems for iPS cell generation. <b>2010</b> , 10, 231-42	31
1857	Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. <b>2010</b> , 70, 7662-73	65
1856	Differential gene expressions in atrial and ventricular myocytes: insights into the road of applying embryonic stem cell-derived cardiomyocytes for future therapies. <b>2010</b> , 299, C1234-49	67
1855	Generation and genetic modification of induced pluripotent stem cells. <b>2010</b> , 10, 1089-103	19
1854	Generation of human-induced pluripotent stem cells from gut mesentery-derived cells by ectopic expression of OCT4/SOX2/NANOG. <b>2010</b> , 12, 237-47	18
1853	Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. <b>2010</b> , 24, 700-11	100
1852	Induced pluripotent stem cells: a new approach for physiological research. <b>2010</b> , 26, 105-24	15
1851	Extracellular matrix isolated from foreskin fibroblasts supports long-term xeno-free human embryonic stem cell culture. <b>2010</b> , 19, 547-56	39

1850	Translational prospects for human induced pluripotent stem cells. <b>2010</b> , 5, 509-19	38
1849	Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. <b>2010</b> , 19, R71-6	116
1848	Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. <b>2010</b> , 5, 521-30	9
1847	Feature. <b>2010</b> , 14, 17-33	
1846	Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. <b>2010</b> , 285, 8719-32	101
1845	Engineering of human pluripotent stem cells by AAV-mediated gene targeting. <b>2010</b> , 18, 1192-9	106
1844	Roadblocks en route to the clinical application of induced pluripotent stem cells. <b>2010</b> , 123, 643-51	36
1843	Defined factors induce reprogramming of gastrointestinal cancer cells. <b>2010</b> , 107, 40-5	230
1842	Viable iPSC mice: a step closer to therapeutic applications in humans?. <b>2010</b> , 16, 57-62	5
1841	Genetic instability in human induced pluripotent stem cells: classification of causes and possible safeguards. <b>2010</b> , 9, 4603-4	36
1840	The use of animal models to study stem cell therapies for diabetes mellitus. <b>2009</b> , 51, 74-81	6
1839	Out of a cell into this darkened space. <b>2010</b> , 111, 13-6	
1838	Classification of genomic changes in breast cancer brain metastasis. <b>2010</b> , 67, N18-9	9
1837	Embolus extravasation: a new mechanism for microvascular recanalization?. <b>2010</b> , 67, N22-3	4
1836	Tinkering with transcription factors uncovers plasticity of somatic cells. <b>2010</b> , 1, 1089-99	5
1835	Human iPS cell-based therapy: considerations before clinical applications. <b>2010</b> , 9, 880-5	106
1834	Vascular potential of human pluripotent stem cells. <b>2010</b> , 30, 1110-7	15
1833	Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. <b>2010</b> , 17, 759-66	69

1832	iPSC lines that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability. <b>2010</b> , 20, 1092-5	48
1831	DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy. <b>2010</b> , 18, 238-40	5
1830	Potentialities of induced pluripotent stem (iPS) cells for treatment of diseases. <b>2010</b> , 10, 756-62	5
1829	Gene therapy for $\beta$ -thalassaemia: the continuing challenge. <b>2010</b> , 12, e31	17
1828	Human induced pluripotent stem cells: a review of the US patent landscape. <b>2010</b> , 5, 581-91	15
1827	Transcriptional Control of Neural Crest Development. <b>2010</b> , 1, 1-227	26
1826	Stem cell approaches for the treatment of type 1 diabetes mellitus. <b>2010</b> , 156, 169-79	25
1825	Pluripotent stem cell-derived natural killer cells for cancer therapy. <b>2010</b> , 156, 147-54	46
1824	Stem cell ping-pong: the politics of science. <b>2010</b> , 156, 315-6	0
1823	Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. <b>2010</b> , 5, e11853	154
1822	Induced Pluripotent Stem Cells-A New Foundation in Medicine. <b>2010</b> , 2, 202-217	15
1821	Quantitative proteome analysis of pluripotent cells by iTRAQ mass tagging reveals post-transcriptional regulation of proteins required for ES cell self-renewal. <b>2010</b> , 9, 2238-51	35
1820	Complete genetic correction of ips cells from Duchenne muscular dystrophy. <b>2010</b> , 18, 386-93	202
1819	Human-induced pluripotent stem cells produced under xeno-free conditions. <b>2010</b> , 19, 1221-9	36
1818	Induced pluripotent stem cells: a new era for hepatology. <b>2010</b> , 53, 738-51	69
1817	Barriers to the successful treatment of liver disease by hepatocyte transplantation. <b>2010</b> , 53, 769-74	122
1816	Rapid and efficient reprogramming of human amnion-derived cells into pluripotency by three factors OCT4/SOX2/NANOG. <b>2010</b> , 80, 123-9	74
1815	Generation of human induced pluripotent stem cells from a Bombay individual: moving towards "universal-donor" red blood cells. <b>2010</b> , 391, 329-34	27

1814	Future approaches in periodontal regeneration: gene therapy, stem cells, and RNA interference. <b>2010</b> , 54, 141-55	19
1813	Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. <b>2010</b> , 6, 71-9	762
1812	Reprogramming of human peripheral blood cells to induced pluripotent stem cells. <b>2010</b> , 7, 20-4	318
1811	Reprogramming of T cells from human peripheral blood. <b>2010</b> , 7, 15-9	251
1810	Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. <b>2010</b> , 7, 249-57	347
1809	Lab-specific gene expression signatures in pluripotent stem cells. <b>2010</b> , 7, 258-62	171
1808	Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. <b>2010</b> , 7, 263-9	133
1807	Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. <b>2010</b> , 7, 521-31	595
1806	Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. <b>2010</b> , 7, 618-30	2025
1805	A mesoderm-derived precursor for mesenchymal stem and endothelial cells. <b>2010</b> , 7, 718-29	218
1804	MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. <b>2010</b> , 7, 671-81	84
1803	Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. <b>2010</b> , 31, 36-45	158
1802	Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. <b>2010</b> , 344, 16-25	145
1801	iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. <b>2010</b> , 19, 469-80	257
1800	Converting human pluripotent stem cells into beta-cells: recent advances and future challenges. <b>2010</b> , 15, 54-60	39
1799	Induced pluripotent stem cells--alchemist's tale or clinical reality?. <b>2010</b> , 12, 25	13
1798	Promotion of direct reprogramming by transformation-deficient Myc. <b>2010</b> , 107, 14152-7	297
1797	Dental pulp cells for induced pluripotent stem cell banking. <b>2010</b> , 89, 773-8	176

1796	Towards organ printing: engineering an intra-organ branched vascular tree. <b>2010</b> , 10, 409-20		177
1795	Induced pluripotent stem cells: characteristics and perspectives. <b>2010</b> , 123, 107-26		7
1794	Modulation of embryonic stem cell fate and somatic cell reprogramming by small molecules. <b>2010</b> , 21, 26-36		8
1793	Induced pluripotent stem cells: developmental biology to regenerative medicine. <b>2010</b> , 7, 700-10		110
1792	Induced pluripotency: history, mechanisms, and applications. <b>2010</b> , 24, 2239-63		576
1791	Master stem cell transcription factors and signaling regulation. <b>2010</b> , 12, 3-13		38
1790	Induced pluripotent stem cells. <b>2010</b> , 476, 309-25		13
1789	Small molecules and stem cells. Potency and lineage commitment: the new quest for the fountain of youth. <b>2010</b> , 53, 3439-53		28
1788	Derivation of human embryonic stem cell lines after blastocyst microsurgery. <b>2010</b> , 88, 479-90		15
1787	Regulatory considerations for the development of autologous induced pluripotent stem cell therapies. <b>2010</b> , 5, 569-79		21
1786	Proteome of mouse oocytes at different developmental stages. <b>2010</b> , 107, 17639-44		167
1785	Electrostatic surface modifications to improve gene delivery. <b>2010</b> , 7, 535-50		60
1784	Experimental approaches for the generation of induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , <b>2010</b> , 1, 26	8.3	26
1783	Bioreactor Systems for Tissue Engineering II. <b>2010</b> ,		1
1782	Reversine enhances generation of progenitor-like cells by dedifferentiation of annulus fibrosus cells. <b>2010</b> , 16, 1443-55		33
1781	ROCK inhibition facilitates the generation of human-induced pluripotent stem cells in a defined, feeder-, and serum-free system. <b>2010</b> , 12, 641-53		48
1780	Molecular mechanisms of pluripotency and reprogramming. <i>Stem Cell Research and Therapy</i> , <b>2010</b> , 1, 33	8.3	10
1779	Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. <b>2010</b> , 107, 4335-40		812



1778	Pluripotent human stem cells: A novel tool in drug discovery. <b>2010</b> , 24, 99-108	21
1777	Proteomics and pluripotency. <b>2011</b> , 46, 493-506	12
1776	Generation of red blood cells from human induced pluripotent stem cells. <b>2011</b> , 20, 1639-47	119
1775	Induced pluripotent stem cells: progress towards a biomedical application. <b>2011</b> , 9, 1265-9	2
1774	Early senescence is not an inevitable fate of human-induced pluripotent stem-derived cells. <b>2011</b> , 13, 361-70	12
1773	Functional modules distinguish human induced pluripotent stem cells from embryonic stem cells. <b>2011</b> , 20, 1937-50	25
1772	Cell Cycle in Development. <b>2011</b> ,	6
1771	Prospects of induced pluripotent stem cell technology in regenerative medicine. <b>2011</b> , 17, 115-24	28
1770	Stem cell therapy for cardiac disease: what can be learned from oncology. <b>2011</b> , 7, 345-55	3
1769	Regenera $\tilde{c}$ ı̃n celular cardı̃ca. <b>2011</b> , 18, 207-215	4
1768	Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage. <b>2011</b> , 131, 857-64	81
1767	Simple generation of human induced pluripotent stem cells using poly-beta-amino esters as the non-viral gene delivery system. <b>2011</b> , 286, 12417-28	60
1766	Regenerative medicine and the gut. <b>2011</b> , 141, 1162-6, 1166.e1-2	9
1765	Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. <b>2011</b> , 21, 486-501	137
1764	Critical Roles of Stromal Fibroblasts in the Cancer Microenvironments. <b>2011</b> , 3-19	
1763	Stem Cells Signaling Pathways in the Heart. <b>2011</b> , 407-429	
1762	Stem cell therapy for retinal diseases: update. <i>Stem Cell Research and Therapy</i> , <b>2011</b> , 2, 50	8.3 29
1761	Chemical strategies for stem cell biology and regenerative medicine. <b>2011</b> , 13, 73-90	52

1760	Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. <b>2011</b> , 10, 915-29		358
1759	Cell cycle adaptations and maintenance of genomic integrity in embryonic stem cells and induced pluripotent stem cells. <b>2011</b> , 53, 415-58		22
1758	Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. <b>2011</b> , 6, 1251-73		57
1757	Male Germline Stem Cells: Developmental and Regenerative Potential. <b>2011</b> ,		4
1756	Tissue Engineering in Regenerative Medicine. <b>2011</b> ,		5
1755	Regenerating the Heart. <b>2011</b> ,		1
1754	Translational Stem Cell Research. <b>2011</b> ,		1
1753	Stem Cells & Regenerative Medicine. <b>2011</b> ,		5
1752	Epigenetics and Disease. <b>2011</b> ,		3
1751	Small molecules in cellular reprogramming and differentiation. <b>2011</b> , 67, 253-66		20
1750	Human pluripotent stem cells for genetic disease modeling and drug screening. <b>2011</b> , 6, 607-22		4
1749	Novel paths towards neural cellular products for neurological disorders. <b>2011</b> , 6, 25-30		7
1748	Generation of Induced Pluripotent Stem Cells from Somatic Cells. <b>2011</b> , 71-82		
1747	Human pluripotent stem cells in pharmacological and toxicological screening: new perspectives for personalized medicine. <b>2011</b> , 8, 347-364		7
1746	Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation. <i>Stem Cell Research and Therapy</i> , <b>2011</b> , 2, 48	8.3	50
1745	Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. <i>Stem Cell Research and Therapy</i> , <b>2011</b> , 2, 46	8.3	25
1744	Therapeutic potential of lung epithelial progenitor cells derived from embryonic and induced pluripotent stem cells. <b>2011</b> , 62, 95-105		33
1743	Induced pluripotent stem cells: emerging techniques for nuclear reprogramming. <b>2011</b> , 15, 1799-820		22

1742	Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming. <b>2011</b> , 445-468	
1741	Toward clinical application of stem cells for cardiac regeneration. <b>2011</b> , 20, 173-9	11
1740	Stem Cell Therapy to Treat Heart Failure. <b>2011</b> , 407-423	1
1739	Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. <b>2011</b> , 286, 4760-71	251
1738	Historical origins of transdifferentiation and reprogramming. <b>2011</b> , 9, 504-16	139
1737	Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia?. <b>2011</b> , 128, 8-13	10
1736	Constructing and deconstructing stem cell models of neurological disease. <b>2011</b> , 70, 626-44	124
1735	Induced pluripotent stem cells: a new tool to confront the challenge of neuropsychiatric disorders. <b>2011</b> , 60, 1355-63	37
1734	Induced Pluripotent Stem Cells. <b>2011</b> , 187-205	
1733	Proteomic and phosphoproteomic comparison of human ES and iPS cells. <b>2011</b> , 8, 821-7	229
1732	Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. <b>2011</b> , 13, 1214-23	200
1731	Current progress and potential practical application for human pluripotent stem cells. <b>2011</b> , 292, 153-96	7
1730	Cardiac cell therapies: the next generation. <b>2011</b> , 29, 2-16	14
1729	Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. <b>2011</b> , 26, 216-24	31
1728	Sources of retinal pigment epithelium (RPE) for replacement therapy. <b>2011</b> , 95, 445-9	29
1727	Type 1 diabetes: etiology, immunology, and therapeutic strategies. <b>2011</b> , 91, 79-118	668
1726	The prospect of induced pluripotent stem cells for diabetes mellitus treatment. <b>2011</b> , 2, 197-210	21
1725	Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. <b>2011</b> , 108, 18283-8	205

1724	Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. <b>2011</b> , 25, 2248-53	326
1723	Cellular therapy for fanconi anemia: the past, present, and future. <b>2011</b> , 17, S109-14	19
1722	Inducing iPSCs to escape the dish. <b>2011</b> , 9, 103-11	53
1721	Generation of iPS cells using a BacMam multigene expression system. <b>2011</b> , 36, 209-22	18
1720	Ethics in Regenerative Medicine. <b>2011</b> , 401-408	
1719	Stem Cell Therapy for Neuromuscular Diseases. <b>2011</b> ,	2
1718	Cell Therapy for Parkinson's Disease: Status and Perspectives. <b>2011</b> ,	
1717	Induced Pluripotent Stem Cells as Human Disease Models. <b>2011</b> , 46, 369-383	3
1716	Generation of Human Induced Pluripotent Stem (iPS) Cells from Liver Progenitor Cells by Two Chemicals and the Clinical Application. <b>2011</b> ,	
1715	The Musashi1 RNA-Binding Protein: A Critical Regulator in Glioblastoma. <b>2011</b> ,	
1714	Stem-Cell Therapy for Retinal Diseases. <b>2011</b> ,	
1713	Generation of ICM-Type Human iPS Cells from CD34+ Cord Blood Cells. <b>2011</b> ,	
1712	Stem Cells for HUMAN Hepatic Tissue Engineering. <b>2011</b> ,	
1711	Battle for Pluripotency: Derivation of Induced Pluripotent Stem Cells. <b>2011</b> , 1, 123-130	
1710	From Pluripotent Stem Cells to Lineage-Specific Chondrocytes: Essential Signalling and Cellular Intermediates. <b>2011</b> ,	3
1709	Rapid Prototyping of Engineered Heart Tissues through Miniaturization and Phenotype-Automation. <b>2011</b> ,	
1708	Advances in the Combined Use of Adult Cell Therapy and Scaffolds for Brain Tissue Engineering. <b>2011</b> ,	2
1707	Induced Pluripotent Stem Cells. <b>2011</b> , 241-252	1

1706	Hepatic differentiation of murine disease-specific induced pluripotent stem cells allows disease modelling in vitro. <b>2011</b> , 2011, 924782	6
1705	Induced pluripotent stem cells in cardiovascular medicine. <b>2011</b> , 2011, 348960	17
1704	Patient-specific pluripotent stem cells in neurological diseases. <b>2011</b> , 2011, 212487	29
1703	Induced Pluripotent Stem Cells. <b>2011</b> , 203-215	1
1702	Stem cell transplantation: Current and prospective therapies to treat leukaemia. <b>2011</b> , 1,	
1701	The Past, Present and Future of Induced Pluripotent Stem Cells. <b>2011</b> ,	
1700	New Techniques in the Generation of Induced Pluripotent Stem Cells. <b>2011</b> ,	
1699	Induced pluripotent stem cells and personalized medicine: current progress and future perspectives. <b>2011</b> , 44, 245-55	55
1698	Induced Pluripotent Stem Cells and Their Application to Personalized Therapy. <b>2011</b> , 377-388	
1697	Trends and clinical application of induced pluripotent stem cells. <b>2011</b> , 54, 502	0
1696	A virus-free poly-promoter vector induces pluripotency in quiescent bovine cells under chemically defined conditions of dual kinase inhibition. <b>2011</b> , 6, e24501	59
1695	Estimating the quality of reprogrammed cells using ES cell differentiation expression patterns. <b>2011</b> , 6, e15336	1
1694	Efficient feeder-free episomal reprogramming with small molecules. <b>2011</b> , 6, e17557	159
1693	A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. <b>2011</b> , 6, e18293	309
1692	Integration-free iPS cells engineered using human artificial chromosome vectors. <b>2011</b> , 6, e25961	58
1691	Efficient generation of fully reprogrammed human iPS cells via polycistronic retroviral vector and a new cocktail of chemical compounds. <b>2011</b> , 6, e26592	32
1690	Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. <b>2011</b> , 6, e27956	64
1689	Liver Tissue Engineering. <b>2011</b> , 575-585	2

1688	Red blood cells from induced pluripotent stem cells: hurdles and developments. <b>2011</b> , 18, 249-53	29
1687	Induced pluripotent stem (iPS) cell research overview. <b>2011</b> , 20, 15-9	24
1686	Cell reprogramming: a new chemical approach to stem cell biology and tissue regeneration. <b>2011</b> , 12, 146-50	8
1685	Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system. <b>2011</b> , 20, 983-1001	6
1684	iPS cells for transplantation. <b>2011</b> , 16, 96-100	7
1683	Stem cells in cardiovascular regeneration: from preservation of endogenous repair to future cardiovascular therapies. <b>2011</b> , 17, 3280-94	11
1682	Stem cell-derived islet cells for transplantation. <b>2011</b> , 16, 76-82	23
1681	Development unchained: how cellular reprogramming is redefining our view of cell fate and identity. <b>2011</b> , 94, 298-322	5
1680	Pluripotente Stammzellquellen heute. <b>2011</b> , 1, 15-21	
1679	Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. <b>2011</b> , 118, 1797-800	51
1678	Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. <b>2011</b> , 118, 1801-5	73
1677	In vitro pathological modelling using patient-specific induced pluripotent stem cells: the case of progeria. <b>2011</b> , 39, 1775-9	12
1676	Induced pluripotent stem cell technology and stem cell therapy for diabetes. <b>2011</b> , 2, 3-7	4
1675	Will cell reprogramming resolve the embryonic stem cell controversy? A narrative review. <b>2011</b> , 155, 114-21	14
1674	Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease. <b>2011</b> , 10, 449-58	21
1673	From embryonic stem cells to iPS - an ethical perspective. <b>2011</b> , 44 Suppl 1, 70-84	5
1672	Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. <b>2011</b> , 46, 438-47	97
1671	Harnessing the potential of induced pluripotent stem cells for regenerative medicine. <b>2011</b> , 13, 497-505	405

1670	Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. <b>2011</b> , 13, 541-9	442
1669	A more efficient method to generate integration-free human iPS cells. <b>2011</b> , 8, 409-12	1358
1668	Chemically defined conditions for human iPSC derivation and culture. <b>2011</b> , 8, 424-9	949
1667	Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. <b>2011</b> , 6, 78-88	152
1666	Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. <b>2011</b> , 6, 296-313	123
1665	Feeder-dependent and feeder-independent iPS cell derivation from human and mouse adipose stem cells. <b>2011</b> , 6, 346-58	75
1664	The tumorigenicity of human embryonic and induced pluripotent stem cells. <b>2011</b> , 11, 268-77	667
1663	Methods for making induced pluripotent stem cells: reprogramming à la carte. <b>2011</b> , 12, 231-42	366
1662	Turning straw into gold: directing cell fate for regenerative medicine. <b>2011</b> , 12, 243-52	218
1661	Progress in understanding reprogramming to the induced pluripotent state. <b>2011</b> , 12, 253-65	220
1660	iPS cells in type 1 diabetes research and treatment. <b>2011</b> , 89, 750-3	24
1659	Human induced pluripotent stem cells: the past, present, and future. <b>2011</b> , 89, 741-5	26
1658	Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. <b>2011</b> , 21, 518-29	363
1657	Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. <b>2011</b> , 21, 530-45	140
1656	Reprogramming of mouse and human somatic cells by high-performance engineered factors. <b>2011</b> , 12, 373-8	75
1655	Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. <b>2011</b> , 18, 283-93	89
1654	Induced pluripotent stem cells as a next-generation biomedical interface. <b>2011</b> , 91, 972-7	22
1653	Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications. <b>2011</b> , 25, 1095-102	21

1652	Population-based and family-based association studies of ZNF804A locus and schizophrenia. <b>2011</b> , 16, 360-1	57
1651	Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. <b>2011</b> , 16, 358-60	137
1650	Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. <b>2011</b> , 471, 68-73	1241
1649	Somatic coding mutations in human induced pluripotent stem cells. <b>2011</b> , 471, 63-7	998
1648	Copy number variation and selection during reprogramming to pluripotency. <b>2011</b> , 471, 58-62	753
1647	Karyotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. <b>2011</b> , 29, 313-4	222
1646	Genomic instability in induced stem cells. <b>2011</b> , 18, 745-53	112
1645	Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation). <b>2011</b> , 129, 29-49	83
1644	Induced pluripotent stem cells: a new revolution for clinical neurology?. <b>2011</b> , 10, 383-94	86
1643	Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. <b>2011</b> , 76, 270-5	39
1642	The generation of iPS cells using non-viral magnetic nanoparticle based transfection. <b>2011</b> , 32, 6683-91	79
1641	Gene therapy, gene targeting and induced pluripotent stem cells: applications in monogenic disease treatment. <b>2011</b> , 29, 1-10	20
1640	The detection of a transgenic soybean biochip using gold label silver stain technology. <b>2011</b> , 21, 6905-8	8
1639	Human induced pluripotent stem cells derived from fetal neural stem cells successfully undergo directed differentiation into cartilage. <b>2011</b> , 20, 1099-112	73
1638	Making Germ Cells from Human Embryonic Stem Cells. <b>2011</b> , 49-86	
1637	Immunological applications of stem cells in type 1 diabetes. <b>2011</b> , 32, 725-54	105
1636	New approaches for the generation of induced pluripotent stem cells. <b>2011</b> , 11, 569-79	21
1635	Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. <b>2011</b> , 20, R109-15	142



1634	The challenges and promises of blood engineered from human pluripotent stem cells. <b>2011</b> , 63, 331-41	11
1633	Advancements in reprogramming strategies for the generation of induced pluripotent stem cells. <b>2011</b> , 28, 291-301	27
1632	Promises of stem cell therapy for retinal degenerative diseases. <b>2011</b> , 249, 1439-48	31
1631	Present state and future perspectives of using pluripotent stem cells in toxicology research. <b>2011</b> , 85, 79-117	119
1630	An improved technique for chromosomal analysis of human ES and iPS cells. <b>2011</b> , 7, 471-7	39
1629	Surface marker epithelial cell adhesion molecule and E-cadherin facilitate the identification and selection of induced pluripotent stem cells. <b>2011</b> , 7, 722-35	48
1628	Application of iPS in assisted reproductive technology: sperm from somatic cells?. <b>2011</b> , 7, 714-21	14
1627	A comparison of stem cells for therapeutic use. <b>2011</b> , 7, 782-96	19
1626	Functional myogenic engraftment from mouse iPS cells. <b>2011</b> , 7, 948-57	96
1625	Generation of pig iPS cells: a model for cell therapy. <b>2011</b> , 4, 121-30	76
1624	Mechanism and methods to induce pluripotency. <b>2011</b> , 2, 792-9	13
1623	Cell therapy for spinal cord injury by neural stem/progenitor cells derived from iPS/ES cells. <b>2011</b> , 8, 668-76	56
1622	Potential pathways to restore cell mass: pluripotent stem cells, reprogramming, and endogenous regeneration. <b>2011</b> , 11, 392-401	17
1621	Cancer stem cell subsets and their relationships. <b>2011</b> , 9, 50	23
1620	Possible linkages between the inner and outer cellular states of human induced pluripotent stem cells. <b>2011</b> , 5 Suppl 1, S17	19
1619	Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology. <b>2011</b> , 11, 3947-61	17
1618	A targeted NKX2.1 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. <b>2011</b> , 29, 462-73	84
1617	Concise review: induced pluripotent stem cells and lineage reprogramming: prospects for bone regeneration. <b>2011</b> , 29, 555-63	47

1616	Concise review: stem cells for the treatment of cerebellar-related disorders. <b>2011</b> , 29, 564-9	6
1615	Concise review: non-cell autonomous reprogramming: a nucleic acid-free approach to induction of pluripotency. <b>2011</b> , 29, 1013-20	8
1614	Brief report: evaluating the potential of putative pluripotent cells derived from human testis. <b>2011</b> , 29, 1304-9	22
1613	Optic vesicle-like structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment. <b>2011</b> , 29, 1206-18	321
1612	In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. <b>2011</b> , 29, 1717-26	261
1611	Site-specific recombinase strategy to create induced pluripotent stem cells efficiently with plasmid DNA. <b>2011</b> , 29, 1696-704	33
1610	Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells. <b>2011</b> , 29, 1933-41	37
1609	Mediators and dynamics of DNA methylation. <b>2011</b> , 3, 281-98	7
1608	Mechanistic insights into reprogramming to induced pluripotency. <b>2011</b> , 226, 868-78	38
1607	Turning skin into brain: using patient-derived cells to model X-linked adrenoleukodystrophy. <b>2011</b> , 70, 350-2	2
1606	Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. <b>2011</b> , 79, 426-35	49
1605	Primer and interviews: promises and realities of induced pluripotent stem cells. <b>2011</b> , 240, 2034-41	1
1604	Chemische Kontrolle des Schicksals und Entwicklungspotenzials von Stammzellen. <b>2011</b> , 123, 210-256	13
1603	Chemical control of stem cell fate and developmental potential. <b>2011</b> , 50, 200-42	112
1602	Viable mice produced from three-factor induced pluripotent stem (iPS) cells through tetraploid complementation. <b>2011</b> , 21, 546-9	27
1601	iPSCs: Unstable origins?. <b>2011</b> , 19, 1188-90	9
1600	Functional multipotency of stem cells: a conceptual review of neurotrophic factor-based evidence and its role in translational research. <b>2011</b> , 9, 574-85	38
1599	The future of induced pluripotent stem cells for cardiac therapy and drug development. <b>2011</b> , 17, 3258-70	16

1598	Generation of melanocytes from induced pluripotent stem cells. <b>2011</b> , 131, 2458-66	34
1597	Pluripotente Stammzellquellen heute. <b>2011</b> , 32, 338-344	
1596	In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. <b>2011</b> , 71, 4742-7	40
1595	Induced pluripotent stem cells: opportunities and challenges. <b>2011</b> , 366, 2198-207	191
1594	Efficient generation of nonhuman primate induced pluripotent stem cells. <b>2011</b> , 20, 795-807	22
1593	Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. <b>2011</b> , 71, 5030-9	78
1592	Defining pluripotent stem cells through quantitative proteomic analysis. <b>2011</b> , 8, 29-42	25
1591	Human endometrial cells express elevated levels of pluripotent factors and are more amenable to reprogramming into induced pluripotent stem cells. <b>2011</b> , 152, 1080-9	34
1590	The evolving biology of cell reprogramming. <b>2011</b> , 366, 2183-97	22
1589	Stem cells as a therapeutic tool for the blind: biology and future prospects. <b>2011</b> , 278, 3009-16	41
1588	Modelling familial dysautonomia in human induced pluripotent stem cells. <b>2011</b> , 366, 2286-96	26
1587	Modeling neurological diseases using patient-derived induced pluripotent stem cells. <b>2011</b> , 6, 363-373	30
1586	The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. <b>2011</b> , 6, 1399-413	68
1585	Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?. <b>2011</b> , 3, 716-29	257
1584	Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. <b>2011</b> , 19, 782-9	187
1583	Insulin-producing surrogate $\beta$ cells from embryonic stem cells: are we there yet?. <b>2011</b> , 19, 1759-68	40
1582	FULLY-PLURIPOTENT iPS CELLS: MOUSE TETRAPLOID COMPLEMENTATION, ETHICAL HUMAN ES-LIKE CELLS AND REPRODUCTIVE CLONING BAN. <b>2011</b> , 06, 21-32	
1581	FROM TETRAPLOID-COMPLEMENTING MOUSE $\beta$ S CELLS TO FULLY PLURIPOTENT PATIENT-SPECIFIC iPS CELLS. <b>2011</b> , 06, 5-20	

1580	Cellular reprogramming: recent advances in modeling neurological diseases. <b>2011</b> , 31, 16070-5	18
1579	Cell Therapy for Blood Substitutes. <b>2011</b> , 747-760	
1578	The different shades of mammalian pluripotent stem cells. <b>2011</b> , 17, 254-71	35
1577	Advances and Technical Standards in Neurosurgery. <b>2011</b> ,	
1576	Potential applications of germline cell-derived pluripotent stem cells in organ regeneration. <b>2011</b> , 7, 116-22	11
1575	Virus-free iPS-derived cardiomyocytes: a new piece in the puzzle of patient-tailored therapies. <b>2011</b> , 91, 559-60	1
1574	Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. <b>2011</b> , 91, 577-86	72
1573	The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. <i>Stem Cell Research and Therapy</i> , <b>2011</b> , 2, 32	8.3 20
1572	Amniocytes can serve a dual function as a source of iPS cells and feeder layers. <b>2011</b> , 20, 962-74	44
1571	Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. <b>2011</b> , 108, 1146-56	58
1570	Pluripotent stem cells and reprogrammed cells in farm animals. <b>2011</b> , 17, 474-97	41
1569	Developmental and regenerative biology of multipotent cardiovascular progenitor cells. <b>2011</b> , 108, 353-64	69
1568	Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. <b>2011</b> , 108, 6537-42	136
1567	Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. <b>2011</b> , 117, e109-19	196
1566	BACK MATTER. <b>2011</b> , 383-428	
1565	Stem cell therapy for digestive tract diseases: current state and future perspectives. <b>2011</b> , 20, 1113-29	21
1564	Stem cell technology for the study and treatment of motor neuron diseases. <b>2011</b> , 6, 201-13	60
1563	Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. <b>2011</b> , 108, 14234-9	431

1562	Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells. <b>2011</b> , 23, 65-74	32
1561	Modeling neurological disorders by human induced pluripotent stem cells. <b>2011</b> , 2011, 350131	11
1560	Framing pluripotency: iPS cells and the shaping of stem cell science. <b>2011</b> , 30, 415-431	17
1559	A case of cellular alchemy: lineage reprogramming and its potential in regenerative medicine. <b>2012</b> , 4, 190-6	8
1558	New Treatment Modalities by Disease-Specific and Patient-Specific Induced Pluripotent Stem Cells. <b>2012</b> , 199-225	
1557	Phosphorylation regulates human OCT4. <b>2012</b> , 109, 7162-8	76
1556	Human pluripotent stem cells: applications and challenges in neurological diseases. <b>2012</b> , 3, 267	30
1555	Feline neural progenitor cells II: use of novel plasmid vector and hybrid promoter to drive expression of glial cell line-derived neurotrophic factor transgene. <b>2012</b> , 2012, 604982	
1554	Novel molecular therapies for heritable skin disorders. <b>2012</b> , 132, 820-8	49
1553	Sources of mesenchymal stem cells: current and future clinical use. <b>2013</b> , 130, 267-86	4
1552	Rapid hierarchical assembly of medium-size DNA cassettes. <b>2012</b> , 40, e92	23
1551	Basic principles in generating induced pluripotent stem cells. <b>2012</b> , 49-63	0
1550	Induced pluripotent stem cells from ataxia-telangiectasia recapitulate the cellular phenotype. <b>2012</b> , 1, 523-35	54
1549	Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. <b>2012</b> , 1, 451-61	68
1548	Endothelial cardiac cell therapy: large-animal studies and the elephant in the room. <b>2012</b> , 111, 824-6	1
1547	Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent. <b>2012</b> , 1, 409-21	46
1546	Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. <b>2012</b> , 25, 125-30	53
1545	Craniofacial reconstruction with induced pluripotent stem cells. <b>2012</b> , 23, 623-6	4

1544	Pluripotent stem cells in research and treatment of hemoglobinopathies. <b>2012</b> , 2, a011841	10
1543	Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. <b>2012</b> , 111, 1125-36	341
1542	Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. <b>2012</b> , 2, 335-45	92
1541	Steering a new course for stem cell research: NIH's intramural Center for Regenerative Medicine. <b>2012</b> , 1, 15-7	11
1540	Engineered MSCs from Patient-Specific iPS Cells. <b>2013</b> , 130, 1-17	8
1539	On-Chip Cellomics: Constructive Understanding of Multicellular Network Using On-Chip Cellomics Technology. <b>2012</b> , 51, 08KA03	
1538	Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. <b>2012</b> , 20, 204-13	59
1537	Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. <b>2012</b> , 23, 238-42	46
1536	NUCLEAR REPROGRAMMING AND THE CURRENT CHALLENGES IN ADVANCING PERSONALIZED PLURIPOTENT STEM CELL-BASED THERAPIES. <b>2012</b> , 07, 1230002	3
1535	Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences. <b>2012</b> , 86, 4463-7	17
1534	Regenerative Biology of the Spine and Spinal Cord. <b>2012</b> ,	
1533	Methods of cell purification: a critical juncture for laboratory research and translational science. <b>2012</b> , 195, 26-40	18
1532	Stem cells and regenerative therapies for Parkinson's disease. <b>2012</b> , 2, 79-92	2
1531	The promise of human induced pluripotent stem cells in dental research. <b>2012</b> , 2012, 423868	10
1530	The potential of iPSC cells in synucleinopathy research. <b>2012</b> , 2012, 629230	4
1529	Cellular therapy and bioartificial approaches to liver replacement. <b>2012</b> , 17, 235-40	29
1528	MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. <b>2012</b> , 7, e40938	58
1527	Lung progenitor and stem cell biology and therapy. <b>2012</b> , 463-500	

1526	Inhibition of glycogen synthase kinase-3 promotes efficient derivation of pluripotent stem cells from neonatal mouse testis. <b>2012</b> , 27, 2312-24	10
1525	Selecting and isolating colonies of human induced pluripotent stem cells reprogrammed from adult fibroblasts. <b>2012</b> ,	6
1524	The role of stem cells in muscular dystrophies. <b>2012</b> , 12, 192-205	11
1523	Induced pluripotent stem cells as a disease modeling and drug screening platform. <b>2012</b> , 60, 408-16	140
1522	Gene therapy: implications for craniofacial regeneration. <b>2012</b> , 23, 333-7	17
1521	Genetics, genomics and the power of stem cells to identify novel treatment options in complex diseases. <b>2012</b> , 9, 821-828	
1520	Induction of Pluripotent Stem Cells from Umbilical Cord Blood. <b>2012</b> ,	3
1519	Cell sources for trachea tissue engineering: past, present and future. <b>2012</b> , 7, 851-63	12
1518	Sumoylation is important for stability, subcellular localization, and transcriptional activity of SALL4, an essential stem cell transcription factor. <b>2012</b> , 287, 38600-8	24
1517	Generation of human induced pluripotent stem cells from urine samples. <b>2012</b> , 7, 2080-9	400
1516	Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. <b>2012</b> , 110, 166-77	49
1515	Pluripotent stem cell-derived pancreatic $\beta$ cells: potential for regenerative medicine in diabetes. <b>2012</b> , 7, 583-93	7
1514	Cell transplantation for spinal cord injury focusing on iPSCs. <b>2012</b> , 12, 811-21	12
1513	Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells. <b>2012</b> , 1266, 179-88	8
1512	Pluripotent stem cell-based cancer therapy: promise and challenges. <b>2012</b> , 4, 127ps9	33
1511	The expanding scope of DNA sequencing. <b>2012</b> , 30, 1084-94	237
1510	Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells. <b>2012</b> , 7, 713-20	12
1509	From cellular therapies to tissue reprogramming and regenerative strategies in the treatment of diabetes. <b>2012</b> , 7, 41-8	14

1508	A poor imitation of a natural process: a call to reconsider the iPSC engineering technique. <b>2012</b> , 11, 4536-44	11
1507	Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. <b>2012</b> , 4, 165ra162	150
1506	Residual undifferentiated cells during differentiation of induced pluripotent stem cells in vitro and in vivo. <b>2012</b> , 21, 521-9	34
1505	Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. <b>2012</b> , 96, 391-400	64
1504	Differentiation of human embryonic stem cell-derived retinal progenitors into retinal cells by Sonic hedgehog and/or retinal pigmented epithelium and transplantation into the subretinal space of sodium iodate-injected rabbits. <b>2012</b> , 21, 42-53	37
1503	Dopaminergic differentiation using pluripotent stem cells. <b>2012</b> , 113, 3610-9	7
1502	Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures. <b>2012</b> , 2, 553-67	142
1501	Inducible pluripotent stem cells for the treatment of ischemic stroke: current status and problems. <b>2012</b> , 23, 393-402	10
1500	Epigenetic Modulations of Induced Pluripotent Stem Cells: Novel Therapies and Disease Models. <b>2012</b> , 9, e153-e160	3
1499	Hepatic differentiation of porcine induced pluripotent stem cells in vitro. <b>2012</b> , 194, 369-74	31
1498	Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. <b>2012</b> , 4, 55	29
1497	Progress on stem cell research towards the treatment of Parkinson's disease. <i>Stem Cell Research and Therapy</i> , <b>2012</b> , 3, 11	8.3 14
1496	Investigating cellular identity and manipulating cell fate using induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , <b>2012</b> , 3, 8	8.3 6
1495	Future challenges for patient-specific induced pluripotent stem cells in cardiovascular medicine. <b>2012</b> , 10, 943-5	4
1494	Zinc-finger nuclease-mediated correction of $\beta$ -thalassemia in iPS cells. <b>2012</b> , 120, 3906-14	79
1493	pLR: a lentiviral backbone series to stable transduction of bicistronic genes and exchange of promoters. <b>2012</b> , 68, 179-85	4
1492	In vivo GABA release and kinetics of transgene loss in a GABAergic cell line after long-term transplantation into the rat brain. <b>2012</b> , 203, 244-54	1
1491	Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. <b>2012</b> , 10, 337-44	202



1490	Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. <b>2012</b> , 10, 610-9		322
1489	Advances and applications of induced pluripotent stem cells. <b>2012</b> , 90, 317-25		9
1488	Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells. <b>2012</b> , 109, 16196-201		129
1487	Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. <b>2012</b> , 30, 783-91		453
1486	Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. <b>2012</b> , 11, 264-78		366
1485	Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. <i>Scientific Reports</i> , <b>2012</b> , 2, 657	4.9	114
1484	Maintenance of human embryonic stem cells in media conditioned by human mesenchymal stem cells obviates the requirement of exogenous basic fibroblast growth factor supplementation. <b>2012</b> , 18, 387-96		19
1483	Induced pluripotent stem cells: the new patient?. <b>2012</b> , 13, 713-26		323
1482	Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells. <b>2012</b> , 180, 2084-96		21
1481	Cross talk between the Notch signaling and noncoding RNA on the fate of stem cells. <b>2012</b> , 111, 175-93		10
1480	Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. <b>2012</b> , 7, 2029-40		245
1479	Assessing iPSC reprogramming methods for their suitability in translational medicine. <b>2012</b> , 113, 3061-8		76
1478	Cells derived from murine induced pluripotent stem cells (iPSC) by treatment with members of TGF-beta family give rise to osteoblasts differentiation and form bone in vivo. <b>2012</b> , 13, 35		40
1477	Progress and bottleneck in induced pluripotency. <b>2012</b> , 1, 5		3
1476	Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. <b>2012</b> , 12, 593-608		423
1475	Nanoparticles for Gene Delivery into Stem Cells and Embryos. <b>2012</b> , 51-85		5
1474	Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures. <b>2012</b> , 9, 509-16		84
1473	Small molecules, big roles -- the chemical manipulation of stem cell fate and somatic cell reprogramming. <b>2012</b> , 125, 5609-20		117

1472	Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application—And Back Again. <b>2012</b> , 113-152	1
1471	Generation of induced pluripotent stem cells from somatic cells. <b>2012</b> , 111, 1-26	17
1470	Functional cardiac tissue engineering. <b>2012</b> , 7, 187-206	87
1469	Reprogramming of somatic cells. <b>2012</b> , 111, 51-82	10
1468	Mouse-induced pluripotent stem cells. <b>2012</b> , 55, 395-411	
1467	Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. <b>2012</b> , 7, 2013-21	123
1466	Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. <b>2012</b> , 31, 4898-911	244
1465	Integration-Free Method for the Generation of Human Induced Pluripotent Stem Cells. <b>2012</b> , 165-173	
1464	Methods for Evaluating Human Induced Pluripotent Stem Cells. <b>2012</b> , 175-184	
1463	Induced Pluripotent Stem Cells (iPSCs). <b>2012</b> , 11-19	
1462	Molecular Mechanisms of Pluripotency. <b>2012</b> , 21-31	
1461	Stem Cell Biology and Application. <b>2012</b> , 75-89	
1460	Induced Pluripotent Stem Cells. <b>2012</b> ,	
1459	Urine as a source of stem cells. <b>2013</b> , 129, 19-32	11
1458	Cell Therapy for Cardiac Disease. <b>2012</b> , 697-705	
1457	Advances in Induced Pluripotent Stem Cell Biology. <b>2012</b> , 67-84	
1456	Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality. <b>2012</b> , 3, 834-45	12
1455	From cell culture to a cure: pancreatic $\beta$ cell replacement strategies for diabetes mellitus. <b>2012</b> , 7, 685-95	3

1454	Treatment options for diabetes: potential role of stem cells. <b>2012</b> , 98, 361-8	17
1453	Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. <b>2012</b> , 20, 408-16	72
1452	Strategies of Regenerative Medicine. <b>2012</b> , 229-260	
1451	Reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) using retroviral vector with GFP. <b>2012</b> ,	4
1450	Ca <sup>2+</sup> activated K channels-new tools to induce cardiac commitment from pluripotent stem cells in mice and men. <b>2012</b> , 8, 720-40	23
1449	Human-induced pluripotent stem cells: in quest of clinical applications. <b>2012</b> , 52, 193-203	23
1448	In vitro uses of human pluripotent stem cell-derived cardiomyocytes. <b>2012</b> , 5, 581-92	19
1447	Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair. <b>2012</b> , 5, 566-80	16
1446	Induced Pluripotent Stem Cells. <b>2012</b> ,	2
1445	Advances in Stem Cell Research. <b>2012</b> ,	1
1444	Adult and Embryonic Stem Cells. <b>2012</b> ,	1
1443	Regenerative Therapy Using Blood-Derived Stem Cells. <b>2012</b> ,	2
1442	Neural Development and Stem Cells. <b>2012</b> ,	
1441	Human Embryonic and Induced Pluripotent Stem Cells. <b>2012</b> ,	5
1440	Human induced pluripotent stem cells derived under feeder-free conditions display unique cell cycle and DNA replication gene profiles. <b>2012</b> , 21, 206-16	20
1439	Stem cells and spinal cord injury repair. <b>2012</b> , 760, 53-73	23
1438	Human ESC/iPSC-based "Omics" and Bioinformatics for Translational Research. <b>2012</b> , 9, e161-e170	4
1437	Stem Cells and Cancer Stem Cells, Volume 3. <b>2012</b> ,	1

1436 Induced Pluripotent Stem Cells in Brain Diseases. **2012,**

1435	Establishment of transgene-free induced pluripotent stem cells reprogrammed from human stem cells of apical papilla for neural differentiation. <i>Stem Cell Research and Therapy</i> , <b>2012</b> , 3, 43	8.3	29
1434	Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. <i>Stem Cell Research and Therapy</i> , <b>2012</b> , 3, 14	8.3	38
1433	Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. <b>2012</b> , 7, e35824		55
1432	Development of an all-in-one inducible lentiviral vector for gene specific analysis of reprogramming. <b>2012</b> , 7, e41007		27
1431	Human pluripotent stem cell-derived cardiomyocytes: response to TTX and lidocain reveals strong cell to cell variability. <b>2012</b> , 7, e45963		40
1430	Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. <b>2012</b> , 7, e52787		217
1429	Induced pluripotent stem cells generated from human adipose-derived stem cells using a non-viral polycistronic plasmid in feeder-free conditions. <b>2012</b> , 7, e48161		30
1428	A synthetic, xeno-free peptide surface for expansion and directed differentiation of human induced pluripotent stem cells. <b>2012</b> , 7, e50880		69
1427	Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources. <b>2012</b> , 1, 83-90		1
1426	Technological progress in generation of induced pluripotent stem cells for clinical applications. <b>2012</b> , 2012, 417809		9
1425	X-chromosome inactivation in rett syndrome human induced pluripotent stem cells. <b>2012</b> , 3, 24		35
1424	Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. <b>2012</b> , 2012, 928127		82
1423	State of the art in stem cell research: human embryonic stem cells, induced pluripotent stem cells, and transdifferentiation. <b>2012</b> , 2012, 317632		11
1422	Generation of human $\beta$ -thalassemia induced pluripotent stem cells from amniotic fluid cells using a single excisable lentiviral stem cell cassette. <b>2012</b> , 58, 404-9		38
1421	Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination. <b>2012</b> , 19, 133-141		0
1420	Genetic Modification of Domestic Animals for Agriculture and Biomedical Applications. <b>2012,</b>		1
1419	Cell Transplantation: A Possible Alternative to Orthotopic Liver Transplant (OLT). <b>2012,</b>		

1418	Neural crest stem cells and their potential application in a therapy for deafness. <b>2012</b> , 4, 121-32	12
1417	5.3 Cancer-associated fibroblast integrins as therapeutic targets in the tumor microenvironment.	
1416	Neural and Dopaminergic Differentiation of Human Pluripotent Stem Cells. <b>2012</b> , 265-287	
1415	Notes. 233-302	
1414	Stem Cell Therapies for Type I Diabetes. <b>2012</b> ,	
1413	The gene expression profiles of induced pluripotent stem cells (iPSCs) generated by a non-integrating method are more similar to embryonic stem cells than those of iPSCs generated by an integrating method. <b>2012</b> , 35, 693-700	15
1412	Proteins reprogramming: present and future. <b>2012</b> , 2012, 453185	2
1411	Minimally invasive cell-seeded biomaterial systems for injectable/epicardial implantation in ischemic heart disease. <b>2012</b> , 7, 5969-94	31
1410	A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles. <b>2012</b> , 8, 367-73	51
1409	Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors. <b>2012</b> , 30, 570-9	40
1408	Concise review: Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?. <b>2012</b> , 30, 33-41	157
1407	Concise review: Human cell engineering: cellular reprogramming and genome editing. <b>2012</b> , 30, 75-81	31
1406	Concise review: The magic act of generating induced pluripotent stem cells: many rabbits in the hat. <b>2012</b> , 30, 28-32	14
1405	Concise review: A chemical approach to control cell fate and function. <b>2012</b> , 30, 61-8	83
1404	Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like. <b>2012</b> , 72, 1453-63	19
1403	Regulation of embryonic stem cell pluripotency by heat shock protein 90. <b>2012</b> , 30, 1624-33	46
1402	MiR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling. <b>2012</b> , 30, 1645-54	80
1401	Non viral reprogramming of skeletal myoblasts with valproic acid for pluripotency. <b>2012</b> , 120507125743002	

1400	Chromatin-modifying enzymes as modulators of reprogramming. <b>2012</b> , 483, 598-602	497
1399	Stem cell sources for vascular tissue engineering and regeneration. <b>2012</b> , 18, 405-25	69
1398	Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. <b>2012</b> , 109, E1848-57	1064
1397	The use of integrated and intelligent testing strategies in the prediction of toxic hazard and in risk assessment. <b>2012</b> , 745, 221-53	6
1396	Human Stem Cell Therapy. <b>2012</b> , 187-207	
1395	A review and update on the current status of stem cell therapy and the retina. <b>2012</b> , 102, 133-46	26
1394	Emerging methods for preparing iPS cells. <b>2012</b> , 42, 773-9	33
1393	Human induced pluripotent stem cells--from mechanisms to clinical applications. <b>2012</b> , 90, 735-45	42
1392	Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. <b>2012</b> , 11, 100-9	427
1391	Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives. <b>2012</b> , 96, 98-108	9
1390	Somatic cell reprogramming for regenerative medicine: SCNT vs. iPS cells. <b>2012</b> , 34, 472-6	13
1389	Methods for iPS cell generation for basic research and clinical applications. <b>2012</b> , 7, 789-97	16
1388	Delineating nuclear reprogramming. <b>2012</b> , 3, 329-45	3
1387	Gene, stem cell, and future therapies for orphan diseases. <b>2012</b> , 92, 182-92	15
1386	Non-viral iPSCs: a safe way for therapy?. <b>2012</b> , 3, 241-5	3
1385	Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine. <b>2012</b> , 8, 100-15	44
1384	Stem cells in the treatment of cardiovascular disease--an overview. <b>2012</b> , 8, 494-502	10
1383	Promise and challenges of human iPSC-based hematologic disease modeling and treatment. <b>2012</b> , 95, 601-9	13

1382	Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. <b>2012</b> , 35, 245-60		19
1381	2011 Rita Schaffer lecture: nanoparticles for intracellular nucleic acid delivery. <b>2012</b> , 40, 1408-18		11
1380	Cell-based transplantation strategies to promote plasticity following spinal cord injury. <b>2012</b> , 235, 78-90		106
1379	Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. <b>2012</b> , 33, 412-7		40
1378	Protecting against wayward human induced pluripotent stem cells with a suicide gene. <b>2012</b> , 33, 3195-204		58
1377	The cytotoxic and immunogenic hurdles associated with non-viral mRNA-mediated reprogramming of human fibroblasts. <b>2012</b> , 33, 4059-68		39
1376	Reprogramming of somatic cells via TAT-mediated protein transduction of recombinant factors. <b>2012</b> , 33, 5047-55		66
1375	Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. <i>Stem Cell Research</i> , <b>2012</b> , 8, 259-73	1.6	76
1374	Perspectives on cell reprogramming with RNA. <b>2012</b> , 30, 243-9		8
1373	Stem cells and veterinary medicine: tools to understand diseases and enable tissue regeneration and drug discovery. <b>2012</b> , 191, 19-27		11
1372	Development of pluripotent stem cells for vascular therapy. <b>2012</b> , 56, 288-96		27
1371	Direct reprogramming of human astrocytes into neural stem cells and neurons. <b>2012</b> , 318, 1528-41		122
1370	Twenty years of embryonic stem cell research in farm animals. <b>2012</b> , 47 Suppl 4, 80-5		28
1369	The science of stem cell biobanking: investing in the future. <b>2012</b> , 227, 14-9		8
1368	Pluripotent human stem cells for the treatment of retinal disease. <b>2012</b> , 227, 457-66		69
1367	Human pluripotent stem cells for disease modelling and drug screening. <b>2012</b> , 34, 61-71		52
1366	Cellular reprogramming: a new technology frontier in pharmaceutical research. <b>2012</b> , 29, 35-52		9
1365	The ethics of moral compromise for stem cell research policy. <b>2012</b> , 20, 50-65		4

1364	Application of epigenome-modifying small molecules in induced pluripotent stem cells. <b>2013</b> , 33, 790-822	11
1363	Human induced pluripotent stem cells differentiated into chondrogenic lineage via generation of mesenchymal progenitor cells. <b>2013</b> , 22, 102-13	73
1362	Stem Cell Biology and Regenerative Medicine in Ophthalmology. <b>2013</b> ,	2
1361	Considerations in the Development of Pluripotent Stem Cell-based Therapies. <b>2013</b> , 373-408	
1360	Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. <b>2013</b> , 19, 998-1004	420
1359	Gene therapy clinical trials worldwide to 2012 - an update. <b>2013</b> , 15, 65-77	582
1358	Lack of genotoxicity due to foamy virus vector integration in human iPSCs. <b>2013</b> , 20, 868-73	12
1357	Stem Cells and Nanotechnology in Tissue Engineering and Regenerative Medicine. <b>2013</b> , 1-26	1
1356	Pluripotent Stem Cells. <b>2013</b> ,	4
1355	Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. <b>2013</b> , 51, 237-48	39
1354	Reprogrammed peripheral blood mononuclear cells are able to survive longer in irradiated female mice. <b>2013</b> , 55, 111-9	
1353	Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block. <b>2013</b> , 7, 299-305	4
1352	RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. <b>2013</b> , 6, 956-68	44
1351	The morphofunctional properties of induced pluripotent stem cells derived from human skin fibroblasts and differentiated to dopaminergic neurons. <b>2013</b> , 7, 207-214	3
1350	Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells. <b>2013</b> , 14, 591-602	12
1349	Survival and differentiation of transplanted neural stem cells derived from human induced pluripotent stem cells in a rat stroke model. <b>2013</b> , 22, 304-8	83
1348	Mapping Science. <b>2013</b> , 259-320	
1347	Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. <b>2013</b> , 31, 1600-23	73



1346	Four recombinant pluripotency transcriptional factors containing a protein transduction domain maintained the in vitro pluripotency of chicken embryonic stem cells. <b>2013</b> , 56, 40-50	5
1345	Myocardial regeneration of the failing heart. <b>2013</b> , 18, 815-33	15
1344	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. <b>2013</b> , 16, 1373-82	306
1343	Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. <b>2013</b> , 2, 468-80	76
1342	A chemical logic for reprogramming to pluripotency. <b>2013</b> , 23, 1337-8	3
1341	The promise of stem cells for age-related macular degeneration and other retinal degenerative diseases. <b>2013</b> , 10, e25-e33	2
1340	Microenvironment-evoked cell lineage conversion: Shifting the focus from internal reprogramming to external forcing. <b>2013</b> , 12, 29-38	3
1339	Integration-free methods for generating induced pluripotent stem cells. <b>2013</b> , 11, 284-7	60
1338	Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. <b>2014</b> , 189, 183-93	36
1337	Cellular reprogramming of human peripheral blood cells. <b>2013</b> , 11, 264-74	42
1336	Cold Shock Domain Proteins in Arabidopsis: Functions in Stress Tolerance and Development. <b>2013</b> , 131-142	1
1335	Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research?. <b>2013</b> , 39, 948-54	2
1334	The Advent of the Golden Era of Animal Alternatives. <b>2013</b> , 49-73	1
1333	Improved hepatic differentiation strategies for human induced pluripotent stem cells. <b>2013</b> , 13, 842-55	27
1332	Induced pluripotent stem cells: origins, applications, and future perspectives. <b>2013</b> , 14, 1059-69	19
1331	Mesenchymal Stem Cells - Basics and Clinical Application II. <b>2013</b> ,	
1330	Hypoxia supports reprogramming of mesenchymal stromal cells via induction of embryonic stem cell-specific microRNA-302 cluster and pluripotency-associated genes. <b>2013</b> , 15, 68-79	21
1329	Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free $\beta$ -thalassemia induced pluripotent stem cells. <b>2013</b> , 288, 34671-9	128

1328	Clinical therapy using iPSCs: hopes and challenges. <b>2013</b> , 11, 294-8		38
1327	Mapping Scientific Frontiers. <b>2013</b> ,		37
1326	Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. <i>Stem Cell Research and Therapy</i> , <b>2013</b> , 4, 87	8.3	36
1325	Generation of tooth-like structures from integration-free human urine induced pluripotent stem cells. <b>2013</b> , 2, 6		84
1324	A gutsy task: generating intestinal tissue from human pluripotent stem cells. <b>2013</b> , 58, 1176-84		35
1323	Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering. <b>2013</b> , 1, 6		14
1322	Pluripotent cells in farm animals: state of the art and future perspectives. <b>2012</b> , 25, 103-28		33
1321	NANOG modulates stemness in human colorectal cancer. <b>2013</b> , 32, 4397-405		86
1320	Activation of pluripotency genes by a nanotube-mediated protein delivery system. <b>2013</b> , 80, 1000-8		13
1319	Chick stem cells: current progress and future prospects. <i>Stem Cell Research</i> , <b>2013</b> , 11, 1378-92	1.6	26
1318	Direct reprogramming of adult somatic cells into other lineages: past evidence and future perspectives. <b>2013</b> , 22, 921-44		18
1317	The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. <b>2013</b> , 169, 304-17		53
1316	Human pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: from the genetic, epigenetic, and tissue modeling perspectives. <i>Stem Cell Research and Therapy</i> , <b>2013</b> , 4, 97	8.3	28
1315	Recreating the female reproductive tract in vitro using iPSC technology in a linked microfluidics environment. <i>Stem Cell Research and Therapy</i> , <b>2013</b> , 4 Suppl 1, S13	8.3	25
1314	Transplantation Frontiers. <b>2013</b> , 2058-2077		3
1313	Generation of integration-free neural progenitor cells from cells in human urine. <b>2013</b> , 10, 84-9		161
1312	Differentiation of stem cells into insulin-producing cells: current status and challenges. <b>2013</b> , 61, 149-58		12
1311	The evolving field of induced pluripotency: recent progress and future challenges. <b>2013</b> , 228, 267-75		37

1310	Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. <b>2013</b> , 23, 70-80		143
1309	An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells. <b>2013</b> , 34, 1041-50		26
1308	Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells. <b>2013</b> , 21, 272-81		39
1307	Stem cells as a potential therapy for epilepsy. <b>2013</b> , 244, 59-66		25
1306	Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. <b>2013</b> , 21, 228-39		79
1305	DNA Repair in Normal Stem Cells. <b>2013</b> , 53-87		1
1304	Induced pluripotent stem cells for spinal cord injury therapy: current status and perspective. <b>2013</b> , 34, 11-7		14
1303	Pluripotent stem cells and gene therapy. <b>2013</b> , 161, 284-92		30
1302	Stem cell models for drug discovery and toxicology studies. <b>2013</b> , 27, 17-27		55
1301	Clinical grade iPS cells: need for versatile small molecules and optimal cell sources. <b>2013</b> , 20, 1311-22		24
1300	Generation of induced pluripotent stem cells from human foetal fibroblasts using the Sleeping Beauty transposon gene delivery system. <b>2013</b> , 86, 30-7		38
1299	Pluripotency of induced pluripotent stem cells. <b>2013</b> , 11, 299-303		9
1298	Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. <i>Stem Cell Research</i> , <b>2013</b> , 11, 1335-47	1.6	74
1297	An induced pluripotent stem cell-mediated and integration-free factor VIII expression system. <b>2013</b> , 431, 336-41		20
1296	Advances in cellular reprogramming: moving toward a reprieve from immunogenicity. <b>2013</b> , 155, 14-7		4
1295	Ontogenic development of cardiomyocytes derived from transgene-free human induced pluripotent stem cells and its homology with human heart. <b>2013</b> , 92, 63-71		9
1294	A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. <b>2013</b> , 6, 22-30		103
1293	MicroRNAs in somatic cell reprogramming. <b>2013</b> , 25, 208-14		40

1292	Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. <b>2013</b> , 34, 4235-41	38
1291	Minireview: the diverse roles of nuclear receptors in the regulation of embryonic stem cell pluripotency. <b>2013</b> , 27, 864-78	10
1290	Microcarrier suspension cultures for high-density expansion and differentiation of human pluripotent stem cells to neural progenitor cells. <b>2013</b> , 19, 166-80	84
1289	Lens Differentiation from Embryonic Stem (ES) and Induced Pluripotent Stem (iPS) Cells. <b>2013</b> , 57-73	
1288	Stem Cells and Mitochondria. <b>2013</b> , 183-201	
1287	How induced pluripotent stem cells are redefining personalized medicine. <b>2013</b> , 520, 1-6	43
1286	An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. <b>2013</b> , 31, 458-66	45 <sup>1</sup>
1285	Progress in the reprogramming of somatic cells. <b>2013</b> , 112, 562-74	94
1284	Generation of mouse and human induced pluripotent stem cells (iPSC) from primary somatic cells. <b>2013</b> , 9, 435-50	22
1283	Induced Pluripotent Stem Cells. <b>2013</b> , 227-235	1
1282	Cell Therapy for Blood Substitutes. <b>2013</b> , 559-572	
1281	Islet Cell Therapy and Pancreatic Stem Cells. <b>2013</b> , 835-853	1
1280	Generation of transgene-free induced pluripotent stem cells with non-viral methods. <b>2013</b> , 28, 50-4	3
1279	Epigenetic Reprogramming Without Genetic Modification: Use of Sendai Virus Vectors for Generating Safe Induced Pluripotent Stem Cells. <b>2013</b> , 59-69	
1278	Induced Pluripotent Stem Cells. <b>2013</b> , 197-218	
1277	Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. <b>2013</b> , 997, 149-61	29
1276	Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. <b>2013</b> , 31, 447-57	47
1275	Expanded complexity of unstable repeat diseases. <b>2013</b> , 39, 164-75	14

1274	Small molecule inhibitors promote efficient generation of induced pluripotent stem cells from human skeletal myoblasts. <b>2013</b> , 22, 114-23	37
1273	Generation of transgene-free iPSC lines from human normal and neoplastic blood cells using episomal vectors. <b>2013</b> , 997, 163-76	22
1272	Reprogramming- and pluripotency-associated membrane proteins in mouse stem cells revealed by label-free quantitative proteomics. <b>2013</b> , 86, 70-84	10
1271	Delivery of reprogramming factors into fibroblasts for generation of non-genetic induced pluripotent stem cells using a cationic bolaamphiphile as a non-viral vector. <b>2013</b> , 34, 5336-43	43
1270	Stem Cells, Induced Pluripotent Stem Cells, and Their Differentiation to Specified Lineage Fates. <b>2013</b> , 204-222	1
1269	Strategies to generate induced pluripotent stem cells. <b>2013</b> , 1029, 77-92	15
1268	Translating Stem Cells to the Clinic: From Modeling Disease to Cellular Products. <b>2013</b> ,	
1267	Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. <b>2013</b> , 31, 467-78	107
1266	Integrating human pluripotent stem cells into drug development. <b>2013</b> , 12, 669-77	106
1265	Reprogramming to pluripotency and differentiation of cells with synthetic mRNA. <b>2013</b> , 969, 221-33	5
1264	Evaluation of polymeric gene delivery nanoparticles by nanoparticle tracking analysis and high-throughput flow cytometry. <b>2013</b> , e50176	5
1263	Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. <b>2013</b> , 31, 1548-62	168
1262	New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. <b>2013</b> , 24, 571-83	28
1261	Induced neural stem cells (iNSCs) in neurodegenerative diseases. <b>2013</b> , 120 Suppl 1, S19-25	22
1260	Hepatogenesis of murine induced pluripotent stem cells in 3D micro-cavitary hydrogel system for liver regeneration. <b>2013</b> , 34, 6659-69	35
1259	Bioengineering of articular cartilage: past, present and future. <b>2013</b> , 8, 333-49	25
1258	Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. <b>2013</b> , 519, 142-9	8
1257	Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. <b>2013</b> , 34, 755-64	50

1256	Embryonic Stem Cell Immunobiology. <b>2013</b> ,	1
1255	Reprogramming human fibroblasts to pluripotency using modified mRNA. <b>2013</b> , 8, 568-82	154
1254	The generation of definitive neural stem cells from PiggyBac transposon-induced pluripotent stem cells can be enhanced by induction of the NOTCH signaling pathway. <b>2013</b> , 22, 383-96	42
1253	Generating insulin-producing cells for diabetic therapy: existing strategies and new development. <b>2013</b> , 12, 469-78	17
1252	Peering into the Black Box of Reprogramming to the Pluripotent State. <b>2013</b> , 1, 129-136	2
1251	Investigation of Rett syndrome using pluripotent stem cells. <b>2013</b> , 114, 2446-53	21
1250	Toward pluripotency by reprogramming: mechanisms and application. <b>2013</b> , 4, 820-32	16
1249	Efficient induction of pluripotent stem cells from menstrual blood. <b>2013</b> , 22, 1147-58	20
1248	Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. <b>2013</b> , 305, H913-22	110
1247	Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia. <b>2013</b> , 15, 503-13	41
1246	Induced pluripotent stem cells from goat fibroblasts. <b>2013</b> , 80, 1009-17	31
1245	Recent advances in the development of new transgenic animal technology. <b>2013</b> , 70, 815-28	26
1244	Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells. <b>2013</b> , 22, 124-35	65
1243	Cell and organ bioengineering technology as applied to gastrointestinal diseases. <b>2013</b> , 62, 774-86	33
1242	Embryonic stem cells from blastomeres maintaining embryo viability. <b>2013</b> , 31, 49-55	5
1241	Cells, stem cells, and cancer stem cells. <b>2013</b> , 31, 5-13	29
1240	Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. <b>2013</b> , 131, 458-69	44
1239	Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. <b>2013</b> , 2, 558-66	50

1238	Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. <b>2013</b> , 41, 1829-47	67
1237	Molecular Mechanisms Underlying Pluripotency. <b>2013</b> ,	
1236	Modeling to optimize terminal stem cell differentiation. <b>2013</b> , 2013, 574354	1
1235	Induced pluripotent stem cells in medicine and biology. <b>2013</b> , 140, 2457-61	179
1234	Implantation site-dependent differences for tracheal regeneration with induced pluripotent stem cells (iPS cells). <b>2013</b> , 133, 405-11	3
1233	Nonviral methods for inducing pluripotency to cells. <b>2013</b> , 2013, 705902	14
1232	Dedifferentiated adipocyte-derived progeny cells (DFAT cells): Potential stem cells of adipose tissue. <b>2013</b> , 2, 122-7	16
1231	Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury. <b>2013</b> , 22, 571-617	45
1230	Developmentally programmed 3' CpG island methylation confers tissue- and cell-type-specific transcriptional activation. <b>2013</b> , 33, 1845-58	38
1229	Unfolded protein response regulates cardiac sodium current in systolic human heart failure. <b>2013</b> , 6, 1018-24	42
1228	Gene delivery techniques for adult stem cell-based regenerative therapy. <b>2013</b> , 8, 1875-91	11
1227	Hematopoietic Stem Cells. <b>2013</b> , 251-277	1
1226	Back to the future: how human induced pluripotent stem cells will transform regenerative medicine. <b>2013</b> , 22, R32-8	35
1225	Reprogramming cells for brain repair. <b>2013</b> , 3, 1215-28	3
1224	Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?. <b>2013</b> , 75, 885-96	61
1223	The pharmacology of regenerative medicine. <b>2013</b> , 65, 1091-133	33
1222	Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line. <b>2013</b> , 87, 7127-39	1
1221	Concise review: the dynamics of induced pluripotency and its behavior captured in gene network motifs. <b>2013</b> , 31, 838-48	9

1220	Feeder-free reprogramming of human fibroblasts with messenger RNA. <b>2013</b> , 27, Unit 4A.6.	17
1219	Induced Pluripotent Stem Cells and Disorders of the Nervous System: Progress, Problems, and Prospects. <b>2013</b> , 19, 567-577	9
1218	Stem cell therapy for chronic heart failure: an updated appraisal. <b>2013</b> , 13, 503-16	8
1217	Chemical approaches to studying stem cell biology. <b>2013</b> , 23, 81-91	28
1216	Stem cell therapy to cure type 1 diabetes: from hype to hope. <b>2013</b> , 2, 328-36	105
1215	[Induced pluripotent stem (iPS) cell - issues for clinical application - ]. <b>2013</b> , 133, 197-200	
1214	Pluripotent stem cell-derived dopaminergic neurons as models of neurodegeneration. <b>2013</b> , 8, 649-661	0
1213	Induced Pluripotent Stem Cells. <b>2013</b> , 1-19	
1212	Cellular Properties of Mesenchymal Cells Derived from the Decidua of Human Term Placenta and Their Applications in Regenerative Medicine. <b>2013</b> , 240-260	1
1211	Human iPS cell-derived hematopoietic progenitor cells induce T-cell anergy in in vitro-generated alloreactive CD8(+) T cells. <b>2013</b> , 121, 5167-75	27
1210	Meiotic recombination in human oocytes. 63-75	
1209	Embryonic stem cells from blastomeres maintaining embryo viability. 84-92	
1208	Induced Pluripotent Stem Cell Labeling Using Quantum Dots. <b>2013</b> , 6, 83-90	10
1207	Small Molecules in Stem Cell Research. <b>2013</b> , 14, 36-45	
1206	Induced pluripotent stem cells and their potential for basic and clinical sciences. <b>2013</b> , 9, 63-72	19
1205	Evaluation of the use of induced pluripotent stem cells (iPSCs) for the regeneration of tracheal cartilage. <b>2013</b> , 22, 341-53	29
1204	Stem cell-based therapy for ischemic heart disease. <b>2013</b> , 22, 663-75	38
1203	[Reconstruction for spinal cord injury]. <b>2013</b> , 116, 53-9	



1202	Novel insights into disease modeling using induced pluripotent stem cells. <b>2013</b> , 36, 182-8	31
1201	[110th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: 1. Frontier of the regenerative medicine; 4) Perspective on regenerative medicine for spinal cord injury using iPS cell—from bench to bedside]. <b>2013</b> , 102, 2247-53	0
1200	Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells. <b>2013</b> , 8, 4641-58	27
1199	The propensity for tumorigenesis in human induced pluripotent stem cells is related with genomic instability. <b>2013</b> , 32, 205-12	16
1198	Animal Models of Regenerative Medicine. 219-234	
1197	Induced pluripotent stem cells: from history to applications. <b>2013</b> , 19, 20-32	
1196	Cell Replacement Therapy in Type 1 Diabetes. <b>2013</b> ,	1
1195	Technological overview of iPS induction from human adult somatic cells. <b>2013</b> , 13, 73-92	83
1194	Safeguarding Stem Cell-Based Regenerative Therapy against Iatrogenic Cancerogenesis: Transgenic Expression of , , , Controlled By Promoter in Proliferating and Directed Differentiation Resisting Human Autologous Pluripotent Induced Stem Cells Leads to their Death. <b>2013</b> , Suppl 9,	6
1193	A small molecule inhibitor of SRC family kinases promotes simple epithelial differentiation of human pluripotent stem cells. <b>2013</b> , 8, e60016	23
1192	Vector-free and transgene-free human iPS cells differentiate into functional neurons and enhance functional recovery after ischemic stroke in mice. <b>2013</b> , 8, e64160	64
1191	To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture. <b>2013</b> , 8, e65324	26
1190	Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells. <b>2013</b> , 8, e70573	121
1189	Targeting of herpes simplex virus 1 thymidine kinase gene sequences into the OCT4 locus of human induced pluripotent stem cells. <b>2013</b> , 8, e81131	11
1188	Generation of human induced pluripotent stem cells using epigenetic regulators reveals a germ cell-like identity in partially reprogrammed colonies. <b>2013</b> , 8, e82838	6
1187	Induced pluripotent stem cells. 19-33	
1186	Thinking outside the liver: induced pluripotent stem cells for hepatic applications. <b>2013</b> , 19, 3385-96	26
1185	Neural Stem/Progenitor Cells for Spinal Cord Regeneration. <b>2013</b> ,	3

1184	Generation of Induced Pluripotent Stem Cells from Dental Pulp Somatic Cells. <b>2013</b> ,	1
1183	Induced Pluripotent Stem Cells: Therapeutic Applications in Monogenic and Metabolic Diseases, and Regulatory and Bioethical Considerations. <b>2013</b> ,	1
1182	Endogenous stem/progenitor cell recruitment for tissue regeneration. 405-418	
1181	Induced Pluripotent Stem Cells: Current and Emerging Technologies. <b>2013</b> ,	
1180	Human Pluripotent Stem Cells Modeling Neurodegenerative Diseases. <b>2013</b> ,	2
1179	Disease Models for the Genetic Cardiac Diseases. <b>2013</b> ,	
1178	Stem and Progenitor Cells in Regenerative Pharmacology. 75-126	2
1177	Recent technological updates and clinical applications of induced pluripotent stem cells. <b>2014</b> , 29, 547-57	26
1176	Dosage and cell line dependent inhibitory effect of bFGF supplement in human pluripotent stem cell culture on inactivated human mesenchymal stem cells. <b>2014</b> , 9, e86031	8
1175	Generation of human induced pluripotent stem (Ips) cells in serum- and feeder-free defined culture and TGF- $\beta$ regulation of pluripotency. <b>2014</b> , 9, e87151	31
1174	Physiological characterisation of human iPS-derived dopaminergic neurons. <b>2014</b> , 9, e87388	103
1173	Sensory neurons do not induce motor neuron loss in a human stem cell model of spinal muscular atrophy. <b>2014</b> , 9, e103112	12
1172	A systemic evaluation of cardiac differentiation from mRNA reprogrammed human induced pluripotent stem cells. <b>2014</b> , 9, e103485	25
1171	Myocardial Reprogramming Medicine: The Development, Application, and Challenge of Induced Pluripotent Stem Cells. <b>2014</b> , 2014, 1-22	
1170	Design and Potential of Non-Integrating Lentiviral Vectors. <b>2014</b> , 2, 14-35	25
1169	The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders. <b>2014</b> , 3, 1490-510	6
1168	Generation of pluripotent stem cells via protein transduction. <b>2014</b> , 58, 21-7	20
1167	Reprogramming fibroblasts to pluripotency using arginine-terminated polyamidoamine nanoparticles based non-viral gene delivery system. <b>2014</b> , 9, 5837-47	15

1166	Progress on diabetic cerebrovascular diseases. <b>2014</b> , 14, 185-90	28
1165	Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem Cells. <b>2014</b> , 3, 1357-72	10
1164	Cell signalling pathways underlying induced pluripotent stem cell reprogramming. <b>2014</b> , 6, 620-8	36
1163	The Role of an NFB-STAT3 Signaling Axis in Regulating the Induction and Maintenance of the Pluripotent State. <b>2014</b> ,	1
1162	. <b>2014</b> ,	1
1161	Gene- and Cell-Based Therapy for Cardiovascular Disease. <b>2014</b> , 783-833	
1160	Solving the puzzle of Parkinson's disease using induced pluripotent stem cells. <b>2014</b> , 239, 1421-32	15
1159	Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: a first step toward a clinical-grade cell source. <b>2014</b> , 3, 433-47	47
1158	Chemicals and Stem Cells in the Promotion of Regeneration. <b>2014</b> , 77-93	
1157	An Introduction to Cellular Reprogramming: The Plasticity of Cell Fates and Identities. <b>2014</b> , 103-139	
1156	Production of Retinal Cells from Confluent Human iPS Cells. <b>2016</b> , 1357, 339-51	8
1155	Generation and Characterization of Patient-Specific Induced Pluripotent Stem Cell for Disease Modeling. <b>2016</b> , 1353, 25-44	4
1154	Cryopreservation of human pluripotent stem cells in defined medium. <b>2014</b> , 31, 1C.17.1-13	11
1153	Reprogramming and carcinogenesis--parallels and distinctions. <b>2014</b> , 308, 167-203	42
1152	Induced Pluripotent Stem Cells. <b>2014</b> , 581-594	5
1151	Blood Components from Pluripotent Stem Cells. <b>2014</b> , 1041-1057	
1150	Understanding the roadmaps to induced pluripotency. <b>2014</b> , 5, e1232	17
1149	Concise review: drug discovery in the age of the induced pluripotent stem cell. <b>2014</b> , 3, 500-9	54

1148	The Synthetic Biology Approach to Stem Cells and Regenerative Medicine. <b>2014</b> , 1-17		
1147	Regenerative Biology of the Eye. <b>2014</b> ,		4
1146	Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. <b>2014</b> , 102, 497-506		84
1145	Advances in Pluripotent and Adult Stem Cells for Eye Research. <b>2014</b> , 101-119		
1144	Pancreatic Islet Regeneration: The Developmental and Stem Cell Biology Approach. <b>2014</b> , 609-625		
1143	International coordination of large-scale human induced pluripotent stem cell initiatives: Wellcome Trust and ISSCR workshops white paper. <b>2014</b> , 3, 931-9		32
1142	Methylation and transcripts expression at the imprinted GNAS locus in human embryonic and induced pluripotent stem cells and their derivatives. <b>2014</b> , 3, 432-43		11
1141	Co-regulation of pluripotency and genetic integrity at the genomic level. <i>Stem Cell Research</i> , <b>2014</b> , 13, 508-19	1.6	6
1140	Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage. <b>2014</b> , 3, 404-13		96
1139	Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. <b>2014</b> , 3, 804-16		215
1138	A mystery unraveled: nontumorigenic pluripotent stem cells in human adult tissues. <b>2014</b> , 14, 917-29		13
1137	[Stem cell-based therapy in orthopaedics and trauma surgery - current concepts]. <b>2014</b> , 152, 320-7		
1136	[Current therapeutic approaches in inherited retinal degeneration: from genes to chip]. <b>2014</b> , 231, 222-31		
1135	Differentiation of pluripotent stem cells into retinal pigmented epithelium. <b>2014</b> , 53, 81-96		21
1134	Spinal Cord. <b>2014</b> , 1353-1373		1
1133	Laser-assisted generation of human induced pluripotent stem cells. <b>2014</b> , 31, 4A.7.1-15		3
1132	Epidermal Differentiation in Barrier Maintenance and Wound Healing. <b>2014</b> , 3, 272-280		66
1131	Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. <b>2014</b> , 6, 259-77		117

1130	Generation of iPS Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors. <b>2016</b> , 1357, 57-69	33
1129	Human stem cells for craniomaxillofacial reconstruction. <b>2014</b> , 23, 1437-51	8
1128	Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. <b>2014</b> , 135, 1790-9	42
1127	Vectorology and factor delivery in induced pluripotent stem cell reprogramming. <b>2014</b> , 23, 1301-15	37
1126	Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy. <b>2014</b> , 23, 2274-82	21
1125	Reprogramming human retinal pigmented epithelial cells to neurons using recombinant proteins. <b>2014</b> , 3, 1526-34	26
1124	A site-specific genetic modification for induction of pluripotency and subsequent isolation of derived lung alveolar epithelial type II cells. <b>2014</b> , 32, 402-13	11
1123	Physiological oxygen prevents frequent silencing of the DLK1-DIO3 cluster during human embryonic stem cells culture. <b>2014</b> , 32, 391-401	27
1122	Neural stem cells differentiated from iPS cells spontaneously regain pluripotency. <b>2014</b> , 32, 2596-604	44
1121	Human induced pluripotent stem cell derived erythroblasts can undergo definitive erythropoiesis and co-express gamma and beta globins. <b>2014</b> , 166, 435-48	29
1120	Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 21840-64	6.3 9
1119	Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. <b>2014</b> , 6, 264ra164	95
1118	Delayed self-regulation and time-dependent chemical drive leads to novel states in epigenetic landscapes. <b>2014</b> , 11, 20140706	14
1117	iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes. <b>2014</b> , 7, 667-76	8
1116	iPS Cells for Modelling and Treatment of Retinal Diseases. <b>2014</b> , 3, 1511-41	17
1115	Cell regeneration and differentiation: how close are we to the 'holy grail'?. <b>2014</b> , 53, R119-29	9
1114	Stem Cells: The Future of Personalised Medicine?. <b>2014</b> , 5, MEI.S13177	
1113	Pluripotent reprogramming and lineage reprogramming: promises and challenges in cardiovascular regeneration. <b>2014</b> , 20, 304-13	6

1112	Preparation of induced pluripotent stem cells on dishes grafted on oligopeptide under feeder-free conditions. <b>2014</b> , 45, 295-301	14
1111	The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. <b>2014</b> , 231, 1079-88	34
1110	Fourier transform infrared microspectroscopy reveals unique phenotypes for human embryonic and induced pluripotent stem cell lines and their progeny. <b>2014</b> , 7, 767-81	8
1109	Generation of mouse induced pluripotent stem cells by protein transduction. <b>2014</b> , 20, 383-92	31
1108	The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. <b>2014</b> , 10, 177-90	46
1107	In vitro neurogenesis: development and functional implications of iPSC technology. <b>2014</b> , 71, 1623-39	32
1106	Neuroprotection and Regeneration of the Spinal Cord. <b>2014</b> ,	1
1105	Retinal stem cells and regeneration of vision system. <b>2014</b> , 297, 137-60	12
1104	Simple derivation of transgene-free iPS cells by a dual recombinase approach. <b>2014</b> , 56, 697-713	2
1103	ONSL and OSKM cocktails act synergistically in reprogramming human somatic cells into induced pluripotent stem cells. <b>2014</b> , 20, 538-49	9
1102	Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog. <b>2014</b> , 2, 26-35	35
1101	Retinal repair with induced pluripotent stem cells. <b>2014</b> , 163, 377-86	36
1100	Induced pluripotent stem cells as a source of hepatocytes. <b>2014</b> , 2, 11-20	33
1099	Neural progenitor cells from human induced pluripotent stem cells generated less autogenous immune response. <b>2014</b> , 57, 162-70	15
1098	Clinicopathological sex- related relevance of musashi1 mRNA expression in esophageal squamous cell carcinoma patients. <b>2014</b> , 20, 427-33	21
1097	Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord. <b>2014</b> , 522, 2707-28	87
1096	Tumor Dormancy, Quiescence, and Senescence, Volume 2. <b>2014</b> ,	1
1095	Vascular Tissue Engineering: Building Perfusable Vasculature for Implantation. <b>2014</b> , 3, 68-74	44

1094	Serum-free spheroid suspension culture maintains mesenchymal stem cell proliferation and differentiation potential. <b>2014</b> , 30, 974-83	59
1093	Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. <b>2014</b> , 14, 592-605	163
1092	On the road to bioartificial organs. <b>2014</b> , 466, 1847-57	17
1091	Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?. <b>2014</b> , 185, 37-44	45
1090	iPSCs, aging and age-related diseases. <b>2014</b> , 31, 411-21	19
1089	Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine. <b>2014</b> , 19, 330-339	6
1088	Generation of transgene-free mouse induced pluripotent stem cells using an excisable lentiviral system. <b>2014</b> , 322, 335-44	8
1087	Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells. <b>2014</b> , 108, 22-9	38
1086	An experimental approach to the generation of human embryonic stem cells equivalents. <b>2014</b> , 56, 12-37	4
1085	Pluripotent stem cells in regenerative medicine: challenges and recent progress. <b>2014</b> , 15, 82-92	351
1084	The genome in three dimensions: a new frontier in human brain research. <b>2014</b> , 75, 961-9	45
1083	Induced neural stem cells: methods of reprogramming and potential therapeutic applications. <b>2014</b> , 114, 15-24	34
1082	Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. <b>2014</b> , 129, 359-72	64
1081	From basics to clinical: a comprehensive review on spinal cord injury. <b>2014</b> , 114, 25-57	459
1080	Mouse-induced pluripotent stem cells generated under hypoxic conditions in the absence of viral infection and oncogenic factors and used for ischemic stroke therapy. <b>2014</b> , 23, 421-33	26
1079	Advanced feeder-free generation of induced pluripotent stem cells directly from blood cells. <b>2014</b> , 3, 1402-9	24
1078	Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of episomal vectors. <b>2014</b> , 3, 787-91	43
1077	Derivation and long-term culture of transgene-free human induced pluripotent stem cells on synthetic substrates. <b>2014</b> , 3, 1410-7	11

1076	GM-CSF and MEF-conditioned media support feeder-free reprogramming of mouse granulocytes to iPS cells. <b>2014</b> , 87, 193-9	6
1075	Can pluripotent stem cells be used in cell-based therapy?. <b>2014</b> , 16, 98-107	15
1074	All roads lead to induced pluripotent stem cells: the technologies of iPSC generation. <b>2014</b> , 23, 1285-300	68
1073	"Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy. <b>2014</b> , 23, 2626-36	25
1072	Improved retroviral episome transfer of transcription factors enables sustained cell fate modification. <b>2014</b> , 21, 938-49	12
1071	The aging signature: a hallmark of induced pluripotent stem cells?. <b>2014</b> , 13, 2-7	62
1070	Gene Therapy. <b>2014</b> , 657-686	3
1069	Induced pluripotent stem cells from familial Alzheimer's disease patients differentiate into mature neurons with amyloidogenic properties. <b>2014</b> , 23, 2996-3010	60
1068	Tissue Engineering: Future Perspectives. <b>2014</b> , 83-123	11
1067	Transcriptomics and proteomics in stem cell research. <b>2014</b> , 8, 433-44	5
1066	Concise review: pluripotent stem cell-based regenerative applications for failing $\beta$ cell function. <b>2014</b> , 3, 653-61	21
1065	Efficient germ-line transmission obtained with transgene-free induced pluripotent stem cells. <b>2014</b> , 111, 10678-83	16
1064	Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor. <b>2014</b> , 64, 299-308	4
1063	iPSC-Derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1. <b>2014</b> , 3, 297-311	28
1062	Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity. <b>2014</b> , 32, 2350-9	10
1061	Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells. <b>2014</b> , 32, 1151-1157	164
1060	Clinical potentials of human pluripotent stem cells in lung diseases. <b>2014</b> , 3, 15	10
1059	Characterisation of human induced pluripotent stem cell-derived hepatocyte-like cells and endodermal progenitors. <b>2014</b> , 19,	2



1058	Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells. <b>2014</b> , 7, 50	29
1057	Small molecules facilitate rapid and synchronous iPSC generation. <b>2014</b> , 11, 1170-6	74
1056	Generation of induced pluripotent stem cells from hair follicle bulge neural crest stem cells. <b>2014</b> , 16, 307-13	3
1055	Pluripotent muse cells derived from human adipose tissue: a new perspective on regenerative medicine and cell therapy. <b>2014</b> , 3, 12	27
1054	OCT4: A penetrant pluripotency inducer. <b>2014</b> , 3, 6	3
1053	Directed cardiomyogenesis of autologous human induced pluripotent stem cells recruited to infarcted myocardium with bioengineered antibodies. <b>2014</b> , 2,	6
1052	Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. <b>2014</b> , 123, 161-72	53
1051	Induced pluripotent stem cell (iPSCs) and their application in immunotherapy. <b>2014</b> , 11, 17-24	40
1050	Footprint- and xeno-free human iPSCs derived from urine cells using extracellular matrix-based culture conditions. <b>2014</b> , 35, 8330-8	17
1049	Nonviral delivery for reprogramming to pluripotency and differentiation. <b>2014</b> , 37, 107-19	12
1048	Transitions between epithelial and mesenchymal states during cell fate conversions. <b>2014</b> , 5, 580-91	34
1047	Generation of insulin-producing $\beta$ like cells from human iPS cells in a defined and completely xeno-free culture system. <b>2014</b> , 6, 394-408	52
1046	Regenerative medicine for the heart: perspectives on stem-cell therapy. <b>2014</b> , 21, 2018-31	22
1045	Human-induced pluripotent stem cells: potential for neurodegenerative diseases. <b>2014</b> , 23, R17-26	87
1044	Strategies for whole lung tissue engineering. <b>2014</b> , 61, 1482-96	40
1043	Embryonic stem cells and induced pluripotent stem cells for skeletal regeneration. <b>2014</b> , 20, 381-91	26
1042	Molecular and cellular regulation of skeletal myogenesis. <b>2014</b> , 110, 1-73	112
1041	A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells. <b>2014</b> , 35, 2816-26	61

1040	Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. <b>2014</b> , 2, 366-81	106
1039	Coordination of engineered factors with TET1/2 promotes early-stage epigenetic modification during somatic cell reprogramming. <b>2014</b> , 2, 253-61	21
1038	From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals. <b>2014</b> , 81, 103-11	48
1037	From confluent human iPS cells to self-forming neural retina and retinal pigmented epithelium. <b>2014</b> , 111, 8518-23	178
1036	Non-viral reprogramming of fibroblasts into induced pluripotent stem cells by Sleeping Beauty and piggyBac transposons. <b>2014</b> , 450, 581-7	35
1035	Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. <b>2014</b> , 114, 1328-45	96
1034	FOXN1 (GFP/w) reporter hESCs enable identification of integrin- $\beta$ , HLA-DR, and EpCAM as markers of human PSC-derived FOXN1(+) thymic epithelial progenitors. <b>2014</b> , 2, 925-37	30
1033	Stem cells and the treatment of Parkinson's disease. <b>2014</b> , 260, 3-11	19
1032	Research progress in animal models and stem cell therapy for Alzheimer's disease. <b>2014</b> , 11	3
1031	Efficient iPS cell generation from blood using episomes and HDAC inhibitors. <b>2014</b> , e52009	7
1030	Cell and gene therapy. <b>2014</b> , 53, 167-77	8
1029	Stem cells, retinal ganglion cells and glaucoma. <b>2014</b> , 53, 111-21	25
1028	Efficient generation human induced pluripotent stem cells from human somatic cells with Sendai-virus. <b>2014</b> ,	8
1027	Gene Therapy. <b>2014</b> , 399-422	
1026	Stem Cell-Based Methods for Identifying Developmental Toxicity Potential. <b>2014</b> , 321-346	
1025	Application of Induced Pluripotent Stem Cells in Liver Diseases. <b>2014</b> , 7, 1-13	12
1024	Generation of integration-free induced hepatocyte-like cells from mouse fibroblasts. <i>Scientific Reports</i> , <b>2015</b> , 5, 15706	4.9 21
1023	Defining minimum essential factors to derive highly pure human endothelial cells from iPS/ES cells in an animal substance-free system. <i>Scientific Reports</i> , <b>2015</b> , 5, 9718	4.9 16

1022	Chromosome microduplication in somatic cells decreases the genetic stability of human reprogrammed somatic cells and results in pluripotent stem cells. <i>Scientific Reports</i> , <b>2015</b> , 5, 10114	4.9	10
1021	Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?. <b>2015</b> , 7, 1090-103		33
1020	Partial somatic to stem cell transformations induced by cell-permeable reprogramming factors. <i>Scientific Reports</i> , <b>2014</b> , 4, 4361	4.9	24
1019	Choice of Feeders Is Important When First Establishing iPSCs Derived From Primarily Cultured Human Deciduous Tooth Dental Pulp Cells. <b>2015</b> , 8, 9-23		9
1018	Bosch etching for the creation of a 3D nanoelectroporation system for high throughput gene delivery. <b>2015</b> , 33, 06F903		4
1017	TRIM32 modulates pluripotency entry and exit by directly regulating Oct4 stability. <i>Scientific Reports</i> , <b>2015</b> , 5, 13456	4.9	13
1016	In vivo reprogrammed pluripotent stem cells from teratomas share analogous properties with their in vitro counterparts. <i>Scientific Reports</i> , <b>2015</b> , 5, 13559	4.9	8
1015	A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. <i>Scientific Reports</i> , <b>2015</b> , 5, 11319	4.9	82
1014	Modeling Kidney Disease with iPS Cells. <b>2015</b> , 10, 153-69		30
1013	Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. <i>Stem Cell Research</i> , <b>2015</b> , 15, 678-693	1.6	25
1012	Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. <b>2015</b> , 16, 1069		56
1011	Understanding the molecular basis of autism in a dish using hiPSCs-derived neurons from ASD patients. <b>2015</b> , 8, 57		12
1010	Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. <i>Stem Cell Research and Therapy</i> , <b>2015</b> , 6, 122	8.3	43
1009	Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency. <b>2015</b> , 4, 10		55
1008	Human induced pluripotent stem cell and nanotechnology-based therapeutics. <b>2015</b> , 24, 2185-95		12
1007	From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease. <b>2015</b> , 10, 31-41		22
1006	Practical Integration-Free Episomal Methods for Generating Human Induced Pluripotent Stem Cells. <b>2015</b> , 87, 21.2.1-21.2.21		10
1005	Barriers for Deriving Transgene-Free Pig iPS Cells with Episomal Vectors. <b>2015</b> , 33, 3228-38		46

1004	Induced pluripotent stem cells model personalized variations in liver disease resulting from $\alpha$ -antitrypsin deficiency. <b>2015</b> , 62, 147-57		64
1003	1. Optical reprogramming and optical characterization of cells using femtosecond lasers. <b>2015</b> , 159-178		1
1002	No Detection of Potential Cancer Risk for Free-Viral Reprogrammed Stem Cell-Derived Dopaminergic Neurons from Adult Mice Fibroblasts. <b>2015</b> , 05,		
1001	Induced pluripotent stem cells: Mechanisms, achievements and perspectives in farm animals. <b>2015</b> , 7, 315-28		33
1000	SCNT versus iPSCs: proteins and small molecules in reprogramming. <b>2015</b> , 59, 179-86		10
999	Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives. <b>2015</b> , 8, 125-34		53
998	Stem Cell Therapies for Ischemic Cardiovascular Diseases. <b>2015</b> , 4, 149-167		
997	Induced Pluripotent Stem Cells: Next Generation Stem Cells to Clinical Applications. <b>2015</b> , 35, 190		1
996	The Potential for iPSC-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and Challenges. <b>2014</b> , 4, 37-65		16
995	Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. <b>2015</b> , 3, 15		17
994	Human Gingival Integration-Free iPSCs; a Source for MSC-Like Cells. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 13633-48	6.3	17
993	Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 18894-922	6.3	37
992	Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 28614-34	6.3	17
991	Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases. <b>2015</b> , 4, 567-78		22
990	Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells. <b>2015</b> , 4, 696-714		8
989	A comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cells. <b>2015</b> , 10, e0118266		33
988	Non-viral methods for generating integration-free, induced pluripotent stem cells. <b>2015</b> , 10, 153-8		38
987	Reprogramming with Small Molecules instead of Exogenous Transcription Factors. <b>2015</b> , 2015, 794632		51

986	Methods of induced pluripotent stem cells for clinical application. <b>2015</b> , 7, 116-25		47
985	Cell Therapy in Huntington's Disease. <b>2015</b> ,		0
984	Reprogramming mature terminally differentiated adipocytes to induced pluripotent stem cells. <b>2015</b> , 60, 1752-1758		3
983	Inhibition of an NAD <sup>+</sup> salvage pathway provides efficient and selective toxicity to human pluripotent stem cells. <b>2015</b> , 4, 483-93		18
982	miRNA control of tissue repair and regeneration. <b>2015</b> , 185, 2629-40		44
981	Systematic optimization of human pluripotent stem cells media using Design of Experiments. <i>Scientific Reports</i> , <b>2015</b> , 5, 9834	4.9	24
980	Mechanisms of pluripotency and epigenetic reprogramming in primordial germ cells: lessons for the conversion of other cell types into the stem cell lineage. <b>2015</b> , 39, 187-193		4
979	CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. <b>2015</b> , 4, e268		94
978	Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts. <b>2015</b> , 5, 1109-1118		71
977	Hepatocyte-Like Cells Derived from Pluripotent Stem Cells. <b>2015</b> , 267-278		
976	Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. <b>2015</b> , 85, 79-88		102
975	Stem cell reprogramming: basic implications and future perspective for movement disorders. <b>2015</b> , 30, 301-12		5
974	Gene delivery in tissue engineering and regenerative medicine. <b>2015</b> , 103, 1679-99		18
973	Reprogramming of prostate cancer cells--technical challenges. <b>2015</b> , 16, 468		3
972	Collaborative rewiring of the pluripotency network by chromatin and signalling modulating pathways. <b>2015</b> , 6, 6188		29
971	Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain. <b>2015</b> , 4, 689-99		20
970	Inhibition of T-cell activation by retinal pigment epithelial cells derived from induced pluripotent stem cells. <b>2015</b> , 56, 1051-62		44
969	The Future of Cord Blood Banks. <b>2015</b> , 291-307		1

968	Biobanks for Induced Pluripotent Stem Cells and Reprogrammed Tissues. <b>2015</b> , 179-194		
967	Cord Blood Content. <b>2015</b> , 9-26		
966	A practical guide to induced pluripotent stem cell research using patient samples. <b>2015</b> , 95, 4-13		45
965	Human induced pluripotent stem cell-derived B lymphocytes express sIgM and can be generated via a hemogenic endothelium intermediate. <b>2015</b> , 24, 1082-95		33
964	Microengineered liver tissues for drug testing. <b>2015</b> , 20, 216-50		78
963	Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. <i>Scientific Reports</i> , <b>2015</b> , 5, 8081	4.9	44
962	TFG clusters COPII-coated transport carriers and promotes early secretory pathway organization. <b>2015</b> , 34, 811-27		64
961	Pluripotent Stem Cells and Gene Therapy. <b>2015</b> , 11-26		1
960	Induced pluripotent stem cell-derived vascular smooth muscle cells: methods and application. <b>2015</b> , 465, 185-94		43
959	Cartilage Regeneration Using Induced Pluripotent Stem Cell Technologies. <b>2015</b> , 85-98		
958	Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming. <b>2015</b> , 48, 140-56		30
957	Quantitative and logic modelling of molecular and gene networks. <b>2015</b> , 16, 146-58		281
956	Role of nanotechnology in epigenetic reprogramming. <b>2015</b> , 24, 535-49		3
955	Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. <b>2015</b> , 290, 3121-36		64
954	Generation of Integration-Free Patient Specific iPS Cells Using Episomal Plasmids Under Feeder Free Conditions. <b>2016</b> , 1353, 355-66		6
953	Glial Precursor Cell Transplantation-Mediated Regeneration after Spinal Cord Injury Repair. <b>2015</b> , 321-335		
952	Reprogramming patient-derived cells to study the epilepsies. <b>2015</b> , 18, 360-6		41
951	Gene Therapy for Diabetes. <b>2015</b> , 115-128		

950	Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators. <b>2015</b> , 4, 468-75		30
949	A new model to study neurodegeneration in ataxia oculomotor apraxia type 2. <b>2015</b> , 24, 5759-74		19
948	Limitless starting materials for large-scale manufacture of MSCs [what does the future hold?]. <b>2015</b> , 3, 281-283		0
947	Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 4043-67	6.3	18
946	Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing. <b>2015</b> , 147, 39-54		82
945	Delivery of episomal vectors into primary cells by means of commercial transfection reagents. <b>2015</b> , 461, 348-53		15
944	The Hope for iPSC in Lung Stem Cell Therapy and Disease Modeling. <b>2015</b> , 113-143		0
943	Multiple sclerosis: getting personal with induced pluripotent stem cells. <b>2015</b> , 6, e1806		13
942	Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis. <b>2015</b> , 11, 598-620		27
941	KLF4 N-terminal variance modulates induced reprogramming to pluripotency. <b>2015</b> , 4, 727-43		27
940	Alzheimer's disease-related amyloid- $\beta$ induces synaptotoxicity in human iPS cell-derived neurons. <b>2015</b> , 6, e1709		71
939	Advances in reprogramming-based study of neurologic disorders. <b>2015</b> , 24, 1265-83		16
938	Current methods and challenges in the comprehensive characterization of human pluripotent stem cells. <b>2015</b> , 11, 357-72		10
937	Cellular reprogramming and its application in regenerative medicine. <b>2015</b> , 12, 80-89		11
936	Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. <i>Stem Cell Research and Therapy</i> , <b>2015</b> , 6, 2	8.3	28
935	Toward stem cell-based phenotypic screens for neurodegenerative diseases. <b>2015</b> , 11, 339-50		55
934	Human embryonic and induced pluripotent stem cell research trends: complementation and diversification of the field. <b>2015</b> , 4, 914-25		25
933	Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease. <b>2015</b> , 17, 665-79		50

932	Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. <b>2015</b> , 3, 2		235
931	Scopoletin has a potential activity for anti-aging via autophagy in human lung fibroblasts. <b>2015</b> , 22, 362-8		23
930	HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. <b>2015</b> , 24, 3257-71		74
929	Overcoming the hurdles for a reproducible generation of human functionally mature reprogrammed neurons. <b>2015</b> , 240, 787-94		9
928	Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming. <b>2015</b> , 17, 131-40		57
927	Methods of Reprogramming to Induced Pluripotent Stem Cell Associated with Chromosomal Integrity and Delineation of a Chromosome 5q Candidate Region for Growth Advantage. <b>2015</b> , 24, 2032-40		14
926	Current status of pluripotent stem cells: moving the first therapies to the clinic. <b>2015</b> , 14, 681-92		182
925	Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling. <b>2015</b> , 134, 161-77		25
924	Stochasticity and Spatial Interaction Govern Stem Cell Differentiation Dynamics. <i>Scientific Reports</i> , <b>2015</b> , 5, 12617	4-9	18
923	Using human induced pluripotent stem cells to model cerebellar disease: hope and hype. <b>2015</b> , 29, 95-102		9
922	Efficient episomal reprogramming of blood mononuclear cells and differentiation to hepatocytes with functional drug metabolism. <b>2015</b> , 338, 203-13		26
921	Concise Review: Cardiac Disease Modeling Using Induced Pluripotent Stem Cells. <b>2015</b> , 33, 2643-51		35
920	Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies. <b>2015</b> , 3, 200-206		9
919	Induction of pluripotency in human umbilical cord mesenchymal stem cells in feeder layer-free condition. <b>2015</b> , 47, 575-82		6
918	Development of stem cell-based therapy for Parkinson's disease. <b>2015</b> , 4, 16		43
917	Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation. <b>2015</b> , 5, 448-59		119
916	Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies. <b>2015</b> , 15, 71		25
915	Generation of Human Induced Pluripotent Stem Cells Using RNA-Based Sendai Virus System and Pluripotency Validation of the Resulting Cell Population. <b>2016</b> , 1353, 285-307		8



914	Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. <b>2015</b> , 26, 751-66	50
913	Targeted Disruption of the $\beta$ -Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. <b>2015</b> , 4, 1234-45	77
912	Generation of Footprint-Free Induced Pluripotent Stem Cells from Human Fibroblasts Using Episomal Plasmid Vectors. <b>2015</b> , 1330, 37-45	5
911	Functional Effects of a Tissue-Engineered Cardiac Patch From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Rat Infarct Model. <b>2015</b> , 4, 1324-32	71
910	A comparison of non-integrating reprogramming methods. <b>2015</b> , 33, 58-63	326
909	Pluripotent stem cells for Schwann cell engineering. <b>2015</b> , 11, 205-18	28
908	Signalling Through Retinoic Acid Receptors is Required for Reprogramming of Both Mouse Embryonic Fibroblast Cells and Epiblast Stem Cells to Induced Pluripotent Stem Cells. <b>2015</b> , 33, 1390-404	18
907	Expression of TAT recombinant Oct4, Sox2, Lin28, and Nanog proteins from baculovirus-infected Sf9 insect cells. <b>2015</b> , 556, 245-8	7
906	Combining TGF- $\beta$ signal inhibition and connexin43 silencing for iPSC induction from mouse cardiomyocytes. <i>Scientific Reports</i> , <b>2014</b> , 4, 7323	4-9 1
905	A Tissue Regeneration Approach to Bone and Cartilage Repair. <b>2015</b> ,	3
904	Reprint of "iPSCs, aging and age-related diseases". <b>2015</b> , 32, 169-79	4
903	Efficient intratracheal delivery of airway epithelial cells in mice and pigs. <b>2015</b> , 308, L221-8	16
902	Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. <b>2015</b> , 21, 467-79	171
901	Cell-laden microfibers for bottom-up tissue engineering. <b>2015</b> , 20, 236-46	113
900	Generation of pluripotent stem cells without the use of genetic material. <b>2015</b> , 95, 26-42	50
899	An Introduction to Stem Cell Biology and Tissue Engineering. <b>2015</b> , 1-13	15
898	Human induced pluripotent stem cell-derived hepatocytes for toxicology testing. <b>2015</b> , 11, 1-5	36
897	Induction of tissue-specific stem cells by reprogramming factors, and tissue-specific selection. <b>2015</b> , 22, 145-55	19

896	iPS cell technologies and cartilage regeneration. <b>2015</b> , 70, 48-54		87
895	Direct Comparison of DNA versus mRNA on the Efficiency of Induced Pluripotent Stem Cells Generation from Human Primary Fibroblasts. <b>2016</b> , 02,		1
894	Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells. <b>2016</b> ,		1
893	Pluripotent Stem Cells and Their Dynamic Niche. <b>2016</b> ,		3
892	Rationale and Methodology of Reprogramming for Generation of Induced Pluripotent Stem Cells and Induced Neural Progenitor Cells. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	4
891	Stem Cell Therapy for Parkinson's Disease. <b>2016</b> ,		
890	Stem Cell Therapy and Immunological Rejection in Animal Models. <b>2016</b> , 9, 284-288		23
889	Induced Pluripotent Stem (iPS) Cells in Dentistry: A Review. <b>2016</b> , 9, 176-185		17
888	A review of Rett syndrome (RTT) with induced pluripotent stem cells. <b>2016</b> , 3, 52		12
887	Recent Stem Cell Advances: Cord Blood and Induced Pluripotent Stem Cell for Cardiac Regeneration- a Review. <b>2016</b> , 9, 21-30		11
886	Extracellular Matrix-Dependent Generation of Integration- and Xeno-Free iPS Cells Using a Modified mRNA Transfection Method. <b>2016</b> , 2016, 6853081		7
885	The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside. <b>2016</b> , 2016, 6484713		15
884	The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming. <b>2016</b> , 2016, 6705927		46
883	Factor-Reduced Human Induced Pluripotent Stem Cells Efficiently Differentiate into Neurons Independent of the Number of Reprogramming Factors. <b>2016</b> , 2016, 4736159		4
882	Pluripotent Stem Cells: Current Understanding and Future Directions. <b>2016</b> , 2016, 9451492		60
881	Cellular Therapy for Heart Failure. <b>2016</b> , 12, 195-215		20
880	Transformation to Inducible Pluripotent Stem Cells. <b>2016</b> , 243-265		
879	A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects. <b>2016</b> , 8, 117		15

878	iPS Cells-The Triumphs and Tribulations. <b>2016</b> , 4,		5
877	Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 256	6.3	22
876	LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1. <b>2016</b> , 11, e0168904		34
875	Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells. <b>2016</b> , 11, e0155274		12
874	Cartilage Regeneration Using Pluripotent Stem Cell-Derived Chondroprogenitors: Promise and Challenges. <b>2016</b> ,		
873	Report from IPITA-TTS Opinion Leaders Meeting on the Future of iCell Replacement. <b>2016</b> , 100 Suppl 2, S1-44		51
872	Review: Induced pluripotent stem cell models of frontotemporal dementia. <b>2016</b> , 42, 497-520		7
871	Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells. <b>2016</b> , 88, 21.4.1-21.4.23		12
870	Human Pluripotent Stem Cells: Advances in Chondrogenic Differentiation and Articular Cartilage Regeneration. <b>2016</b> , 2, 113-122		11
869	10th anniversary of iPS cells: the challenges that lie ahead. <b>2016</b> , 160, 121-9		25
868	Pluripotent stem cells: the last 10 years. <b>2016</b> , 11, 831-847		28
867	Generating Blood from iPS Cells. <b>2016</b> , 399-420		1
866	Bioethical and legal perspectives on cell reprogramming technologies. <b>2016</b> , 16, 206-228		
865	High-efficiency generation of induced pluripotent mesenchymal stem cells from human dermal fibroblasts using recombinant proteins. <i>Stem Cell Research and Therapy</i> , <b>2016</b> , 7, 99	8.3	15
864	Generation and Characterization of a MYF5 Reporter Human iPS Cell Line Using CRISPR/Cas9 Mediated Homologous Recombination. <i>Scientific Reports</i> , <b>2016</b> , 6, 18759	4.9	23
863	The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis. <b>2016</b> , 7, 10869		17
862	Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance. <b>2016</b> , 57, 120-132		7
861	Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors. <b>2016</b> , 5, e320		18

860	Induced Pluripotent Stem Cell-Derived Retinal Pigmented Epithelium: A Comparative Study Between Cell Lines and Differentiation Methods. <b>2016</b> , 32, 317-30		39
859	Generation of Integration-free Induced Neural Stem Cells from Mouse Fibroblasts. <b>2016</b> , 291, 14199-14212		21
858	In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. <b>2016</b> , 36, 862-90		414
857	Integration-Free Reprogramming of Lamina Propria Progenitor Cells. <b>2016</b> , 95, 882-8		1
856	Generation of human induced pluripotent stem cells using non-synthetic mRNA. <i>Stem Cell Research</i> , <b>2016</b> , 16, 662-72	1.6	27
855	Effects of neural differentiation maturity status of human induced pluripotent stem cells prior to grafting in a subcortical ischemic stroke model. <b>2016</b> , 22, 178-182		6
854	Induced Pluripotent Stem Cells in Regenerative Medicine. <b>2016</b> , 51-75		1
853	Chemical-only reprogramming to pluripotency. <b>2016</b> , 11, 75-84		5
852	Optimized Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder. <b>2016</b> , 6, 717-728		30
851	Induced Pluripotent Stem Cells Meet Genome Editing. <b>2016</b> , 18, 573-86		304
850	Regenerative Medicine - from Protocol to Patient. <b>2016</b> ,		0
849	Enhanced Generation of Integration-free iPSCs from Human Adult Peripheral Blood Mononuclear Cells with an Optimal Combination of Episomal Vectors. <b>2016</b> , 6, 873-884		38
848	Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. <b>2016</b> , 48, e232		23
847	Overcoming the Specific Toxicity of Large Plasmids Electrotransfer in Primary Cells In Vitro. <b>2016</b> , 5, e291		43
846	Induced pluripotent stem cells: A new addition to the virologists armamentarium. <b>2016</b> , 235, 191-195		2
845	Generation of induced pluripotent stem cell line from foreskin fibroblasts. <i>Stem Cell Research</i> , <b>2016</b> , 17, 572-575	1.6	8
844	Tankyrase inhibition promotes a stable human naïve pluripotent state with improved functionality. <b>2016</b> , 143, 4368-4380		51
843	Hepatic Differentiation of Human Induced Pluripotent Stem Cells in a Perfused Three-Dimensional Multicompartment Bioreactor. <b>2016</b> , 5, 235-48		35

842	The other side of the coin: Leveraging Epstein-Barr virus in research and therapy. <b>2016</b> , 60, 112-7	1
841	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells. <b>2016</b> , 16-26	1
840	Disease modelling using human iPSCs. <b>2016</b> , 25, R173-R181	17
839	Concise Review: Advances in Generating Hepatocytes from Pluripotent Stem Cells for Translational Medicine. <b>2016</b> , 34, 1421-6	26
838	Induced pluripotent stem cells and Parkinson's disease: modelling and treatment. <b>2016</b> , 49, 14-26	11
837	hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine. <b>2016</b> , 20, 1571-88	64
836	ECell regeneration through the transdifferentiation of pancreatic cells: Pancreatic progenitor cells in the pancreas. <b>2016</b> , 7, 286-96	25
835	MiR-134-Mbd3 axis regulates the induction of pluripotency. <b>2016</b> , 20, 1150-8	17
834	An episomal CRISPR/Cas9 system to derive vector-free gene modified mammalian cells. <b>2016</b> , 7, 689-91	3
833	Stem Cells for the Regeneration of Chronic Wounds. <b>2016</b> , 291-312	
832	Genetic Engineering in Stem Cell Biomanufacturing. <b>2016</b> , 1-25	
831	Single-cell RNA-seq reveals novel regulators of human embryonic stem cell differentiation to definitive endoderm. <b>2016</b> , 17, 173	195
830	Stem cell characterisation: a guide to stem cell types, technologies, and future applications. <b>2016</b> , 317-340	
829	Overview of the Moral Status of iPS Cells. <b>2016</b> , 22, 148-154	
828	Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction. <i>Scientific Reports</i> , <b>2016</b> , 6, 30422	4.9 23
827	Induced pluripotent stem cell technologies for tissue engineering. <b>2016</b> , 1-19	
826	Stem cell tools for compound development. <b>2016</b> , 193-214	
825	Human Pluripotent Stem Cells (iPSC) Generation, Culture, and Differentiation to Lung Progenitor Cells. <b>2019</b> , 1576, 55-92	10

824	Artificial Liver Bioreactor Design. <b>2016</b> , 147-174	1
823	Anti-Aging Strategies Based on Cellular Reprogramming. <b>2016</b> , 22, 725-738	42
822	Transient Tcf3 Gene Repression by TALE-Transcription Factor Targeting. <b>2016</b> , 180, 1559-1573	2
821	Prediction of Differentiation Tendency Toward Hepatocytes from Gene Expression in Undifferentiated Human Pluripotent Stem Cells. <b>2016</b> , 25, 1884-1897	14
820	Gene Therapy. <b>2016</b> , 1-19	
819	cGMP Generation of Human Induced Pluripotent Stem Cells with Messenger RNA. <b>2016</b> , 39, 4A.6.1-4A.6.25	2
818	Stem cell therapies for congenital heart disease. <b>2016</b> , 84, 1163-1171	16
817	ZIKA virus elicits P53 activation and genotoxic stress in human neural progenitors similar to mutations involved in severe forms of genetic microcephaly. <b>2016</b> , 7, e2440	57
816	Gene Modified Stem/Progenitor-Cell Therapy for Ischemic Stroke. <b>2016</b> , 347-362	
815	Three-Dimensional Culture Systems and Humanized Liver Models Using Hepatic Stem Cells for Enhanced Toxicity Assessment. <b>2016</b> , 145-154	1
814	Stem Cell Processing. <b>2016</b> ,	1
813	The mitochondrial protein CHCHD2 primes the differentiation potential of human induced pluripotent stem cells to neuroectodermal lineages. <b>2016</b> , 215, 187-202	27
812	New Trends in Clinical Applications of Induced Pluripotent Stem Cells. <b>2016</b> , 77-98	
811	Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases. <b>2016</b> , 5, 192-201	20
810	The quest for an effective and safe personalized cell therapy using epigenetic tools. <b>2016</b> , 8, 119	8
809	The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases. <b>2016</b> , 67, 14.13.1-14.13.27	
808	Establishment and adipocyte differentiation of polycystic ovary syndrome-derived induced pluripotent stem cells. <b>2016</b> , 49, 352-61	7
807	NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming. <b>2016</b> , 14, 1883-91	97

806	Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells. <b>2016</b> , 235, 222-235	76
805	Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. <b>2016</b> , 96, 1093-126	72
804	Full biological characterization of human pluripotent stem cells will open the door to translational research. <b>2016</b> , 90, 2173-2186	6
803	A reliable and economical method for gaining mouse embryonic fibroblasts capable of preparing feeder layers. <b>2016</b> , 68, 1603-14	5
802	Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine. <b>2016</b> , 10, 893-907	37
801	Articular cartilage tissue engineering: the role of signaling molecules. <b>2016</b> , 73, 1173-94	49
800	Recent approaches and challenges in iPSCs: modeling and cell-based therapy of Alzheimer's disease. <b>2016</b> , 27, 457-64	2
799	Cell-Based Therapy for Degenerative Retinal Disease. <b>2016</b> , 22, 115-134	107
798	Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions. <b>2016</b> , 15, 234-49	29
797	Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration. <b>2016</b> , 5, 694-702	24
796	Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage. <b>2016</b> , 5, 417-26	27
795	A decade of transcription factor-mediated reprogramming to pluripotency. <b>2016</b> , 17, 183-93	468
794	Transposons and Retrotransposons. <b>2016</b> ,	4
793	Pluripotent stem cells and livestock genetic engineering. <b>2016</b> , 25, 289-306	31
792	Pluripotent Stem Cell-Based Therapies in Combination with Substrate for the Treatment of Age-Related Macular Degeneration. <b>2016</b> , 32, 261-71	25
791	Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells with Sleeping Beauty Transposon-Based Stable Gene Delivery. <b>2016</b> , 1400, 419-27	8
790	Dynamic stem cell states: naive to primed pluripotency in rodents and humans. <b>2016</b> , 17, 155-69	332
789	Conversion of adult human peripheral blood mononuclear cells into induced neural stem cell by using episomal vectors. <i>Stem Cell Research</i> , <b>2016</b> , 16, 236-42	1.6 24

788	Use of human stem cells in Huntington disease modeling and translational research. <b>2016</b> , 278, 76-90	25
787	Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation. <b>2016</b> , 30, 61-70	11
786	Calcium and voltage mapping in hiPSC-CM monolayers. <b>2016</b> , 59, 84-90	11
785	Smooth Muscle Precursor Cells Derived from Human Pluripotent Stem Cells for Treatment of Stress Urinary Incontinence. <b>2016</b> , 25, 453-61	27
784	The potential of induced pluripotent stem cell derived hepatocytes. <b>2016</b> , 65, 182-199	67
783	Generation and validation of PAX7 reporter lines from human iPS cells using CRISPR/Cas9 technology. <i>Stem Cell Research</i> , <b>2016</b> , 16, 220-8	1.6 23
782	Techniques of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derivation. <b>2016</b> , 64, 349-70	26
781	GSK3 $\beta$ Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells. <b>2016</b> , 6, 243-56	21
780	Two Histone Variants TH2A and TH2B Enhance Human Induced Pluripotent Stem Cell Generation. <b>2016</b> , 25, 251-8	17
779	Overview of Chemistry, Manufacturing, and Controls (CMC) for Pluripotent Stem Cell-Based Therapies. <b>2016</b> , 157-203	1
778	Regenerative Medicine for Degenerative Muscle Diseases. <b>2016</b> ,	
777	Induced Pluripotent Stem Cells for Cardiac Regeneration. <b>2016</b> , 31-43	
776	Erase and Rewind: Epigenetic Conversion of Cell Fate. <b>2016</b> , 12, 163-70	3
775	The triumph of chemically enhanced cellular reprogramming: a patent review. <b>2016</b> , 26, 265-80	4
774	Recombinant Xeno-Free Vitronectin Supports Self-Renewal and Pluripotency in Protein-Induced Pluripotent Stem Cells. <b>2016</b> , 22, 85-90	5
773	In situ label-free quantification of human pluripotent stem cells with electrochemical potential. <b>2016</b> , 75, 250-259	20
772	Patient-Specific Induced Pluripotent Stem Cell Models. <b>2016</b> ,	1
771	Neural Stem Cells (NSCs) and Proteomics. <b>2016</b> , 15, 344-54	28



770	Gene Expression Studies on Human Trisomy 21 iPSCs and Neurons: Towards Mechanisms Underlying Down's Syndrome and Early Alzheimer's Disease-Like Pathologies. <b>2016</b> , 1303, 247-65	6
769	Pluripotent Conversion of Muscle Stem Cells Without Reprogramming Factors or Small Molecules. <b>2016</b> , 12, 73-89	2
768	Induced pluripotent stem (iPS) cells from human fetal stem cells. <b>2016</b> , 31, 112-20	4
767	Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies. <b>2016</b> , 12, 54-72	61
766	Derivation, Expansion, and Motor Neuron Differentiation of Human-Induced Pluripotent Stem Cells with Non-Integrating Episomal Vectors and a Defined Xenogeneic-free Culture System. <b>2016</b> , 53, 1589-1600	20
765	Revisiting Mitochondrial Function and Metabolism in Pluripotent Stem Cells: Where Do We Stand in Neurological Diseases?. <b>2017</b> , 54, 1858-1873	10
764	Modeling Huntington's disease with patient-derived neurons. <b>2017</b> , 1656, 76-87	20
763	Studying human disease using human neurons. <b>2017</b> , 1656, 40-48	8
762	Progress in stem cell-based therapy for liver disease. <b>2017</b> , 47, 127-141	26
761	Generation of Neural Crest-Like Cells From Human Periodontal Ligament Cell-Derived Induced Pluripotent Stem Cells. <b>2017</b> , 232, 402-416	10
760	Generation of LIF-independent induced pluripotent stem cells from canine fetal fibroblasts. <b>2017</b> , 92, 75-82	24
759	Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells. <b>2017</b> , 89, 2440-2448	10
758	Human neural progenitors derived from integration-free iPSCs for SCI therapy. <i>Stem Cell Research</i> , <b>2017</b> , 19, 55-64	1.6 25
757	MINT: a multivariate integrative method to identify reproducible molecular signatures across independent experiments and platforms. <b>2017</b> , 18, 128	45
756	p53 switches off pluripotency on differentiation. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 44	8.3 18
755	Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction. <b>2017</b> , 25, 321-330	28
754	Clinical potentials of human pluripotent stem cells. <b>2017</b> , 33, 351-360	30
753	Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease. <b>2017</b> , 120, 876-894	49

752	Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. <b>2017</b> , 8, 605-618	23
751	Recent Advances in Therapeutic Applications of Induced Pluripotent Stem Cells. <b>2017</b> , 19, 65-74	12
750	Biophysical regulation of cell reprogramming. <b>2017</b> , 15, 95-101	18
749	Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. <b>2017</b> , 19, 445-456	90
748	Transactivator protein: An alternative for delivery of recombinant proteins for safer reprogramming of induced Pluripotent Stem Cell. <b>2017</b> , 235, 106-114	9
747	Induced Pluripotent Stem Cells and Cartilage Regeneration. <b>2017</b> , 73-93	1
746	Cartilage. <b>2017</b> ,	1
745	Transdifferentiation and reprogramming: Overview of the processes, their similarities and differences. <b>2017</b> , 1864, 1359-1369	52
744	Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells. <b>2017</b> , 33, 99-112	23
743	Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review. <b>2017</b> , 50,	39
742	Disease in a Dish Modeling of Retinal Diseases. <b>2017</b> , 107-115	
741	Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult Common Marmoset Fibroblasts. <b>2017</b> , 26, 1225-1235	21
740	Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo. <b>2017</b> , 9, 149-161	43
739	Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. <b>2017</b> , 120, 1958-1968	155
738	Efficient method to create integration-free, virus-free, and -free human induced pluripotent stem cells from adherent cells. <b>2017</b> , 3, FSO211	8
737	Fluorescent tagged episomals for stoichiometric induced pluripotent stem cell reprogramming. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 132	8,3 4
736	Generation of Integration-Free Induced Pluripotent Stem Cells from Urine-Derived Cells Isolated from Individuals with Down Syndrome. <b>2017</b> , 6, 1465-1476	18
735	Derivation of Human-Induced Pluripotent Stem Cells in Chemically Defined Medium. <b>2017</b> , 1590, 131-137	

734	Enhanced generation of human induced pluripotent stem cells by ectopic expression of Connexin 45. <i>Scientific Reports</i> , <b>2017</b> , 7, 458	4-9	7
733	iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review. <b>2017</b> , 8, 321-327		52
732	Spinal cord injuries: how could cell therapy help?. <b>2017</b> , 17, 529-541		42
731	Derivation of Transgene-Free Rat Induced Pluripotent Stem Cells Approximating the Quality of Embryonic Stem Cells. <b>2017</b> , 6, 340-351		3
730	Effect of small molecules on cell reprogramming. <b>2017</b> , 13, 277-313		11
729	A new era of disease modeling and drug discovery using induced pluripotent stem cells. <b>2017</b> , 40, 1-12		25
728	The potential of induced pluripotent stem cells as a tool to study skeletal dysplasias and cartilage-related pathologic conditions. <b>2017</b> , 25, 616-624		9
727	Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. <b>2017</b> , 10, 295-304		9
726	Induced pluripotent stem cell technology: a decade of progress. <b>2017</b> , 16, 115-130		701
725	The expanding horizon of MicroRNAs in cellular reprogramming. <b>2017</b> , 148, 21-39		27
724	Acquired Genetic and Epigenetic Variation in Human Pluripotent Stem Cells. <b>2018</b> , 163, 187-206		4
723	Nonintegrating Human Somatic Cell Reprogramming Methods. <b>2018</b> , 163, 1-21		4
722	TRIM28 regulates Igf2-H19 and Dlk1-Gtl2 imprinting by distinct mechanisms during sheep fibroblast proliferation. <b>2017</b> , 637, 152-160		4
721	Cardiac Regeneration. <b>2017</b> ,		
720	Chemical reprogramming of mouse embryonic and adult fibroblast into endoderm lineage. <b>2017</b> , 292, 19122-19132		11
719	Induced Pluripotent Stem Cells from Ovarian Tissue. <b>2017</b> , 95, 21.10.1-21.10.22		1
718	Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. <b>2017</b> , 7, 199-204		5
717	Stem Cell Therapy in Duchenne Muscular Dystrophy. <b>2017</b> , 297-317		

7 <sup>16</sup>	Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1. <b>2017</b> , 8, 595		16
7 <sup>15</sup>	Epigenetic foundations of pluripotent stem cells that recapitulate in vivo pluripotency. <b>2017</b> , 97, 1133-1141		20
7 <sup>14</sup>	Generation of iPSC-derived Human Brain Organoids to Model Early Neurodevelopmental Disorders. <b>2017</b> ,		18
7 <sup>13</sup>	Footprint-free human fetal foreskin derived iPSCs: A tool for modeling hepatogenesis associated gene regulatory networks. <i>Scientific Reports</i> , <b>2017</b> , 7, 6294	4.9	7
7 <sup>12</sup>	Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations. <b>2017</b> , 35, 2095-2102		16
7 <sup>11</sup>	Engineering-derived approaches for iPSC preparation, expansion, differentiation and applications. <b>2017</b> , 9, 032001		16
7 <sup>10</sup>	Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. <b>2017</b> , 21, 319-331.e8		158
7 <sup>09</sup>	Purification of functional reprogramming factors in mammalian cell using FLAG -Tag. <b>2017</b> , 492, 154-160		3
7 <sup>08</sup>	The Differentiation Stage of Transplanted Stem Cells Modulates Nerve Regeneration. <i>Scientific Reports</i> , <b>2017</b> , 7, 17401	4.9	39
7 <sup>07</sup>	Reprogramming. <b>2017</b> , 49-97		
7 <sup>06</sup>	Gene and Cell Therapy for $\beta$ -Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. <b>2017</b> , 1013, 219-240		4
7 <sup>05</sup>	Gene and Cell Therapies for Beta-Globinopathies. <b>2017</b> ,		3
7 <sup>04</sup>	Differentiation and Use of Induced Pluripotent Stem Cells for Cardiovascular Therapy and Tissue Engineering. <b>2017</b> , 107-122		1
7 <sup>03</sup>	Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells. <b>2017</b> , 3, e1701679		112
7 <sup>02</sup>	Progress of stem/progenitor cell-based therapy for retinal degeneration. <b>2017</b> , 15, 99		42
7 <sup>01</sup>	Simple and effective generation of transgene-free induced pluripotent stem cells using an auto-erasable Sendai virus vector responding to microRNA-302. <i>Stem Cell Research</i> , <b>2017</b> , 23, 13-19	1.6	42
7 <sup>00</sup>	Induced pluripotent stem cell-based therapy for age-related macular degeneration. <b>2017</b> , 17, 1113-1126		22
6 <sup>99</sup>	Hepatocyte-like cells derived from induced pluripotent stem cells. <b>2017</b> , 11, 54-69		29

698	Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges. <b>2017</b> , 35, 68-79		45
697	Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. <b>2017</b> , 13, 7-16		153
696	Biotechnological Management of Skin Burn Injuries: Challenges and Perspectives in Wound Healing and Sensory Recovery. <b>2017</b> , 23, 59-82		28
695	10 Neural Stem Cell Transplantation for Spinal Cord Repair. <b>2017</b> ,		
694	Induction of pluripotency in long-term cryopreserved human neonatal fibroblasts in feeder-free condition. <b>2017</b> , 18, 45-52		2
693	Injection of hTERT-Transduced Endothelial Progenitor Cells Promotes Beneficial Aortic Changes in a High-Fat Dietary Model of Early Atherosclerosis. <b>2017</b> , 136, 230-240		1
692	Stem Cell Biology. <b>2017</b> , 54-75.e5		
691	Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. <b>2017</b> , 35, 42-50		76
690	Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions. <b>2017</b> ,		1
689	FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells. <b>2017</b> , 26, 4416-4428		16
688	Using low-risk factors to generate non-integrated human induced pluripotent stem cells from urine-derived cells. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 245	8.3	21
687	Interaction of iPSC-derived neural stem cells on poly(L-lactic acid) nanofibrous scaffolds for possible use in neural tissue engineering. <b>2018</b> , 41, 697-708		18
686	Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy. <b>2017</b> , 81, 929-935		8
685	Application of Stem Cells in Oral Disease Therapy: Progresses and Perspectives. <b>2017</b> , 8, 197		31
684	Current and Future Perspectives of Stem Cell Therapy in Dermatology. <b>2017</b> , 29, 667-687		13
683	Effects of Co-Culture Media on Hepatic Differentiation of hiPSC with or without HUVEC Co-Culture. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	11
682	Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	31
681	Genetic Epilepsy Modeling With Human Pluripotent Stem Cells. <b>2017</b> , 247-260		

680	Induced Pluripotent Stem Cells for Traumatic Spinal Cord Injury. <b>2016</b> , 4, 152		44
679	Paying the Toll in Nuclear Reprogramming. <b>2017</b> , 5, 70		4
678	Reprogramming Methods Do Not Affect Gene Expression Profile of Human Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	19
677	Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells. <b>2017</b> , 11, 671		34
676	Generation of Urine Cell-Derived Non-integrative Human iPSCs and iNSCs: A Step-by-Step Optimized Protocol. <b>2017</b> , 10, 348		17
675	Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia. <b>2017</b> , 2017, 7492914		4
674	Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. <b>2017</b> , 12, e0182018		20
673	Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 217	8.3	33
672	Human iPSC Models in Drug Discovery: Opportunities and Challenges. <b>2017</b> , 48-73		4
671	Selected small molecules as inducers of pluripotency. <b>2016</b> , 63, 709-716		4
670	A mini-review of TAT-MyoD fused proteins: state of the art and problems to solve. <b>2017</b> , 27, 6039		1
669	Ips Progression a Decade Devoted. <b>2017</b> , 08,		
668	Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. <b>2017</b> , 13, 585-596		15
667	Cellular Reprogramming Using Protein and Cell-Penetrating Peptides. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	27
666	Regenerative Medicine in Liver Cirrhosis: Promises and Pitfalls. <b>2017</b> ,		1
665	Aged induced pluripotent stem cell (iPSCs) as a new cellular model for studying premature aging. <b>2017</b> , 9, 1453-1469		24
664	The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells. <b>2018</b> , 24, 173-184		9
663	Enhancing endogenous capacity to repair a stroke-damaged brain: An evolving field for stroke research. <b>2018</b> , 163-164, 5-26		53

662	Engineering and Application of Pluripotent Stem Cells. <b>2018,</b>		
661	Freezing Responses in DMSO-Based Cryopreservation of Human iPS Cells: Aggregates Versus Single Cells. <b>2018, 24, 289-299</b>		28
660	Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases. <b>2018, 20, 38</b>		0
659	Comparison of two different culture conditions for derivation of early hiPSC. <b>2018, 42, 1467-1473</b>		9
658	Simultaneous reprogramming and gene editing of human fibroblasts. <b>2018, 13, 875-898</b>		40
657	Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. <b>2018, 168, 1-20</b>		47
656	A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis. <i>Scientific Reports</i> , <b>2018, 8, 1873</b>	4.9	81
655	Biological Bases of Cardiac Function and the Pro-regenerative Potential of Stem Cells in the Treatment of Myocardial Disorder. <b>2018, 79-108</b>		0
654	Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. <b>2018, 11, e000043</b>		95
653	Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification. <b>2018, 1706, 17-38</b>		23
652	Toxic responses of Sox2 gene in the regeneration of the earthworm <i>Eisenia foetida</i> exposed to Retnoic acid. <b>2018, 204, 106-112</b>		1
651	Establishment of integration-free induced pluripotent stem cells from human recessive dystrophic epidermolysis bullosa keratinocytes. <b>2018, 89, 263-271</b>		11
650	Modeling rare diseases with induced pluripotent stem cell technology. <b>2018, 40, 52-59</b>		17
649	Application of induced pluripotency in cancer studies. <b>2018, 23, 207-214</b>		8
648	Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. <b>2018, 543, 107-120</b>		14
647	Optimization of episomal reprogramming for generation of human induced pluripotent stem cells from fibroblasts. <b>2018, 22, 132-139</b>		16
646	Augmentation of musculoskeletal regeneration: role for pluripotent stem cells. <b>2018, 13, 189-206</b>		7
645	Gene therapy clinical trials worldwide to 2017: An update. <b>2018, 20, e3015</b>		433

644	Stem/Progenitor Cells and Biodegradable Scaffolds in the Treatment of Retinal Degenerative Diseases. <b>2018</b> , 13, 160-173	6
643	Human stem cell modeling in neurofibromatosis type 1 (NF1). <b>2018</b> , 299, 270-280	16
642	Harnessing neural stem cells for treating psychiatric symptoms associated with fetal alcohol spectrum disorder and epilepsy. <b>2018</b> , 80, 10-22	7
641	Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier. <b>2018</b> , 12, 923-935	34
640	Automated Cell Culture Systems and Their Applications to Human Pluripotent Stem Cell Studies. <b>2018</b> , 23, 315-325	26
639	Endothelial Progenitor Cells for the Vascularization of Engineered Tissues. <b>2018</b> , 24, 1-24	91
638	Functional analysis of p.Ala253_Leu254insAsn mutation in PLS3 responsible for X-linked osteoporosis. <b>2018</b> , 93, 178-181	8
637	Three-dimensional hydrogel culture conditions promote the differentiation of human induced pluripotent stem cells into hepatocytes. <b>2018</b> , 20, 95-107	30
636	Lung development, regeneration and plasticity: From disease physiopathology to drug design using induced pluripotent stem cells. <b>2018</b> , 183, 58-77	13
635	Highly Mature Human iPSC Derived Cardiomyocytes as Models for Cardiac Electrophysiology and Drug Testing. <b>2018</b> , 541-551	
634	Functional Odontoblastic-Like Cells Derived from Human iPSCs. <b>2018</b> , 97, 77-83	19
633	Cardiac Cell Culture Technologies. <b>2018</b> ,	2
632	Low Osteogenic Yield in Human Pluripotent Stem Cells Associates with Differential Neural Crest Promoter Methylation. <b>2018</b> , 36, 349-362	14
631	Efficient generation of transgene- and feeder-free induced pluripotent stem cells from human dental mesenchymal stem cells and their chemically defined differentiation into cardiomyocytes. <b>2018</b> , 495, 2490-2497	13
630	Induced pluripotent stem cells derived from human amnion in chemically defined conditions. <b>2018</b> , 17, 330-347	2
629	Psychiatry in a Dish: Stem Cells and Brain Organoids Modeling Autism Spectrum Disorders. <b>2018</b> , 83, 558-568	38
628	CRISPR-Trap: a clean approach for the generation of gene knockouts and gene replacements in human cells. <b>2018</b> , 29, 75-83	21
627	Reprogramming of Adult Peripheral Blood Cells into Human Induced Pluripotent Stem Cells as a Safe and Accessible Source of Endothelial Cells. <b>2018</b> , 27, 10-22	12



626	Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosis-related genes. <b>2017</b> , 9, 481		20
625	The Development of Cancer through the Transient Overexpression of Reprogramming Factors. <b>2018</b> , 10, 2155179017733172		3
624	hiPSC-Based Tissue Organoid Regeneration. <b>2018</b> ,		1
623	Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns. <b>2018</b> , 2, 046103		11
622	Stem Cell Research for the Treatment of Malignant Glioma. <b>2018</b> ,		
621	A morphology-based assay platform for neuroepithelial-like cells differentiated from human pluripotent stem cells. <b>2018</b> , 62, 613-621		0
620	Induced Pluripotent Stem Cells in Disease Modelling and Regeneration. <b>2019</b> , 1144, 91-99		3
619	Myotonic Dystrophy. <b>2018</b> ,		1
618	Generation of transgene-free porcine intermediate type induced pluripotent stem cells. <b>2018</b> , 17, 2547-2563		16
617	MicroRNA characterization in equine induced pluripotent stem cells. <b>2018</b> , 13, e0207074		8
616	Functional Assessment of Patient-Derived Retinal Pigment Epithelial Cells Edited by CRISPR/Cas9. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	12
615	Generation of pancreatic β cells for treatment of diabetes: advances and challenges. <i>Stem Cell Research and Therapy</i> , <b>2018</b> , 9, 355	8.3	51
614	Benchmarking in vitro tissue-engineered blood-brain barrier models. <b>2018</b> , 15, 32		69
613	Virus-free and oncogene-free induced pluripotent stem cell reprogramming in cord blood and peripheral blood in patients with lung disease. <b>2018</b> , 13, 889-915		6
612	Peroxisome Proliferator-Activated Receptor Agonist and Its Target Nanog Cooperate to Induce Pluripotency. <b>2018</b> , 7,		3
611	Intravenous Delivery of Bac Transposons as a Useful Tool for Liver-Specific Gene-Switching. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	8
610	Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. <b>2018</b> , 12, 413		8
609	Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. <b>2018</b> , 6, e4370		72

608	Urine-derived cells provide a readily accessible cell type for feeder-free mRNA reprogramming. <i>Scientific Reports</i> , <b>2018</b> , 8, 14363	4.9	23
607	Channelopathies in Heart Disease. <b>2018</b> ,		
606	Nanotechnology in Generation and Biomedical Application of Induced Pluripotent Stem Cells. <b>2018</b> , 08, 1841002		0
605	Pluripotent Stem Cell-Based Approaches to Explore and Treat Optic Neuropathies. <b>2018</b> , 12, 651		15
604	Generation of two induced pluripotent stem cells lines from Mucopolysaccharydosis IIIA patient: IMEDEAi004-A and IMEDEAi004-B. <i>Stem Cell Research</i> , <b>2018</b> , 32, 110-114	1.6	6
603	Disease Modeling and Drug Development with DM1 Patient-Derived iPSCs. <b>2018</b> , 189-201		
602	Efficient Generation of Non-Integration and Feeder-Free Induced Pluripotent Stem Cells from Human Peripheral Blood Cells by Sendai Virus. <b>2018</b> , 50, 1318-1331		15
601	Modern Approaches to Tissue Engineering of the Spinal Cord: Analytical Review. <b>2018</b> , 7, 3-32		
600	Epigenetic Enzymes, Age, and Ancestry Regulate the Efficiency of Human iPSC Reprogramming. <b>2018</b> , 36, 1697-1708		10
599	Human Pluripotent Stem Cell-Derived Cells: A Cell Source for Transplantation. <b>2018</b> , 01,		
598	Transfection of Peripheral Blood Monocytes with Enhances Multipotency, Proliferation, and Redifferentiation into Neohepatocytes and Insulin-Producing Cells. <b>2018</b> , 2018, 4271875		1
597	Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. <b>2018</b> , 48, 974-988		15
596	Human Cortical Neuron Generation Using Cell Reprogramming: A Review of Recent Advances. <b>2018</b> , 27, 1674-1692		10
595	3 Spinal Cord Protective and Regenerative Therapies. <b>2018</b> ,		
594	Cell Therapies: New Frontier for the Management of Diabetic Foot Ulceration. <b>2018</b> , 219-235		
593	On the Viability and Potential Value of Stem Cells for Repair and Treatment of Central Neurotrauma: Overview and Speculations. <b>2018</b> , 9, 602		10
592	Generation and Applications of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells. <b>2018</b> , 2018, 9601623		40
591	Presenilin 1 deficiency suppresses autophagy in human neural stem cells through reducing $\beta$ -secretase-independent ERK/CREB signaling. <b>2018</b> , 9, 879		32

590	Do Induced Pluripotent Stem Cell Characteristics Correlate with Efficient In Vitro Smooth Muscle Cell Differentiation? A Comparison of Three Patient-Derived Induced Pluripotent Stem Cell Lines. <b>2018</b> , 27, 1438-1448		5
589	Pluripotent stem cells: induction and self-renewal. <b>2018</b> , 373,		11
588	Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications. <b>2018</b> , 27, 379-392		22
587	Cellular Models: HD Patient-Derived Pluripotent Stem Cells. <b>2018</b> , 1780, 41-73		6
586	Stem Cell Sources and Graft Material for Vascular Tissue Engineering. <b>2018</b> , 14, 642-667		25
585	PCDH19 regulation of neural progenitor cell differentiation suggests asynchrony of neurogenesis as a mechanism contributing to PCDH19 Girls Clustering Epilepsy. <b>2018</b> , 116, 106-119		25
584	Drug screening for human genetic diseases using iPSC models. <b>2018</b> , 27, R89-R98		70
583	Blood and Lymphatic System. <b>2018</b> , 681-708		
582	Establishment of a human induced stem cell line (FU002-A) from Dravet syndrome patient carrying heterozygous R1525X mutation in SCN1A gene. <i>Stem Cell Research</i> , <b>2018</b> , 31, 11-15	1.6	3
581	Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism. <b>2018</b> , 41, 1103-1116		1
580	Direct Control of Stem Cell Behavior Using Biomaterials and Genetic Factors. <b>2018</b> , 2018, 8642989		9
579	Investigation of human iPSC-derived cardiac myocyte functional maturation by single cell traction force microscopy. <b>2018</b> , 13, e0194909		30
578	Origin of Reparative Stem Cells in Fracture Healing. <b>2018</b> , 16, 490-503		25
577	Pluripotent Stem Cell Banks. <b>2018</b> , 337-367		
576	Stem Cell-Derived Spermatozoa. <b>2018</b> , 315-345		2
575	Leading-Edge Approaches for In Vitro Hepatotoxicity Evaluation. <b>2018</b> , 651-712		
574	Emerging roles of Myc in stem cell biology and novel tumor therapies. <b>2018</b> , 37, 173		101
573	Peak MSC-Are We There Yet?. <b>2018</b> , 5, 178		45

572	Efficient Computational Design of a Scaffold for Cartilage Cell Regeneration. <b>2018</b> , 5,		5
571	Induced Tissue-Specific Stem Cells and Epigenetic Memory in Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	35
570	Bioprocesses for Cell Therapies. <b>2018</b> , 899-930		3
569	New insight into functional limb regeneration: A to Z approaches. <b>2018</b> , 12, 1925-1943		3
568	Transcription factor induced conversion of human fibroblasts towards the hair cell lineage. <b>2018</b> , 13, e0200210		16
567	Modeling Schizophrenia with Human Stem Cells. <b>2018</b> , 13-26		1
566	Nitric oxide promotes cancer cell dedifferentiation by disrupting an Oct4:caveolin-1 complex: A new regulatory mechanism for cancer stem cell formation. <b>2018</b> , 293, 13534-13552		22
565	Stem Cell Applications in Spinal Cord Injury: A Primer. <b>2018</b> , 43-72		2
564	Human cellular models of medium spiny neuron development and Huntington disease. <b>2018</b> , 209, 179-196		10
563	Characterization of induced tissue-specific stem cells from pancreas by a synthetic self-replicative RNA. <i>Scientific Reports</i> , <b>2018</b> , 8, 12341	4.9	10
562	Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. <b>2018</b> , 48, 2607-2655		108
561	Ultra-High Signal Detection of Human Embryonic Stem Cells Driven by Two-Dimensional Materials.. <b>2018</b> , 1, 210-215		1
560	Loss of hierarchical imprinting regulation at the Prader-Willi/Angelman syndrome locus in human iPSCs. <b>2018</b> , 27, 3999-4011		12
559	Making HSCs in vitro: don't forget the hemogenic endothelium. <b>2018</b> , 132, 1372-1378		13
558	The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy. <b>2018</b> , 9, 345		10
557	Transplantation of Human-Induced Pluripotent Stem Cell-Derived Neural Precursor Cells for Treatment of Spinal Cord Injury. <b>2018</b> , 299-325		
556	Induced Pluripotent Stem Cells: A Powerful Neurodegenerative Disease Modeling Tool for Mechanism Study and Drug Discovery. <b>2018</b> , 27, 1588-1602		19
555	Biomanufacturing for clinically advanced cell therapies. <b>2018</b> , 2, 362-376		86

554	Induced pluripotent stem cells to generate skin tissue models. <b>2018</b> , 399-419		2
553	Single-Factor SOX2 Mediates Direct Neural Reprogramming of Human Mesenchymal Stem Cells via Transfection of In Vitro Transcribed mRNA. <b>2018</b> , 27, 1154-1167		17
552	Cell Therapy for Blood Substitutes. <b>2019</b> , 923-936		
551	Ethical Considerations. <b>2019</b> , 1331-1343		2
550	Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies. <i>Stem Cell Research and Therapy</i> , <b>2019</b> , 10, 238	8.3	34
549	Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells. <b>2019</b> , 9, 5200-5213		5
548	Recent advances in the applications of iPSC technology. <b>2019</b> , 60, 250-258		28
547	A 'poly-transfection' method for rapid, one-pot characterization and optimization of genetic systems. <b>2019</b> , 47, e106		14
546	Alzheimer's in a dish - induced pluripotent stem cell-based disease modeling. <b>2019</b> , 8, 21		13
545	Proteomics in the World of Induced Pluripotent Stem Cells. <b>2019</b> , 8,		7
544	Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction. <b>2019</b> , 10, 3123		97
543	Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods. <i>Stem Cell Research and Therapy</i> , <b>2019</b> , 10, 211	8.3	8
542	Efficient exogenous DNA-free reprogramming with suicide gene vectors. <b>2019</b> , 51, 1-12		9
541	Major Histocompatibility Complex-Matched Arteries Have Similar Patency to Autologous Arteries in a Mauritian Cynomolgus Macaque Major Histocompatibility Complex-Defined Transplant Model. <b>2019</b> , 8, e012135		3
540	Astrocyte lineage cells are essential for functional neuronal differentiation and synapse maturation in human iPSC-derived neural networks. <b>2019</b> , 67, 1893-1909		13
539	Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34 cells using the auto-erasable Sendai virus vector. <i>Stem Cell Research and Therapy</i> , <b>2019</b> , 10, 185	8.3	17
538	Generation of iPSCs by Nonintegrative RNA-Based Reprogramming Techniques: Benefits of Self-Replicating RNA versus Synthetic mRNA. <b>2019</b> , 2019, 7641767		13
537	Minimum damping profile of micro/nano-robot and as the carrier for drug delivery: theory study. <b>2019</b> , 1209, 012019		1

536	Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide. <i>Scientific Reports</i> , <b>2019</b> , 9, 14568	4.9	12
535	Human iPSC banking: barriers and opportunities. <b>2019</b> , 26, 87		79
534	AAV-Mediated Gene Augmentation Therapy Restores Critical Functions in Mutant PRPF31 iPSC-Derived RPE Cells. <b>2019</b> , 15, 392-402		13
533	Effective and Rapid Generation of Functional Neutrophils from Induced Pluripotent Stem Cells Using ETV2-Modified mRNA. <b>2019</b> , 13, 1099-1110		9
532	Pluripotent Cell Models for Gonadal Research. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	3
531	Mass cytometry-based single-cell analysis of human stem cell reprogramming uncovers differential regulation of specific pluripotency markers. <b>2019</b> , 294, 18547-18556		3
530	Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. <i>Stem Cell Research and Therapy</i> , <b>2019</b> , 10, 274	8.3	29
529	Application of iPSC to Modelling of Respiratory Diseases. <b>2020</b> , 1237, 1-16		5
528	Generation of an induced pluripotent stem cell line (XHCSUi001-A) from urine cells of a patient with spinocerebellar ataxia type 3. <i>Stem Cell Research</i> , <b>2019</b> , 40, 101555	1.6	6
527	Reprogramming of Urine-Derived Renal Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into Beating Cardiomyocytes. <b>2019</b> , 17, 907-921		13
526	mRNA-Driven Generation of Transgene-Free Neural Stem Cells from Human Urine-Derived Cells. <b>2019</b> , 8,		7
525	Overview: an iPS cell stock at CiRA. <b>2019</b> , 39, 17		51
524	iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants. <i>Stem Cell Research and Therapy</i> , <b>2019</b> , 10, 290	8.3	21
523	An Unbiased Proteomics Method to Assess the Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. <b>2019</b> , 125, 936-953		33
522	Transposon mediated reprogramming of buffalo fetal fibroblasts to induced pluripotent stem cells in feeder free culture conditions. <b>2019</b> , 123, 252-260		7
521	The eye as a novel imaging site in diabetes research. <b>2019</b> , 197, 103-121		14
520	Measles vector as a multigene delivery platform facilitating iPSC reprogramming. <b>2019</b> , 26, 151-164		7
519	Cell-Based Assays Using iPSCs for Drug Development and Testing. <b>2019</b> ,		0

518	On Mammalian Totipotency: What Is the Molecular Underpinning for the Totipotency of Zygote?. <b>2019</b> , 28, 897-906		6
517	Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model. <i>Stem Cell Research</i> , <b>2019</b> , 38, 101483	1.6	4
516	Generation and comprehensive characterization of induced pluripotent stem cells for translational research. <b>2019</b> , 14, 505-524		0
515	Biomarkers of Cancer Stem Cells in Cancer Therapy. <b>2019</b> , 51-59		
514	Modeling blood diseases with human induced pluripotent stem cells. <b>2019</b> , 12,		12
513	Establishment of induced pluripotent stem cells from common marmoset fibroblasts by RNA-based reprogramming. <b>2019</b> , 515, 593-599		9
512	Micropatterned substrates with physiological stiffness promote cell maturation and Pompe disease phenotype in human induced pluripotent stem cell-derived skeletal myocytes. <b>2019</b> , 116, 2377-2392		21
511	Biomarkers in Cancer Therapy. <b>2019</b> ,		1
510	Cell Biology and Translational Medicine, Volume 5. <b>2019</b> ,		1
509	Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. <b>2019</b> , 8,		143
508	How Does Reprogramming to Pluripotency Affect Genomic Imprinting?. <b>2019</b> , 7, 76		27
507	Effect of inoculum density on human-induced pluripotent stem cell expansion in 3D bioreactors. <b>2019</b> , 52, e12604		10
506	Emerging opportunities for induced pluripotent stem cells in orthopaedics. <b>2019</b> , 17, 73-81		7
505	Online measurement of oxygen enables continuous noninvasive evaluation of human-induced pluripotent stem cell (hiPSC) culture in a perfused 3D hollow-fiber bioreactor. <b>2019</b> , 13, 1203-1216		1
504	From embryonic stem cells to induced pluripotent stem cells-Ready for clinical therapy?. <b>2019</b> , 33, e13573		8
503	Insulin Stimulates PI3K/AKT and Cell Adhesion to Promote the Survival of Individualized Human Embryonic Stem Cells. <b>2019</b> , 37, 1030-1041		10
502	Applying hydrodynamic pressure to efficiently generate induced pluripotent stem cells via reprogramming of centenarian skin fibroblasts. <b>2019</b> , 14, e0215490		5
501	Somatic cell reprogramming as a tool for neurodegenerative diseases. <b>2019</b> , 112, 108663		5

500	Induction of Expandable Tissue-Specific Progenitor Cells from Human Pancreatic Tissue through Transient Expression of Defined Factors. <b>2019</b> , 13, 243-252	3
499	Reporter-based fate mapping in human kidney organoids confirms nephron lineage relationships and reveals synchronous nephron formation. <b>2019</b> , 20,	30
498	Coculture of Endothelial Cells with Human Pluripotent Stem Cell-Derived Cardiac Progenitors Reveals a Differentiation Stage-Specific Enhancement of Cardiomyocyte Maturation. <b>2019</b> , 14, e1800725	25
497	Directed Differentiation of Human Pluripotent Stem Cells to Podocytes under Defined Conditions. <i>Scientific Reports</i> , <b>2019</b> , 9, 2765	4.9 18
496	Distinctive Krebs cycle remodeling in iPSC-derived neural and mesenchymal stem cells. <b>2019</b> , 511, 658-664	3
495	Successful Derivation of an Induced Pluripotent Stem Cell Line from a Genetically Nonpermissive Enhanced Green Fluorescent Protein-Transgenic FVB/N Mouse Strain. <b>2019</b> , 21, 270-284	
494	Human Pluripotent Stem Cells: Applications and Challenges for Regenerative Medicine and Disease Modeling. <b>2020</b> , 171, 189-224	0
493	Induced Pluripotent Stem Cells as Vasculature Forming Entities. <b>2019</b> , 8,	7
492	Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications. <b>2019</b> , 28, 112S-131S	9
491	Stem Cell-Based Therapy for Lung Disease. <b>2019</b> ,	3
490	Efficient Production of Cell-permeable Oct4 Protein Using 30Kc19 Protein Originating from Silkworm. <b>2019</b> , 24, 964-971	3
489	Cancer stem cells in relation to treatment. <b>2019</b> , 49, 232-237	7
488	mRNA-Based Genetic Reprogramming. <b>2019</b> , 27, 729-734	31
487	Evaluation of variability in human kidney organoids. <b>2019</b> , 16, 79-87	114
486	Comparison of the characteristics of mesenchymal stem-like cells derived by integration-free induced pluripotent stem cells in different single-cell culture media under feeder-free conditions. <b>2019</b> , 52, 147-155	
485	Modern Ways of Obtaining Stem Cells. <b>2019</b> , 17-36	3
484	An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. <b>2019</b> , 686, 146-159	52
483	Aberrant hiPSCs-Derived from Human Keratinocytes Differentiates into 3D Retinal Organoids that Acquire Mature Photoreceptors. <b>2019</b> , 8,	14



482	Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. <b>2019</b> , 99, 79-114	111
481	Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease. <b>2019</b> , 10, 839-851	18
480	Retinal Degeneration. <b>2019</b> ,	3
479	Cell-Based Therapy for Retinal Disease: The New Frontier. <b>2019</b> , 1834, 367-381	13
478	Arterial identity of hemogenic endothelium: a key to unlock definitive hematopoietic commitment in human pluripotent stem cell cultures. <b>2019</b> , 71, 3-12	17
477	Ethics of Issues and Stem Cell Research: the Unresolved Issues. <b>2019</b> , 584-597	1
476	Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. <b>2020</b> , 1471, 18-56	31
475	Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases. <b>2020</b> , 1866, 165431	12
474	Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells. <b>2020</b> , 28, 129-141	4
473	Transgenic Mouse. <b>2020</b> ,	
472	Modeling Sporadic Alzheimer's Disease by Efficient Direct Reprogramming of the Elderly Derived Disease Dermal Fibroblasts into Neural Stem Cells. <b>2020</b> , 73, 919-933	4
471	Essential Current Concepts in Stem Cell Biology. <b>2020</b> ,	0
470	Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. <b>2020</b> , 16, 3-32	151
469	A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair. <b>2020</b> , 41, 2397-2404	15
468	Human-induced pluripotent stem cells (iPSC) as a source of insulin-producing cells. <b>2020</b> , 381-396	
467	Generation of induced pluripotent stem cell PLAFMCI002-A derived from peripheral blood mononuclear cells of polycystic kidney disease patient with PKD1 mutation. <i>Stem Cell Research</i> , <b>2020</b> , 49, 102039	1.6
466	Scaffolds of Macroporous Tannin Spray With Human-Induced Pluripotent Stem Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2020</b> , 8, 951	5.8
465	Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val. <i>Stem Cell Research</i> , <b>2020</b> , 48, 101940	1.6

464	Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation. <i>Stem Cell Research</i> , <b>2020</b> , 49, 102022	1.6	2
463	Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. <b>2020</b> , 432, 2754-2798		7
462	Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes. <b>2020</b> , 9,		7
461	Focus on germ-layer markers: A human stem cell-based model for in vitro teratogenicity testing. <b>2020</b> , 98, 286-298		6
460	Nanoengineering of stem cells for musculoskeletal regeneration. <b>2020</b> , 159-196		0
459	Co-administration of TiO-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury. <b>2020</b> , 258, 101-155		8
458	Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. <b>2020</b> , 9,		14
457	Controlling the Switch from Neurogenesis to Pluripotency during Marmoset Monkey Somatic Cell Reprogramming with Self-Replicating mRNAs and Small Molecules. <b>2020</b> , 9,		3
456	Quick, Coordinated and Authentic Reprogramming of Ribosome Biogenesis during iPSC Reprogramming. <b>2020</b> , 9,		0
455	Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
454	Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HBV Replication through Production of IFN- $\lambda$ and TNF- $\gamma$ . <b>2020</b> , 23, 101333		2
453	Generation of Human Neutrophils from Induced Pluripotent Stem Cells in Chemically Defined Conditions Using Modified mRNA. <b>2020</b> , 1, 100075-100075		1
452	Examining the co-expression, transcriptome clustering and variation using fuzzy cluster network of testicular stem cells and pluripotent stem cells compared with other cell types. <b>2020</b> , 85, 107227		
451	Application of induced pluripotent stem cells in epilepsy. <b>2020</b> , 108, 103535		5
450	Stem Cell Therapy for Alzheimer's Disease. <b>2020</b> , 1266, 39-55		9
449	Stem Cell-based Therapy for Neurodegenerative Diseases. <b>2020</b> ,		0
448	Kyoto probe-1 reveals phenotypic differences between mouse ES cells and iPS-P cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 18084	4.9	1
447	CSS: cluster similarity spectrum integration of single-cell genomics data. <b>2020</b> , 21, 224		11

446	From Hair to iPSCs-A Guide on How to Reprogram Keratinocytes and Why. <b>2020</b> , 55, e121			3
445	Human Urinal Cell Reprogramming: Synthetic 3D Peptide Hydrogels Enhance Induced Pluripotent Stem Cell Population Homogeneity. <b>2020</b> , 6, 6263-6275			3
444	Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine. <b>2020</b> , 16, 1049-1061			10
443	The Alzheimer's disease-associated C99 fragment of APP regulates cellular cholesterol trafficking. <b>2020</b> , 39, e103791			36
442	Human transcription factors responsive to initial reprogramming predominantly undergo legitimate reprogramming during fibroblast conversion to iPSCs. <i>Scientific Reports</i> , <b>2020</b> , 10, 19710	4-9		4
441	Going Back and Forth: Episomal Vector Reprogramming of Peripheral Blood Mononuclear Cells to Induced Pluripotent Stem Cells and Subsequent Differentiation into Cardiomyocytes and Neuron-Astrocyte Co-cultures. <b>2020</b> , 22, 300-310			2
440	Analyzing Impetus of Regenerative Cellular Therapeutics in Myocardial Infarction. <b>2020</b> , 9,			4
439	Generation of GABAergic striatal neurons by a novel iPSC differentiation protocol enabling scalability and cryopreservation of progenitor cells. <b>2020</b> , 72, 649-663			8
438	A human preadipocyte cell strain with multipotent differentiation capability as an in vitro model for adipogenesis. <b>2020</b> , 56, 399-411			1
437	Advancing physiological maturation in human induced pluripotent stem cell-derived cardiac muscle by gene editing an inducible adult troponin isoform switch. <b>2020</b> , 38, 1254-1266			8
436	Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. <b>2020</b> , 39, 100			21
435	Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. <i>Scientific Reports</i> , <b>2020</b> , 10, 9262	4-9		10
434	Generation of HIV-1-infected patients' gene-edited induced pluripotent stem cells using feeder-free culture conditions. <b>2020</b> , 34, 1127-1139			2
433	Generation of Otic Lineages from Integration-Free Human-Induced Pluripotent Stem Cells Reprogrammed by mRNAs. <b>2020</b> , 2020, 3692937			7
432	The Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders. <b>2020</b> , 29, 1131-1141			2
431	Establishment of human induced pluripotent stem cells derived from skin cells of a patient with Dravet syndrome. <i>Stem Cell Research</i> , <b>2020</b> , 47, 101857		1.6	1
430	Genome-wide R-loop Landscapes during Cell Differentiation and Reprogramming. <b>2020</b> , 32, 107870			20
429	Direct Readout of Neural Stem Cell Transgenesis with an Integration-Coupled Gene Expression Switch. <b>2020</b> , 107, 617-630.e6			10

428	Neural In Vitro Models for Studying Substances Acting on the Central Nervous System. <b>2021</b> , 265, 111-141	6
427	Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. <b>2020</b> , 138, 104788	11
426	Modeling Down syndrome in cells: From stem cells to organoids. <b>2020</b> , 251, 55-90	10
425	Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy. <b>2020</b> , 112, 58-66	2
424	Human Induced Pluripotent Stem Cells Derived from a Cardiac Somatic Source: Insights for an In-Vitro Cardiomyocyte Platform. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3 6
423	Stem Cell Transcriptional Networks. <b>2020</b> ,	1
422	Engineering Biomaterials with Micro/Nanotechnologies for Cell Reprogramming. <b>2020</b> , 14, 1296-1318	16
421	Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. <b>2020</b> , 9, 121-136	14
420	Modelling the pathogenesis of X-linked distal hereditary motor neuropathy using patient-derived iPSCs. <b>2020</b> , 13,	3
419	Multimodal Therapeutic Effects of Neural Precursor Cells Derived from Human-Induced Pluripotent Stem Cells through Episomal Plasmid-Based Reprogramming in a Rodent Model of Ischemic Stroke. <b>2020</b> , 2020, 4061516	7
418	Induced neural stem cells-derived spinal cord progenitor cells as stable stage for rapid and efficient generation of human oligodendrocytes and motor neurons. <b>2021</b> , 62, 206-214	
417	Redox and Epigenetics in Human Pluripotent Stem Cells Differentiation. <b>2021</b> , 34, 335-349	6
416	Fabrication of centimeter-sized 3D constructs with patterned endothelial cells through assembly of cell-laden microbeads as a potential bone graft. <b>2021</b> , 121, 204-213	5
415	Reprogramming of Fibroblasts to Human iPSCs by CRISPR Activators. <b>2021</b> , 2239, 175-198	3
414	Episomal Reprogramming of Human Peripheral Blood Mononuclear Cells into Pluripotency. <b>2021</b> , 2239, 117-133	
413	Nuclear Reprogramming. <b>2021</b> ,	
412	Physicochemical Properties in 3D Hydrogel Modulate Cellular Reprogramming into Induced Pluripotent Stem Cells. <b>2021</b> , 31, 2007041	4
411	Modeling human embryo development with embryonic and extra-embryonic stem cells. <b>2021</b> , 474, 91-99	9

410	Human stem cell models of polyglutamine diseases: Sources for disease models and cell therapy. <b>2021</b> , 337, 113573	3
409	Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments. <b>2021</b> , 18, 459-473	3
408	A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine. <b>2021</b> , 17, 748-776	6
407	Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. <b>2021</b> , 10, 198-208	9
406	iPSCs and cell therapy for Parkinson's disease. <b>2021</b> , 23-47	
405	Induced pluripotent stem cells in the modeling and therapy of lung diseases and airway production. <b>2021</b> , 61-71	
404	An overview of reprogramming approaches to derive integration-free induced pluripotent stem cells for prospective biomedical applications. <b>2021</b> , 231-287	7
403	Generation of Neural Stem Cells from Pluripotent Stem Cells for Characterization of Early Neuronal Development. <b>2021</b> , 2269, 233-244	0
402	Gene Expression in Pancreatic Cancer-Like Cells and Induced Pancreatic Stem Cells Generated by Transient Overexpression of Reprogramming Factors. <b>2021</b> , 10,	
401	Induced pluripotent stem cells in species conservation: advantages, applications, and the road ahead. <b>2021</b> , 221-245	0
400	Transcriptome profiling of human pluripotent stem cell-derived cerebellar organoids reveals faster commitment under dynamic conditions.	
399	Induced pluripotent stem cells as tools to investigate the neurobiology of bipolar disorder and advance novel therapeutic discovery. <b>2021</b> , 155-173	
398	Induced pluripotent stem cell derived from postmortem tissue in neurodegenerative disease research. <b>2021</b> , 221-249	0
397	The progress in the study of reprogramming to acquire the features of stem cells in iPSCs and cancers. <b>2021</b> , 87-114	1
396	Oral tissues as sources for induced pluripotent stem cell derivation and their applications for neural, craniofacial, and dental tissue regeneration. <b>2021</b> , 71-106	1
395	Episomal reprogramming of Duchenne muscular dystrophy patients derived CD3 T cells towards induced pluripotent stem cells. <b>2021</b> , 37, 432-438	
394	Pluripotent stem cell-derived epithelium misidentified as brain microvascular endothelium requires ETS factors to acquire vascular fate. <b>2021</b> , 118,	43
393	Donor-specific phenotypic variation in hiPSC cardiomyocyte-derived exosomes impacts endothelial cell function. <b>2021</b> , 320, H954-H968	4

392	Generation of iPSC from peripheral blood mononuclear cells obtained from a patient with TSC2-PKD1 contiguous gene deletion syndrome. <i>Stem Cell Research</i> , <b>2021</b> , 51, 102181	1.6	
391	Sex differences in the blood-brain barrier and neurodegenerative diseases. <b>2021</b> , 5, 011509		19
390	Myofibrillar Structural Variability Underlies Contractile Function in Stem Cell-Derived Cardiomyocytes. <b>2021</b> , 16, 470-477		1
389	An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells. <b>2021</b> , 2, 100264		1
388	Efficient induction of neural progenitor cells from human ESC/iPSCs on Type I Collagen. <b>2021</b> , 1		0
387	5-Aza-2'-Deoxycytidine and Valproic Acid in Combination with CHIR99021 and A83-01 Induce Pluripotency Genes Expression in Human Adult Somatic Cells. <b>2021</b> , 26,		0
386	Long QT Syndrome Variant Induces hERG1a/1b Subunit Imbalance in Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <b>2021</b> , 14, e009343		1
385	Non-viral Induction of Transgene-free iPSCs from Somatic Fibroblasts of Multiple Mammalian Species. <b>2021</b> , 16, 754-770		10
384	Induced Pluripotent Stem Cells from Animal Models: Applications on Translational Research.		0
383	In vitro model of ischemic heart failure using human induced pluripotent stem cell-derived cardiomyocytes. <b>2021</b> , 6,		4
382	Transcriptome profiling of human pluripotent stem cell-derived cerebellar organoids reveals faster commitment under dynamic conditions. <b>2021</b> , 118, 2781-2803		6
381	Establishment of PLAFMCi004-A induced pluripotent stem cells derived from PBMCs from a healthy individual. <i>Stem Cell Research</i> , <b>2021</b> , 53, 102316	1.6	
380	Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy. <i>Stem Cell Research</i> , <b>2021</b> , 53, 102278	1.6	1
379	Establishment of a human iPSC line XMDYYYi001-A from a patient with Becker muscular dystrophy harboring duplications of exons 2-19 in dystrophin gene. <i>Stem Cell Research</i> , <b>2021</b> , 53, 102298	1.6	
378	Impaired $\alpha$ -tubulin re-tyrosination leads to synaptic dysfunction and is a feature of Alzheimer's disease.		2
377	Image entropy-based label-free functional characterization of human induced pluripotent stem cell-derived 3D cardiac spheroids. <b>2021</b> , 179, 113055		4
376	Generation of SIV resistant T cells and Macrophages from Nonhuman Primate Induced Pluripotent Stem Cells with Edited CCR5 locus.		
375	Potential of Induced Pluripotent Stem Cells for Use in Gene Therapy: History, Molecular Bases, and Medical Perspectives. <b>2021</b> , 11,		2

374	Therapeutic effects of CXCR4 subpopulation of transgene-free induced cardiosphere-derived cells on experimental myocardial infarction. <b>2021</b> , 54, e13041		1
373	Novel cell sources for bone regeneration. <b>2021</b> , 2, 145-174		3
372	Contemporary Transposon Tools: A Review and Guide through Mechanisms and Applications of , and for Genome Engineering. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	10
371	Induce Pluripotency via Specific distal enhancer-promoter associations.		
370	Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes. <b>2021</b> , 10,		3
369	NSun2 deficiency promotes tau hyperphosphorylation and neurodegeneration through epitranscriptomic regulation of miR-125b.		
368	Neurotrophic Factors Secreted by Induced Pluripotent Stem Cell-Derived Retinal Progenitors Promote Retinal Survival and Preservation in an Adult Porcine Neuroretina Model. <b>2021</b> , 37, 301-312		0
367	Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart. <b>2021</b> , 8,		5
366	Targeting cancer stem cells in refractory cancer. <b>2021</b> , 17, 13-19		2
365	Recent trends in stem cell-based therapies and applications of artificial intelligence in regenerative medicine. <b>2021</b> , 13, 521-541		1
364	Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
363	Clinically compatible advances in blood-derived endothelial progenitor cell isolation and reprogramming for translational applications. <b>2021</b> , 63, 1-9		1
362	Nanomaterials and Stem Cell Differentiation Potential: An Overview of Biological Aspects and Biomedical Efficacy. <b>2021</b> ,		0
361	Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
360	Rock inhibitor may compromise human induced pluripotent stem cells for cardiac differentiation in 3D. <b>2022</b> , 9, 508-522		0
359	Generation of a human induced pluripotent stem cell line (PSHi002-A) from a Treacher-Collins syndrome patient carrying a TCOF1 gene mutation (c.1966_1969dup). <i>Stem Cell Research</i> , <b>2021</b> , 55, 102437 <sup>16</sup>		
358	Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches. <b>2021</b> , 167221		0
357	Applicability of organ-on-chip systems in toxicology and pharmacology. <b>2021</b> , 51, 540-554		2

356	Current status and future directions of clinical applications using iPSC cells-focus on Japan. <b>2021</b> ,		2
355	Generation of SCN1A Knock out induced pluripotent stem cell (iPSC) line. <i>Stem Cell Research</i> , <b>2021</b> , 55, 102452	1.6	0
354	Identification of New Transcription Factors that Can Promote Pluripotent Reprogramming. <b>2021</b> , 17, 2223-2234		
353	Kidney organoids generated from erythroid progenitors cells of patients with autosomal dominant polycystic kidney disease. <b>2021</b> , 16, e0252156		0
352	Immunological aspects of RPE cell transplantation. <b>2021</b> , 84, 100950		12
351	Generation of pancreatic progenitors from human pluripotent stem cells by small molecules. <b>2021</b> , 16, 2395-2409		4
350	Industrially Compatible Transfusable iPSC-Derived RBCs: Progress, Challenges and Prospective Solutions. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
349	Generation of iPSC lines with high cytogenetic stability from peripheral blood mononuclear cells (PBMCs).		
348	Hepatic Regeneration in Cirrhosis.. <b>2022</b> , 12, 603-616		1
347	The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease. <b>2021</b> , 10,		7
346	Generation of SCN1B knock out induced pluripotent stem cell (iPSC) line (refractory epilepsy syndrome and Brugada syndrome related cell line). <i>Stem Cell Research</i> , <b>2021</b> , 56, 102545	1.6	1
345	Bioreactors and microphysiological systems for adipose-based pharmacologic screening. <b>2022</b> , 121-146		
344	Rabbit induced pluripotent stem cells: the challenges. <b>2021</b> , 187-203		
343	Induced pluripotent stem cell-derived odontoblasts for disease modeling, drug development, and craniofacial applications. <b>2021</b> , 81-94		
342	Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms. <b>2021</b> , 181, 271-287		
341	Xeno-free cultivation of human induced pluripotent stem cells for clinical applications. <b>2021</b> , 309-341		
340	Current reprogramming methods to generate high-quality iPSCs. <b>2021</b> , 1-36		
339	Comprehensive Perspectives on Experimental Models for Parkinson's Disease. <b>2021</b> , 12, 223-246		2



338	Induced pluripotent stem cells for vascular tissue engineering. <b>2021</b> , 77-97	
337	Human Induced Pluripotent Stem Cells: Challenges and Opportunities in Developing New Therapies for Muscular Dystrophies. 1-10	3
336	Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. <b>2012</b> , Chapter 4, Unit4A.5	16
335	Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering. <b>2020</b> , 3, 1900182	9
334	Comparison of two human organoid models of lung and intestinal inflammation reveals Toll-like receptor signalling activation and monocyte recruitment. <b>2020</b> , 9, e1131	9
333	Human oligodendrocytes in remyelination research. <b>2015</b> , 63, 513-30	29
332	Reprogramming Fibroblasts to Neural Stem Cells by Overexpression of the Transcription Factor Ptf1a. <b>2020</b> , 2117, 245-263	2
331	Efficient RNA-Based Reprogramming of Disease-Associated Primary Human Fibroblasts into Induced Pluripotent Stem Cells. <b>2020</b> , 2117, 271-284	2
330	Transcriptome analyses to investigate the pathogenesis of RNA splicing factor retinitis pigmentosa. <b>2012</b> , 723, 519-25	6
329	Derivation of Retinal Pigmented Epithelial Cells for the Treatment of Ocular Disease. <b>2013</b> , 411-418	1
328	Synthetic mRNA Reprogramming of Human Fibroblast Cells. <b>2015</b> , 1330, 17-28	6
327	Preparation of iPSCs for Targeted Proteomic Analysis. <b>2019</b> , 1994, 131-139	1
326	Reprogramming of Primary Human Cells to Induced Pluripotent Stem Cells Using Sendai Virus. <b>2020</b> , 2066, 217-234	1
325	Generation and Characterization of Induced Pluripotent Stem Cells from Pig. <b>2011</b> , 413-425	1
324	Chimeras and Hybrids [How to Approach Multifaceted Research?]. <b>2011</b> , 193-209	1
323	Therapeutic Possibilities of Induced Pluripotent Stem Cells. <b>2011</b> , 77-90	1
322	Generation of Nonviral Integration-Free Induced Pluripotent Stem Cells from Plucked Human Hair Follicles. <b>2011</b> , 203-227	2
321	Utility of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for an In Vitro Model of Proliferative Vitreoretinopathy. <b>2019</b> , 1186, 33-53	4

320	CRISPR/Cas9 Editing in Induced Pluripotent Stem Cells: A Way Forward for Treating Cystic Fibrosis?. <b>2019</b> , 153-178	1
319	Genomic Instability of iPSCs and Challenges in Their Clinical Applications. <b>2019</b> , 1201, 23-47	24
318	Pluripotent Stem Cells: Sources and Characterization. <b>2011</b> , 69-82	0
317	Experimental reconstruction of the injured spinal cord. <b>2011</b> , 65-95	5
316	Induction of Human Pluripotent Stem Cells by the Sendai Virus Vector: Establishment of a Highly Efficient and Footprint-Free System. <b>2013</b> , 171-183	1
315	The Ethical Basis for Using Human Embryonic Stem Cells in the Treatment of Aging. <b>2010</b> , 63-86	1
314	Use of Human Embryonic Stem Cells in Therapy. <b>2014</b> , 1-19	2
313	Modeling severe congenital neutropenia in induced pluripotent stem cells. <b>2020</b> , 85-101	1
312	Mesenchymal stem cells for bone repair and metabolic bone diseases. <b>2009</b> , 84, 893-902	73
311	Stem cells: novel players in the treatment of erectile dysfunction. <b>2012</b> , 14, 145-55	30
310	Reprogramming human fibroblasts to pluripotency using modified mRNA.	3
309	The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson disease.	3
308	Transcriptional evaluation of the developmental accuracy, reproducibility and robustness of kidney organoids derived from human pluripotent stem cells.	2
307	Optogenetic control of Wnt signaling for modeling early embryogenic patterning with human pluripotent stem cells.	9
306	Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. <b>2020</b> , 5,	20
305	Stemming vision loss with stem cells. <b>2010</b> , 120, 3012-21	32
304	Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. <b>2011</b> , 121, 2326-35	186
303	Effect of Over-Expression of Zinc-Finger Protein (ZFX) on Self-Renewal and Drug-Resistance of Hepatocellular Carcinoma. <b>2016</b> , 22, 3025-34	4

302	Enhanced Reprogramming Efficiency and Kinetics of Induced Pluripotent Stem Cells Derived from Human Duchenne Muscular Dystrophy. <b>2015</b> , 7,	3
301	Comparative RNA-seq analysis in the unsequenced axolotl: the oncogene burst highlights early gene expression in the blastema. <b>2013</b> , 9, e1002936	92
300	Transcriptional signature and memory retention of human-induced pluripotent stem cells. <b>2009</b> , 4, e7076	247
299	Human induced pluripotent stem cells on autologous feeders. <b>2009</b> , 4, e8067	79
298	Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. <b>2009</b> , 4, e8152	326
297	Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. <b>2010</b> , 5, e8975	224
296	Initial colony morphology-based selection for iPS cells derived from adult fibroblasts is substantially improved by temporary UTF1-based selection. <b>2010</b> , 5, e9580	23
295	Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs). <b>2010</b> , 5, e9861	38
294	Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. <b>2010</b> , 5, e11373	127
293	Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. <b>2010</b> , 5, e12445	318
292	Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. <b>2010</b> , 5, e12487	55
291	Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. <b>2010</b> , 5, e14397	82
290	Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. <b>2012</b> , 7, e39113	108
289	Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. <b>2012</b> , 7, e42838	27
288	Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells. <b>2013</b> , 8, e59908	21
287	Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. <b>2013</b> , 8, e64496	63
286	Mutation in integrin-linked kinase (ILK(R211A)) and heat-shock protein 70 comprise a broadly cardioprotective complex. <b>2013</b> , 8, e77331	11
285	A simple alkaline method for decellularizing human amniotic membrane for cell culture. <b>2013</b> , 8, e79632	45

284	A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells. <b>2013</b> , 8, e81622	50
283	CD44 is a negative cell surface marker for pluripotent stem cell identification during human fibroblast reprogramming. <b>2014</b> , 9, e85419	38
282	Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. <b>2014</b> , 9, e96279	24
281	Non-viral generation of marmoset monkey iPS cells by a six-factor-in-one-vector approach. <b>2015</b> , 10, e0118424	31
280	Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype. <b>2016</b> , 11, e0152105	88
279	Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived iPSCs-Based Modeling of Late-Onset Parkinson's Disease. <b>2019</b> , 10, 1037-1048	6
278	Porcine pluripotent stem cells: progress, challenges and prospects. <b>2019</b> , 6, 8	2
277	Applications of 3D Bioprinted-Induced Pluripotent Stem Cells in Healthcare. <b>2020</b> , 6, 280	9
276	Vascular Microphysiological Systems to Model Diseases. <b>2020</b> , 6, 93-102	2
275	Nuclear delivery of recombinant OCT4 by chitosan nanoparticles for transgene-free generation of protein-induced pluripotent stem cells. <b>2016</b> , 7, 37728-37739	15
274	The quest for tissue stem cells in the pancreas and other organs, and their application in beta-cell replacement. <b>2010</b> , 7, 112-23	14
273	Hepatocyte transplantation in children with liver cell failure. <b>2016</b> , 8, 3096-3101	6
272	Stem cell-based tissue engineering approaches for musculoskeletal regeneration. <b>2013</b> , 19, 3429-45	39
271	Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective. <b>2013</b> , 13, 93-8	30
270	Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases. <b>2013</b> , 13, 139-51	44
269	Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. <b>2016</b> , 14, 914-934	16
268	iPS cell transplantation for traumatic spinal cord injury. <b>2016</b> , 11, 321-8	13
267	Electrospun Nanofibers for Diabetes: Tissue Engineering and Cell-Based Therapies. <b>2019</b> , 14, 152-168	4

266	Generated Hepatocyte-Like Cells: A Novel Tool in Regenerative Medicine and Drug Discovery. <b>2017</b> , 19, 204-217	8
265	Effects on Wound Healing of Human-Induced Pluripotent Stem Cell-Derived Cells Similar to Endothelial Colony-Forming Cells. <b>2020</b> , 16, 3-12	1
264	Toward using iPS cells to treat spinal cord injury: Their safety and therapeutic efficacy. <b>2011</b> , 31, 2-9	1
263	Human Induced Pluripotent Stem Cells : Clinical Significance and Applications in Neurologic Diseases. <b>2019</b> , 62, 493-501	10
262	Disease-specific pluripotent stem cells. <b>2010</b> , 53, 786-9	5
261	Induced pluripotent stem (iPS) cells: an up-to-the-minute review. <b>2009</b> , 1, 84	10
260	Future of liver transplantation: non-human primates for patient-specific organs from induced pluripotent stem cells. <b>2011</b> , 17, 3684-90	15
259	Present and future cell therapies for pancreatic beta cell replenishment. <b>2012</b> , 18, 6876-84	15
258	Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review). <b>2019</b> , 20-24	2
257	Targeting drug resistant stem cells in a human epidermal growth factor receptor-2-enriched breast cancer model.	2
256	Modelling neurodegenerative diseases in vitro: Recent advances in 3D iPSC technologies. <b>2018</b> , 2, 1-23	4
255	Progenitor/stem cell transplantation for repair of myocardial infarction: Hype or hope?. <b>2012</b> , 1, 65-77	15
254	The impact of neural stem cell biology on CNS carcinogenesis and tumor types. <b>2011</b> , 2011, 685271	2
253	Induced pluripotent stem cell-derived neural stem cell therapies for spinal cord injury. <b>2015</b> , 10, 10-6	24
252	Cell replacement therapy for central nervous system diseases. <b>2015</b> , 10, 1356-8	18
251	Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies. <b>2013</b> , 3,	9
250	Induced Pluripotent Stem Cells: Next Generation Cells for Tissue Regeneration. <b>2016</b> , 09, 226-244	26
249	Temporal epigenetic modifications differentially regulate ES cell-like colony formation and maturation. <b>2012</b> , 02, 45-57	8

248	Potential of transposon-mediated cellular reprogramming towards cell-based therapies. <b>2020</b> , 12, 527-544	6
247	Functional ion channels in stem cells. <b>2011</b> , 3, 19-24	43
246	Repressors of reprogramming. <b>2015</b> , 7, 541-6	1
245	iPS cells generation: an overview of techniques and methods. <b>2013</b> , 9, 2-8	5
244	Induced pluripotent stem cells as a cellular model for studying Down Syndrome. <b>2016</b> , 12, 54-60	12
243	Establishment of Hepatocellular Cancer Induced Pluripotent Stem Cells Using a Reprogramming Technique. <b>2017</b> , 11, 261-269	12
242	Baboon induced pluripotent stem cell generation by transposition of reprogramming factors. <b>2019</b> , 6, 75-86	6
241	Current Opinion on the Role of Neurogenesis in the Therapeutic Strategies for Alzheimer Disease, Parkinson Disease, and Ischemic Stroke; Considering Neuronal Voiding Function. <b>2016</b> , 20, 276-287	19
240	On-Chip Cellomics: Constructive Understanding of Multicellular Network Using On-Chip Cellomics Technology. <b>2012</b> , 51, 08KA03	1
239	Gammaretroviral vector encoding a fluorescent marker to facilitate detection of reprogrammed human fibroblasts during iPSC generation. <b>2013</b> , 1, e224	4
238	Genetic reprogramming of human amniotic cells with episomal vectors: neural rosettes as sentinels in candidate selection for validation assays. <b>2014</b> , 2, e668	2
237	Human iPSC-derived neurons reveal early developmental alteration of neurite outgrowth in the late-occurring neurodegenerative Wolfram syndrome. <b>2021</b> , 108, 2171-2185	1
236	Recent progress of iPSC technology in cardiac diseases. <b>2021</b> , 95, 3633-3650	4
235	Safe and stable generation of induced pluripotent stem cells using doggybone DNA vectors. <b>2021</b> , 23, 348-358	0
234	Stem cell therapy for hemophilia A. <b>2009</b> , 20, 292-300	
233	Stem-cell therapies closer to the clinic.	
232	Chapter 6:Induced Pluripotent Stem Cells: Their Role in Modeling Disease and Regenerative Medicine. <b>2010</b> , 117-140	
231	Chapter 15:Regenerative Strategies for the Endocrine Pancreas: From Islets to Stem Cells and Tissue Reprogramming. <b>2010</b> , 308-323	

230 A Quantity Study of Marital Satisfaction, Romantic Jealousy and Female Aggression (Psychological and Physical). **2010**, 5, 82-88

229 Nuclear Transfer from Cell Lines.

228 Induced pluripotent stem (iPS) cells offer a powerful new tool for the life sciences. **2010**, 6, 2-9

227 Generation of Induced Pluripotent Stem Cells From Porcine Fibroblasts\*. **2010**, 37, 607-612

226 Induced Pluripotent Stem Cells: On the Road Toward Clinical Applications. **2011**, 427-438

225 Cellular Reprogramming: Current Technology, Perspectives, and Generation of Induced Pluripotent Cells. 297-310

224 Human Pluripotent Cells: The Biology of Pluripotency. 311-325

223 Generation and clinical application of human T cell-derived induced pluripotent stem cells. **2011**, 31, 393-398

222 Generation, Maintenance, and Differentiation of Human iPS Cells from Cord Blood. **2011**, 113-131

221 Induced Pluripotent Cells for Myocardial Infarction Repair. **2011**, 263-280

220 Breakthrough in Stem Cell Research? The Reprogramming of Somatic Cells to Pluripotent Stem Cells: Overview and Outlook. **2011**, 7-24

219 Liver Regeneration and Tissue Engineering. **2011**, 315-332

218 Islet Cell Therapy and Pancreatic Stem Cells. **2011**, 403-426

217 Ethical Considerations. **2011**, 1117-1130

216 Multistage Hepatic Differentiation from Human Induced Pluripotent Stem Cells. **2011**, 387-396

215 Generation of Multipotent CD34+CD45+ Hematopoietic Progenitors from Human Induced Pluripotent Stem Cells. **2011**, 337-350

214 Methods for Inducing Pluripotency. **2011**, 219-239

213 The Progress of Induced Pluripotent Stem Cells (iPSCs) for Research and Applications. **2011**, 38, 101-112

212 [Progress and application prospect of pig induced pluripotent stem cells]. **2011**, 33, 307-13

211 Strategies for Pancreatic Differentiation of Pluripotent Stem Cells. **2012**, 177-187

210 Induced Pluripotent Stem Cells from Blood. **2012**, 87-95

209 Applications of Human Induced Pluripotent Stem Cell Derived Hepatocytes. **2012**, 213-220

208 Modified Stem Cells as Disease Models and in Toxicology Screening. 227-250

207 Episomal Vectors. 49-83

206 Nonintegrating RNA Viruses. 103-118

205 Reprogramming: A New Era in Regenerative Medicine. **2012**, 1-25

204 Neural Crest and Hirschsprung Disease. **2012**, 353-386

203 Transdifferentiation in the Nervous System. **2012**, 245-264

202 iPS Cells: New Applications for Metabolic Liver Diseases. **2012**, 85-95

201 [The genetic safety of induced pluripotent stem (iPS) cells]. **2012**, 34, 260-8

200 Mice as Experimental Organisms.

199 [Cell fate switch: lineage reprogramming]. **2012**, 34, 985-92

198 Pancreatic Reprogramming. **2013**, 155-168

197 Derivation and Expansion of Human Pluripotent Stem Cells. **2012**, 1-18

196 . **2012**, 39, 1061-1065

1

195 Generate Induced Pluripotent Stem Cells by Three Factors under Feeder-Free Condition with Higher Efficiencies. **2012**, 11, 2110-2115



- 194 Genetically Modified Stem Cells for Transplantation. **2013**, 119-146
- 193 Commercial Opportunities for Induced Pluripotent Stem Cells. **2013**, 177-199
- 192 Alternative Future Therapies for Lysosomal Storage Diseases: Embryonic Stem Cell- and Induced Pluripotent Stem Cell Therapy. **2013**, 139-158
- 191 Stem Cells and Diabetes. **2013**, 419-426
- 190 iPS Cell Technology and Disease Research: Issues To Be Resolved. **2013**, 1-7
- 189 hiPSCs: Reprogramming towards cell-based therapies. **2013**, 02, 61-73
- 188 Primary evaluation of induced pluripotent stem cells using flow cytometry. **2013**, 33, 003-012
- 187 Induced Pluripotent Stem Cells: New Advances in Cardiac Regenerative Medicine. **2013**, 225-249
- 186 Fulminant Hepatic Failure and Liver Support Systems. **2013**, 1536-1543
- 185 Human-Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Their Cardiomyocyte Derivatives: An Overview. **2013**, 321-345
- 184 Stem Cell Applications in Retinal Diseases. **2013**, 85-103
- 183 Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming. **2013**, 505-528
- 182 Human iPS Cell Generation Methods for Clinical Usage. **2013**, 20-34
- 181 Meet the Stem Cells. **2013**, 111-142
- 180 Cancer Gene Therapy Potential of Neural Stem Cells Derived from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. **2014**, 51-63
- 179 Senescent-Derived Pluripotent Stem Cells Are Able to Redifferentiate into Fully Rejuvenated Cells. **2014**, 265-276
- 178 Large Animal Induced Pluripotent Stem Cells as Models of Human Diseases. **2014**, 49-68
- 177 Stem Cell Therapy to Treat Heart Failure. **2014**,

- 176 Use of Induced Pluripotent Stem Cells in Drug Toxicity Screening. **2014**, 335-350
- 175 Researches for iPS Cell-based Transplantation : Current Status and Issues. **2014**, 28, 252-257
- 174 Regenerative Medicine for Spinal Cord Injury Utilizing iPS Cells. **2014**, 229-245
- 173 Advances in Stem Cell Research for Parkinson Disease. **2014**, 653-690
- 172 Stem Cell Therapy for Neurological Disorders: From Bench to Bedside. **2014**, 41-70
- 171 Molecular Life Sciences. **2014**, 1-12
- 170 Stem Cell Applications: An Overview. **2014**, 3-15
- 169 Human therapeutic cloning, pitfalls and lack luster because of rapid developments in induced pluripotent stem cell technology. **2014**, 8, 5-10 1
- 168 Identification of Candidate Porcine miRNA-302/367 Cluster and Its Function in Somatic Cell Reprogramming. **2014**, 38, 79-84
- 167 Chemicals Facilitating Reprogramming: Targeting the SAM Binding Site to Identify Novel Methyltransferase Inhibitors. 163-179
- 166 Chemicals Facilitating Reprogramming. 141-162
- 165 Network based meta-analysis prediction of microenvironmental relays involved in stemness of human embryonic stem cells. **2014**, 2, e618 1
- 164 Induced Pluripotent Stem Cell, a Rising Star in Regenerative Medicine. **2015**, 85-109
- 163 Hematopoietic Stem Cells. **2016**, 111-143
- 162 Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming. **2016**, 41-64
- 161 Fetal Cell Reprogramming and Transformation. **2016**, 101-130
- 160 Advances in Umbilical Cord Blood Therapy: Hematopoietic Stem Cell Transplantation and Beyond. **2017**, 139-168 1
- 159 Use of Stem Cells in Toxicology. **2017**, 177-194

- 158 [Tissue engineering of the tooth: directions of development, achievements and unresolved problems]. **2017**, 96, 72-79
- 157 Induced Pluripotent Stem Cells (iPSCs) and Nuclear Reprogramming. **2017**, 71-91
- 156 Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization. 1
- 155 1 Human-Induced Pluripotent Stem Cells: Derivation. **2017**, 1-22
- 154 The prospect of pluripotent stem cells for diabetes mellitus treatment. **2017**, 1, 13-17
- 153 Structurally conserved primate lncRNAs are transiently expressed during human cortical differentiation and influence cell type specific genes.
- 152 Molecular Life Sciences. **2018**, 925-935
- 151 Making iPSC Cells in the Laboratory. **2018**, 107-146
- 150 Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Towards Personalized Therapeutic Strategies?. **2018**, 421-437
- 149 Cell-Based Therapy for Retinal Degenerative Disease. **2018**, 73-85
- 148 Evaluating Cell Identity from Transcription Profiles.
- 147 Structurally Conserved Primate lncRNAs Are Transiently Expressed During Human Cortical Differentiation and Influence Cell Type Specific Genes.
- 146 Acute Liver Failure and Bioartificial Liver Support. **2019**, 1508-1516 1
- 145 Stem Cell Therapy to Treat Heart Failure. **2019**, 286-303
- 144 Chapter 1:Introduction. **2019**, 1-11
- 143 AAV-mediated gene augmentation therapy restores critical functions in mutant iPSC-derived PRPF31<sup>+/-</sup> cells.
- 142 Regenerative treatment of spinal cord injury. Literature review. Part 2. **2019**, 21, 83-92
- 141 Microfluidic Chip for Label-Free Removal of Teratoma-forming Cells from Therapeutic Human Stem Cells.

140	In Vitro Methods for Generating Induced Pluripotent Stem Cells. <b>2020</b> , 265-288	
139	Controlling the switch from neurogenesis to pluripotency during marmoset monkey somatic cell reprogramming with self-replicating mRNAs and small molecules.	0
138	Generation of Human Induced Pluripotent Stem Cells and Differentiation into Cardiomyocytes. <b>2021</b> , 2158, 125-139	1
137	Stem cell models for genetically predisposed colon cancer. <b>2020</b> , 20, 138	2
136	Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) into Osteoclasts. <b>2020</b> , 10, e3854	
135	Stem Cell-Derived Liver Cells. <b>2020</b> , 1015-1021	
134	Cord Blood Stem Cells. <b>2020</b> , 41-58	0
133	Induced Pluripotent Stem Cells. <b>2020</b> , 123-136	
132	Induced pluripotent stem cells and derivative photoreceptor precursors as therapeutic cells for retinal degenerations. <b>2020</b> , 32, 101-112	0
131	Cluster similarity spectrum integration of single-cell genomics data.	2
130	Human Induced Pluripotent Stem Cell-Derived Vascular Cells: Recent Progress and Future Directions. <b>2021</b> , 8,	1
129	Hematopoietic Stem Cells and Regeneration. <b>2021</b> ,	0
128	Myofibrillar Structural Variability Underlies Contractile Function in Stem Cell-Derived Cardiomyocytes.	1
127	Reprogramming Human Fibroblasts to Induced Pluripotent Stem Cells Using the GFP-Marked Lentiviral Vectors in the Chemically Defined Medium. <b>2021</b> , 2239, 101-116	0
126	Stem Cell Therapy for Ophthalmic Vascular Disease. <b>2021</b> , 367-384	
125	Regeneration of a heart cell. <b>2009</b> , 82, 117-9	2
124	Imaging of Induced Pluripotent Stem Cells: From Cellular Reprogramming to Transplantation. <b>2011</b> , 1, 18-28	23
123	Recent concepts for the roles of progenitor/stem cell niche in heart repair. <b>2012</b> , 2, 75-83	5

122	Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. <b>2010</b> , 2, 18-28	65
121	Molecular mechanisms of induced pluripotency. <b>2012</b> , 4, 12-22	4
120	Regenerative therapy for retinal disorders. <b>2010</b> , 5, 250-64	12
119	No factor left behind: generation of transgene-free induced pluripotent stem cells. <b>2012</b> , 1, 75-80	9
118	Cell therapy: cGMP facilities and manufacturing. <b>2012</b> , 2, 243-7	44
117	Stem cell and tissue engineering in breast reconstruction. <b>2014</b> , 3, 55-61	6
116	Induced pluripotent stem cells in dentistry. <b>2016</b> , 8, S23-S27	2
115	Stem cell-derived liver cells for drug testing and disease modeling. <b>2015</b> , 19, 349-58	48
114	GATA6 regulates aging of human mesenchymal stem/stromal cells. <b>2021</b> , 39, 62-77	2
113	Blood and Lymphatic System. <b>2022</b> , 749-781	
112	Induced pluripotent stem cells-derived hematopoietic progenitors for cellular immunotherapies. <b>2022</b> , 233-263	0
111	Pluripotent Stem Cells: Embryonic/Fetal Stem Cells and Induced Pluripotent Stem Cells. <b>2022</b> , 371-381	
110	Induced pluripotent stem cells-derived mesothelial progenitors; implications in cell-based regenerative medicine. <b>2022</b> , 91-110	
109	Generation of Primordial Germ Cell-like Cells from iPSCs Derived from Turner Syndrome Patients. <b>2021</b> , 10,	0
108	Simultaneous high-efficiency base editing and reprogramming of patient fibroblasts. <b>2021</b> ,	1
107	Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through.. <b>2022</b> , 10,	2
106	Establishment and characterization of an induced pluripotent stem cell line CPGHi004-A from peripheral blood mononuclear cells of a healthy adult.. <i>Stem Cell Research</i> , <b>2022</b> , 59, 102656	1.6
105	GATA6 regulates aging of human mesenchymal stem/stromal cells. <b>2021</b> , 39, 62-77	6

104	Derivation of Clinical-Grade Induced Pluripotent Stem Cell Lines from Erythroid Progenitor Cells in Xenofree Conditions. <b>2021</b> , 1	0
103	Methods for Isolation and Reprogramming of Various Somatic Cell Sources into iPSCs. <b>2021</b> , 1	
102	Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective.. <b>2021</b> , 10,	0
101	Applications for induced pluripotent stem cells in reproductive medicine. <b>2022</b> , 225-273	
100	Synthetic mRNA for ex vivo therapeutic applications.. <b>2022</b> , 44, 100447	0
99	Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer's disease.. <b>2022</b> ,	1
98	An update on clinical applications of iPSCs from a genomic point of view. <b>2022</b> , 147-175	
97	Applications of iPSCs in Gaucher Disease and other rare sphingolipidoses. <b>2022</b> , 197-224	
96	RNA-Based Strategies for Cell Reprogramming toward Pluripotency.. <b>2022</b> , 14,	1
95	Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma.. <b>2022</b> , 10, 2	2
94	Induced pluripotent stem cells for cystic fibrosis. <b>2022</b> , 303-332	
93	Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives.. <b>2022</b> , 11,	7
92	Establishment of the induced pluripotent stem cell line PLAFMCI006-A from peripheral blood mononuclear cells of polycystic kidney disease patients with PKD2 gene mutation.. <i>Stem Cell Research</i> , <b>2022</b> , 60, 102681	1.6
91	Generation of iPSC line from urine cells of hemophilia A with F8 (p. R814X) mutation.. <i>Stem Cell Research</i> , <b>2022</b> , 60, 102682	1.6
90	Robust genome and RNA editing via CRISPR nucleases in PiggyBac systems.. <b>2022</b> , 14, 313-320	2
89	CRISPR/Cas System and Stem Cell Editing: Prospects and Possibilities in Veterinary Sciences. <b>2021</b> , 323-354	0
88	Methods of Identification and Characterization of Stem Cells. <b>2021</b> , 51-62	
87	Cardiovascular Regeneration via Stem Cells and Direct Reprogramming: A Review.. <b>2022</b> , 52, 341-353	1

86	Cell Surface Proteins for Enrichment and Characterization of Human Pluripotent Stem Cell-Derived Myogenic Progenitors.. <b>2022</b> , 2022, 2735414	0
85	Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses.. <b>2022</b> , 1	0
84	Specific mesoderm subset derived from human pluripotent stem cells ameliorates microvascular pathology in type 2 diabetic mice.. <b>2022</b> , 8, eabm5559	0
83	Elimination of Reprogramming Transgenes Facilitates the Differentiation of Induced Pluripotent Stem Cells into Hepatocyte-like Cells and Hepatic Organoids.. <b>2022</b> , 11,	1
82	Pluripotent stem cell-based cell therapies: current applications and future prospects. <b>2022</b> , 100390	0
81	The Modular $\mu$ SiM: a Mass Produced, Rapidly Assembled, and Reconfigurable Platform for the Study of Barrier Tissue Models In Vitro.	0
80	Induction of Corneal Epithelial Differentiation of Induced Pluripotent and Orbital Fat-Derived Stem Cells Seeded on Decellularized Human Corneas.. <b>2022</b> , 1	1
79	Generation and characterization of human-derived iPSC lines from one pair of dizygotic twins discordant for schizophrenia.. <i>Stem Cell Research</i> , <b>2022</b> , 60, 102710	1.6
78	Differentiation of Human Induced Pluripotent Stem Cells into Keratinocytes.. <b>2022</b> , 2, e408	1
77	Retinoids rescue ceruloplasmin secretion and alleviate oxidative stress in Wilson's disease-specific hepatocytes.. <b>2022</b> ,	
76	Two Sets of Compound Complex Driving for High Efficiency of Nonintegration Reprogramming of Human Fibroblasts.. <b>2022</b> ,	
75	Prime time for doxorubicin-induced cardiotoxicity genetic testing.. <b>2022</b> ,	
74	Changing Fate: Reprogramming Cells via Engineered Nanoscale Delivery Materials.. <b>2022</b> , e2108757	1
73	Generation of the integration-free induced pluripotent stem cell line (FHUSTCi001-A) from a patient with glomerulopathy with fibronectin deposits harboring FN1 mutation.. <i>Stem Cell Research</i> , <b>2022</b> , 61, 102751	1.6
72	Generation of induced pluripotent stem cells from peripheral blood mononuclear cells obtained from an adult with autosomal recessive polycystic kidney disease.. <i>Stem Cell Research</i> , <b>2022</b> , 61, 102772	1.6
71	Noncovalent reversible binding-enabled facile fabrication of leak-free PDMS microfluidic devices without plasma treatment for convenient cell loading and retrieval.. <b>2022</b> , 16, 346-358	1
70	Label-free imaging to track reprogramming of human somatic cells.	
69	iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams.. <b>2021</b> , 9,	1

68	Somatic Lineage Reprogramming. <b>2021</b> ,		0
67	Assessment of Safety and Immunogenicity of MHC homozygous iPSC-derived CD34+ Hematopoietic Progenitors in a NHP Model.. <b>2022</b> ,		1
66	Label-Free Imaging to Track Reprogramming of Human Somatic Cells.. <b>2022</b> , 1, 176-191		
65	Image_1.TIF. <b>2018</b> ,		
64	Image_2.tif. <b>2018</b> ,		
63	Induced pluripotent stem cells in dentistry. <b>2016</b> , 8, 23		2
62	Differentiation of Human Induced Pluripotent Stem Cells into Cortical Neurons to Advance Precision Medicine.. <b>2022</b> , 2429, 143-174		1
61	Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD.. <b>2022</b> ,		0
60	Biomarkers of Cancer Stem Cells for Experimental Research and Clinical Application. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 715	3.6	0
59	An improved pipeline for reprogramming human induced pluripotent stem cells with TET1.		
58	Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment.. <b>2022</b> , e13232		1
57	Scalable manufacturing of clinical-grade differentiated cardiomyocytes derived from human-induced pluripotent stem cells for regenerative therapy.. <b>2022</b> , e13248		0
56	Identifying Features of Cardiac Disease Phenotypes Based on Mechanical Function in a Catecholaminergic Polymorphic Ventricular Tachycardia Model. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2022</b> , 10,	5.8	0
55	Establishment and Characterization of MUi027-A: A Novel Patient-Derived Cell Line of Polycystic Kidney Disease with PKD1 Mutation. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 766	3.6	0
54	Surgical strategies for AMD. <b>2012</b> , 541-549		0
53	Epigenetic regulation of BAF60A determines efficiency of miniature swine iPSC generation. <i>Scientific Reports</i> , <b>2022</b> , 12,	4.9	
52	Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , <b>2022</b> , 13,	8.3	0
51	Generation of integration-free induced pluripotent stem cell line (KSCBi012-A) from urinary epithelial cells of a healthy male individual. <i>Stem Cell Research</i> , <b>2022</b> , 102841	1.6	



50	Generation and characterization of human-derived iPSC lines from two cousins with schizophrenia and bipolar disorder and their unaffected cousin. <i>Stem Cell Research</i> , <b>2022</b> , 102832	1.6	
49	Using liver models generated from human-induced pluripotent stem cells (iPSCs) for evaluating chemical-induced modifications and disease across liver developmental stages. <i>Toxicology in Vitro</i> , <b>2022</b> , 83, 105412	3.6	
48	Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave. <i>Molecular Diagnosis and Therapy</i> , <b>2022</b> , 26, 353-367	4.5	
47	Stem Cell Models for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7055	6.3	1
46	New Insights into TRP Ion Channels in Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7766	6.3	1
45	Step-by-step protocols for non-viral derivation of transgene-free induced pluripotent stem cells from somatic fibroblasts of multiple mammalian species. <i>Development Growth and Differentiation</i> ,	3	0
44	THE MAIN SIGNALING SYSTEMS INVOLVED IN THE FUNCTIONING OF STEM CELLS (review of literature data). <b>2022</b> , 327-354		
43	Bilirubin-Induced Neurological Damage: Current and Emerging iPSC-Derived Brain Organoid Models. <b>2022</b> , 11, 2647		0
42	Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery. <b>2022</b> , 23, 9223		
41	Tumor suppressors inhibit reprogramming of African spiny mouse ( <i>Acomys</i> ) fibroblasts to induced pluripotent stem cells. 7, 215		
40	Motor neuron-derived induced pluripotent stem cells as a drug screening platform for amyotrophic lateral sclerosis. 10,		
39	The Modular $\mu$ SiM: A Mass Produced, Rapidly Assembled, and Reconfigurable Platform for the Study of Barrier Tissue Models In Vitro. 2200804		1
38	Presenilin-1 F105C mutation leads to tau accumulation in human neurons via the Akt/mTORC1 signaling pathway. <b>2022</b> , 12,		
37	Generating Human Induced Pluripotent Stem Cell Via Low-Dose Polyethylenimine-Mediated Transfection: An Optimized Protocol.		0
36	Novel gene-intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy: A new mechanism for motor neuron degeneration.		
35	Crosstalk between acetylation and the tyrosination/detyrosination cycle of $\beta$ tubulin in Alzheimer's disease. 10,		1
34	Generation and Application of Directly Reprogrammed Endothelial Cells. <b>2022</b> , 52, 643		0
33	Molecular Signature of Stem Cells Undergoing Cardiomyogenic Differentiation. <b>2022</b> , 1-43		0

32	An iPS -derived in vitro model of human atrial conduction. <b>2022</b> , 10,	0
31	An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool. <b>2022</b> , 2022, 1-17	0
30	Transient inhibition of p53 enhances prime editing and cytosine base-editing efficiencies in human pluripotent stem cells. <b>2022</b> , 13,	1
29	Establishment of human induced trophoblast stem cells via reprogramming of fibroblasts.	0
28	Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. <b>2022</b> , 12,	0
27	Generation of mitochondria-rich kidney organoids from expandable intermediate mesoderm progenitors reprogrammed from human urine cells under defined medium. <b>2022</b> , 12,	0
26	Regeneration of the human segmentation clock in somitoids in vitro.	0
25	MSCs vs. iPSCs: Potential in therapeutic applications. 10,	2
24	Generation of an induced pluripotent stem cell JTUi005-A from a patient with neuronal intranuclear inclusion disease. <b>2022</b> , 65, 102938	0
23	Molecular Signature of Stem Cells Undergoing Cardiomyogenic Differentiation. <b>2022</b> , 725-767	0
22	Novel gene-intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy.	1
21	Generation of integration-free induced pluripotent stem cell line (KSCBi017-A) from peripheral blood mononuclear cells of a healthy male individual. <b>2022</b> , 65, 102965	0
20	Generation of an induced pluripotent stem cell line (SHCDNi007-A) from a patient with pyruvate carboxylase deficiency carrying compound heterozygous (c.182 T>C/ c.2581G>A) variants in PC. <b>2023</b> , 66, 102997	0
19	Stem Cell-Based Therapeutic Strategies for Premature Ovarian Insufficiency and Infertility: A Focus on Aging. <b>2022</b> , 11, 3713	1
18	An Optogenetic-Controlled Cell Reprogramming System for Driving Cell Fate and Light-Responsive Chimeric Mice. 2202858	0
17	Current Application of iPS Cells in the Dental Tissue Regeneration. <b>2022</b> , 10, 3269	0
16	Cardiac muscle patches containing four types of cardiac cells derived from human pluripotent stem cells improve recovery from cardiac injury in mice.	0
15	Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research. 10,	0

- 14 A human induced pluripotent stem cell model from a patient with hereditary cerebral small vessel disease carrying a heterozygous R302Q mutation in HTRA1. **2023**, 43,
- 13 Exploring the reprogramming potential of B cells and comprehending its clinical and therapeutic perspective. **2023**, 78, 101804
- 12 Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects. **2023**, 111, 1191-1204.e5
- 11 DUX4 double whammy: The transcription factor that causes a rare muscular dystrophy also kills the precursors of the human nose. **2023**, 9,
- 10 Single cell RNA sequencing in isogenic FUS and TARDBP mutant ALS lines reveals early mitochondrial dysfunction as a common pathway in motor neurons.
- 9 Advancing cell-based cancer immunotherapy through stem cell engineering. **2023**,
- 8 ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in Alzheimer's disease.
- 7 Somatic Cell Reprogramming for Nervous System Diseases: Techniques, Mechanisms, Potential Applications, and Challenges. **2023**, 13, 524
- 6 Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease. **2023**, 12, 988
- 5 Homogeneity of XEN Cells Is Critical for Generation of Chemically Induced Pluripotent Stem Cells. **2022**, 46, 209-218
- 4 Reprogramming of human peripheral blood mononuclear cells into induced mesenchymal stromal cells using non-integrating vectors. **2023**, 6,
- 3 Endothelial cell direct reprogramming: Past, present, and future. **2023**,
- 2 Retinal cone photoreceptors from pluripotent stem cells for macular regeneration. **2023**, 221-241
- 1 Generation of stable integration-free pig induced pluripotent stem cells under chemically defined culture condition.